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Summary
The circadian clock is an internal timing system that allows the entrainment of physiological
and behavioural processes to the geophysical time with a periodicity of about 24 hours. It
consists of a central pacemaker in the suprachiasmatic nucleus (SCN) and peripheral clocks in
every cell. In mammals, a distinct set of genes is interconnected in regulatory feedback loops,
thereby generating oscillations in gene expression in the core-clock itself as well as in numerous
target genes. Known clock target genes are, among others, involved in cellular processes
connected to tumour development and progression, including metabolic pathways, drug
response pathways and the cell cycle. Malfunctions of the circadian clock are associated with
different pathologies including cancer and studies link the disruption of the clock to an
enhanced susceptibility to develop cancer, bad treatment response and poor prognosis. Attempts
have already been made to apply chronotherapy in cancer treatment. However, to date studies
fail to give clear messages due to tumour heterogeneity, genetic complexity and the missing
knowledge about the involvement of the circadian clock in stage-specific tumour signatures.
The aim of this project was to study the role of the circadian clock in tumour development and
progression with a focus on cancer metabolism and treatment response. The role of a
deregulated clock was investigated in an in vitro model of colorectal cancer progression,
namely, SW480 cells derived from a primary tumour and SW620 cells derived from a lymph
node metastasis of the same patient. The investigated cell lines showed clear differences with
respect to their clock phenotypes. A time course analysis of both cell lines on the transcriptome
level revealed a global shift of 24 h oscillating genes as well as distinct alterations in metabolic
pathways such as glycolysis and oxidative phosphorylation. Within these pathways a set of
candidate genes, including the glycolytic gene Hkdc1, was identified that might mediate
clock-driven metabolic alterations in tumourigenesis. A knockdown (KD) of the core-clock
gene Bmal1 was introduced to study the effects of a disrupted clock on gene expression and cell
metabolism. Bmal1-KD in SW480 cells induced a metastatic phenotype similar to SW620 wild
type (WT) cells, as indicated by faster proliferation, lower apoptosis rate and a highly energetic
metabolic phenotype. Furthermore, Bmal1-KD induced metabolic phenotype rewiring as seen
by altered glycolytic activity and mitochondrial respiration, a change in time-dependent
metabolic profile, gene expression changes in the tested candidate genes and modified treatment
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response to metabolism-targeting anticancer treatment. A reciprocal interplay between Bmal1
and the glycolytic gene Hkdc1 seems to be a possible mechanism of clock-driven metabolic
reprogramming in tumorigenesis. Findings from the model system could partly be confirmed
in two primary cell systems, primary fibroblasts isolated from normal colon (NF) and colon
adenocarcinoma (CAF) of the same patient and human fallopian tube organoids. Furthermore,
co-culture experiments with NFs and CAFs and cancer cell lines showed that cell-to-cell
communication influences both the clock phenotype and cell metabolism. The results obtained
in this project reinforce the postulated role of Bmal1 as a tumour suppressor and elucidate a
reciprocal interplay between the circadian clock and cancer metabolism with implications in
metabolic phenotype rewiring during tumour progression. Novel connections between both
systems identified in this project may play a pivotal role in colorectal cancer progression and
in response to anticancer therapy.
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Zusammenfassung
Die zirkadiane Uhr ist ein endogenes Zeitmesssystem, das die Anpassung physiologischer
Prozesse und Verhaltensweisen von Lebewesen an die geophysikalische Zeit mit einer
Periodizität von etwa 24 Stunden ermöglicht. Die zirkadiane Uhr besteht aus einem zentralen
Schrittmacher im suprachiasmatischen Kern (SCN) und peripheren Uhren in jeder Zelle. Bei
Säugetieren ist eine bestimmte Anzahl sogenannter Uhr-Gene in regulatorischen
Rückkopplungsschleifen miteinander verbunden, wodurch Oszillationen in der Expression der
Uhr-Gene selbst sowie in zahlreichen Zielgenen erzeugt werden. Zielgene der zirkadianen Uhr
sind unter anderem an zellulären Prozessen beteiligt, die eine Rolle bei der Tumorentstehung
und -progression spielen. Dazu gehören eine Vielzahl von Stoffwechselwegen,
Arzneimittelreaktionswege sowie der Zellzyklus. Funktionsstörungen der zirkadianen Uhr
stehen im Zusammenhang mit verschiedenen Krankheitsbildern, unter anderem Krebs.
Studienergebnisse konnten eine Funktionsstörung der zirkadianen Uhr mit einer erhöhten
Anfälligkeit für Krebserkrankungen, einer schlechten Behandlungsreaktion und einer
ungünstigen Prognose in Zusammenhang bringen. Es gibt bereits Therapieansätze, welche die
zirkadiane Uhr des Patienten bei der Behandlung von Tumoren einbeziehen, die sogenannte
Chronotherapie. Bisherige Studien konnten jedoch aufgrund der Tumorheterogenität, der
genetischen Komplexität und des fehlenden Wissens über die Beteiligung der zirkadianen Uhr
an spezifischen Stadien der Tumorprogression keine klaren Aussagen über die Anwendung und
den Erfolg von chronotherapeutischen Behandlungsansätzen liefern.
Ziel dieses Projekts war es, die Rolle der zirkadianen Uhr bei der Tumorentstehung
und -entwicklung zu untersuchen. Der Fokus lag dabei auf tumorspezifischen
Stoffwechselwegen. Die Rolle einer deregulierten zirkadianen Uhr wurde in einem in-vitro
Zellmodel untersucht. Die SW480 Zelllinie wurde aus einem Primärtumor isoliert und die
SW620 Zelllinie aus einer Lymphknotenmetastase desselben Patienten, sodass diese Zelllinien
zwei Tumorstadien repräsentieren und als Verlaufsmodel von kolorektalen Karzinomen genutzt
werden konnten. Die untersuchten Zelllinien zeigten deutliche Unterschiede in Bezug auf ihre
Uhr Phänotypen. Eine Zeitreihenanalyse beider Zelllinien auf Transkriptomebene offenbarte
eine globale Verschiebung von oszillierenden Genen mit einer Periode von 24 Stunden, sowie
deutliche Unterschiede in verschiedenen Stoffwechselwegen wie der Glykolyse und oxidativer
Phosphorylierung. Innerhalb dieser veränderten Stoffwechselwege wurden Kandidatengene
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identifiziert, die eine Rolle bei der Vermittlung von Uhr gesteuerten metabolischen
Veränderungen in der Tumorgenese spielen könnten. Darunter war auch das glykolytische Gen
Hkdc1. Um die Auswirkungen einer gestörten zirkadianen Uhr auf Genexpressions- und
Zellstoffwechselebene zu untersuchen, wurde eine Runterregulation des Uhr-Gens Bmal1
durchgeführt. Die Runterregulation von Bmal1 führte in SW480 Zellen zu einem
metastatischen Phänotyp, der stark dem von SW620 Wildtypzellen ähnelte, was durch eine
schnellere Proliferation, eine niedrigere Apoptoserate und einen hochenergetischen
Stoffwechselphänotyp ersichtlich war. Darüber hinaus führte die Runterregulation von Bmal1
zu einer Veränderung des metabolischen Phänotyps, zu Genexpressionsveränderungen in den
getesteten Kandidatengenen und zu einer modifizierten Antwort auf die Behandlung mit einem
Glykolyseinhibitor. Des Weiteren wurde das zeitabhängige Stoffwechselprofil durch die
Runterregulation von Bmal1 in den getesteten Zelllinien verändert. Ein Mechanismus der
uhrgesteuerten Reprogrammierung des Zellstoffwechsels während der Tumorgenese scheint
das gegenseitige Wechselspiel zwischen Bmal1 und dem glykolytischen Gen Hkdc1 zu sein.
Die Ergebnisse, die mit dem verwendeten Modellsystem gewonnen wurden, konnten teilweise
in zwei primären Zellsystemen bestätigt werden. Zum einen in primären Fibroblasten, die aus
normalem Kolon (NFs) und Kolonkarzinomzellen (CAFs) desselben Patienten isoliert wurden
und zum anderen in humanen Eileiterorganoiden. Co-Kultur Experimente mit NFs und CAFs
und Krebszelllinien verdeutlichten außerdem, dass die Zell-zu-Zell Kommunikation den Uhr
Phänotyp sowie den Zellstoffwechsel beeinflusst. Die in diesem Projekt erzielten Ergebnisse
unterstützen die postulierte Rolle von Bmal1 als Tumorsuppressor und verdeutlichen das
reziproke Wechselspiel zwischen der zirkadianen Uhr und dem Stoffwechsel von Krebszellen
und zeigen mögliche Auswirkungen einer deregulierten Uhr auf den Zellmetabolismus während
der Tumorentwicklung. Neue Verbindungen zwischen beiden Systemen, die in diesem Projekt
identifiziert wurden, könnten eine wichtige Rolle beim Verlauf von Darmkrebs und bei der
Reaktion auf Krebstherapien spielen.
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Introduction
1.1 The circadian clock – a powerful time-generating system
After a recovering night of sleep, we wake up in the morning, undergo our everyday routines, 
eat regular meals, and fall asleep in the evening to sleep during another night. A precise internal 
timing system is responsible for this rhythmic behaviour. To anticipate the light/dark cycles of 
the earth, most organisms evolved an internal timing system which adapts physiology and 
behaviour to the geophysical time – the circadian clock [3].
Figure 1: Organisation of the circadian timing system
The circadian timing system is organised in input pathways, clock mechanism and output pathways. In 
consequence of a deregulated clock, different pathologies may arise. Adapted from Albrecht [4]. 
The word circadian derives from the Latin words circa diem, which means about a day. As 
indicated by the name, the period of the circadian clock does not exactly measure 24 h. When 
organisms are kept under constant conditions such as constant light or temperature, 
physiological and behavioural cycles last only approximately 24 h. In humans, the free-running 
period length of the circadian clock is about 24.3 h [5]. Therefore, the circadian clock needs to 
be synchronised with the geophysical time periodically [6]. 
The circadian clock drives a large number of physiological and behavioural processes, which 
consequently follow a rhythm of around 24 h and allow an adaption to external daily rhythms 
[3]. Processes regulated by the circadian clock include cerebral activity, sleep-wake cycles, 
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metabolism, energy homeostasis, heart rate, blood pressure, body temperature, renal activity,
hormone secretion and cytokine secretion [3] (Figure 1).
Although circadian research started already hundreds of years ago, the research field of
chronobiology only came into focus during the last decades partly due to a new awareness of
the role of the circadian clock in health and disease. Already in 1729 evidence for the existence
of circadian rhythms was provided based on the research on leaf movements of the heliotrope
plant, Mimosa pudica, which persisted in constant darkness and suggested the existence of an
endogenous time-generating mechanism, in line with the geophysical time [7]. 200 years later,
the first evidence for a genetic basis of circadian rhythms was provided by the German biologist
Erwin Bünning, who reported that in common beans, the period lengths of the offspring ranged
between the extremes of period lengths of the parent generation [7]. The first clock gene Period
was identified in 1971 [8] and in 1990 the suprachiasmatic nucleus (SCN), a brain region
located in the hypothalamus, was identified as the central pacemaker of the circadian clock [9].
Since then 14 core-clock genes have been identified in mammals, which generate a complex
network of transcriptional and translational feedback loops, that drive oscillations in gene
expression and thereby have systemic effects at the organismic level that influence numerous
cellular processes [10]. The circadian clock can be described by several key characteristics. It
is self-sustained, meaning that the circadian rhythm persists in the absence of environmental
inputs. It is entrainable, meaning that the oscillator can be reset or phase-shifted by exposure to
different time cues (e.g. light) which allows the synchronisation to the light/dark cycle. It is
temperature-compensated, meaning that the circadian period only slightly changes under
different physiological temperatures. Another characteristic of the circadian clock is the ability
to transmit a time-signal to peripheral oscillators, thereby resetting them to the dominant
zeitgeber [11].
1.1.1 Architecture of the circadian timing system
The mammalian circadian clock is hierarchically organised in three main components: input
signalling pathways coming from the environment, the central pacemaker in the brain and
output signalling pathways with peripheral clocks in virtually every cell. The central pacemaker
is the SCN in the brain. It is built by two neuronal clusters and is located in the hypothalamus
above the optic chiasm [3] (Figure 2). Each neuron harbours a self-sustained, cell-autonomous
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molecular oscillator. The neurons of the SCN communicate with each other through synaptic
and paracrine mechanisms or gap junctions to maintain phase coherence between their clocks.
Additionally, peripheral clocks that have the same compositions as the ones in neurons can be
found in virtually every body cell [3].
Figure 2: Architecture of the circadian timing system
The circadian timing system consists of a central pacemaker, the suprachiasmatic nucleus in the brain and
peripheral clocks in virtually every cell. The phase of the SCN is synchronised to the geophysical time every day.
Peripheral clocks in all cells are synchronised by the SCN through systemic signals, including metabolites,
hormones, cytokines, body temperature, and neuronal signals from the peripheral nervous system. Adapted from
Bollinger and Schibler [3].
The SCN coordinates rest-activity cycles and synchronises peripheral clocks but is only able to
generate cycles of approximately, but not exactly 24 h. To generate cycles with a period of 24 h,
it must be synchronised daily by the photoperiod to stay in synchrony with the geophysical time
[3]. For this purpose, input signals are received from the environment and propagated via the
input pathway to the SCN. These signals are called zeitgebers or timing cues. They are used to
synchronise the pacemaker oscillations with the solar day-night cycle. Light is consequently
the strongest zeitgeber, but temperature, noise, food, exercise and melatonin can act as
zeitgebers as well [12], [13].
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More precisely, light signals are received by rhodopsin and conopsin expressing photoreceptor
cells and by intrinsically melanopsin expressing photosensitive ganglion cells in the inner layer
of the retina and transmitted to the SCN via the retinohypothalamic tract (RHT) [4]. Light
stimulation of the retina leads to neurotransmitter release, including glutamate, at the terminal
synapses of the RHT, and the signal is then propagated to the SCN [4]. In the SCN glutamate
activates NMDA-receptors, leading to a calcium influx in postsynaptic neurons. The influx
results in the phosphorylation and activation of several signalling pathways that induce
chromatin remodelling and the induction of immediate early genes and clock genes and the
activation of protein kinases and the cAMP response element binding protein (CREB), a
transcription factor which subsequently strongly activates Per transcription, one of the core-
clock genes [13], [14]. The rapid increase of PER inhibits its own transcription as well as the
transcription of Cry. As a result, the transcriptional rhythm of Per and Cry is reset and the clock
phase is changed [3], [15]. Upon signal reception, the SCN generates and sustains rhythms that
are subsequently diffused to the peripheral organs via output pathways such as the
glucocorticoid pathway [16]. The SCN also transmits its rhythmic information signals to other
cells within the brain and peripheral organs by other mechanisms, for example through
endocrine signals (e.g. cortisol), body temperature, cytokines (e.g. transforming growth
factor-β), metabolites (e.g. nicotinamide adenine dinucleotides) and neuronal signals from the
peripheral nervous system [6]. The transmission of rhythmic information through neural and
humoral output signals ultimately leads to the synchronisation of downstream physiology and
behaviour such as sleep/wake rhythms, body temperature and hormone secretion [17].
1.1.2 The core-clock network
Clock genes are defined as genes that interact with each other to make up an auto-regulatory
feedback loop, in which its activation and repression cycle takes about one day [4]. In mammals
a defined number of core-clock genes interacts with one another to generate oscillations in gene
expression. A sequential activation of genes leads to an auto-regulatory feedback loop with a
circadian periodicity [4]. The mammalian molecular core-clock network existing in the SCN
and peripheral cells is formed by a set of 14 genes interconnected in regulatory transcriptional
and translational feedback loops, building the core-clock network (CCN), that accounts for the
generation of circadian rhythms within individual cells [12]. These core-clock genes are
members of the Per (period), Cry (cryptochrome), Bmal (brain and muscle ARNT-like protein),
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Clock (circadian locomotor output cycles kaput, NPAS2 in neuronal tissue), Ror (RAR-related
orphan receptor) and Rev-Erb (nuclear receptor, reverse strand of ERBA) gene and protein
families [18].
During the early time of the circadian day, the CLOCK/ BMAL1 heterodimer complex is
formed and regulates the transcription of all other CCN genes, by binding to E-Box sequences
within the promoter regions of the target genes, Ror, Rev-Erb, Per and Cry [12], [18].
Figure 3: The circadian clock is a precise internal timing system
The circadian clock is present in a large variety of organisms from simple unicellular organisms to complex
mammalian systems. In mammals, a main pacemaker is located in the SCN, and peripheral clocks exist in each
organ which regulate the timing of physiological processes. Virtually every cell has its own clock that are
synchronised by signals received from the main pacemaker. At the cellular level the complex CLOCK/BMAL
regulates a set of positive (green) and negative (orange) interactions which form feedback-loops, thereby
generating oscillations in gene expression. Adapted from Fuhr et al. [11].
More detailed, the human circadian clock consists of two regulatory feedback loops, the
RORs/Bmal/REV-ERBs (RBR) loop and the PERs/CRYs (PC) loop [18]. In the PC feed-back
loop, the rhythmically active transcription factors BMAL1 and CLOCK form heterodimers in
the cytoplasm and enter the nucleus, where they bind to E-box sequences in promoters of the
clock genes Per (Period 1-3) and Cry(Cryptochrome 1-2), thereby activating the expression of
these genes [19]. PER and CRY proteins translocate into the cytoplasm where they form
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PER/CRY complexes which translocate back into the nucleus where they act as corepressor
complexes and inhibit CLOCK/BMAL- mediated transcription. They bind to CLOCK/BMAL1
heterodimers and when these complexes reach a certain concentration, they inhibit the activity
of CLOCK/BMAL1 complexes. Consequently, Per and Cry transcription is no longer activated,
the amounts of PER/CRY complexes decrease until they cannot longer interfere with
CLOCK/BMAL1 heterodimers and a new PER/CRY accumulation cycle begins [3]. Hence,
they inhibit their own transcription [19]. The second feed-back loop, the RBR loop is necessary
for the robustness of the system and seems to be able to generate rhythms by itself [18].
For robustness of the circadian system, both feedback loops need to be interconnected [20]
(Figure 3). In the RBR loop, BMAL1 and CLOCK regulate their own transcription. The
CLOCK/BMAL1 complex binds to E-boxes in the promoter regions of Rev-Erb α, β and Ror
α, β, γ, thereby activating their transcription. The nuclear receptors REV-ERB and ROR both
compete for ROR elements (RORE) in the Bmal1-promoter and have antagonistic effects on
Bmal1 thereby finetuning its expression. Binding of ROR activates Bmal1 expression, whereas
binding of REV-ERB represses Bmal1 expression. When activation prevails, the BMAL1
protein is produced which can again build heterodimers with CLOCK in the cytoplasm. These
heterodimers translocate to the nucleus and initiate the next cycle of gene expression of both
loops [19] (Figure 3).
Apart from the transcriptional network of core-clock genes, different posttranscriptional
modifications on clock proteins are necessary to maintain oscillations of 24 hours. These
include protein phosphorylation or acetylation as well as the histone acetyl transferase (HAT)
of CLOCK [3], [19]. The acetylation of histones supports the transcription of other clock genes
and makes the transcription machinery accessible, by opening condensed chromatin. The HAT
activity is for example important for the transcriptional activation of Per and Cry, which are in
turn key players for the maintenance of endogenous circadian rhythms [19].
1.1.3 The extended core-clock network
The CCN regulates the transcription of a large group of target genes, the so-called clock-
controlled genes (CCG). To define an extended core-clock network (ECCN) a text-mining
approach was used by our group. The ECCN contains 14 core-clock genes as well as their direct
interacting target genes leading to a total number of 43 genes in the ECCN. Members of the
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ECCN belong to pathways involved in cancer, cell cycle, immune defence, metabolism,
xenobiotic detoxification and drug response [10]. Using different bioinformatic approaches, the
ECCN was extended by a set of 118 genes that interact with the ECCN, leading to the network
of circadian-regulated genes (NCRG), containing 161 genes in total [10], [21]. Members of the
NCRG are involved in diverse biological processes, such as immune defence, apoptosis and
metabolism, as well as the regulation of several miRNAs [21]. The deregulation of genes
belonging to the NCRG is associated with cancer development and progression [22] (Figure 4).
Figure 4: The network of circadian-regulated genes
Boxes represent individual genes. Connecting lines indicate interactions that are known (grey), predicted by
co-expression (blue), text-mining (green) or by both (red). The CCN (orange), ECCN (green) and NCRG (purple)
are indicated by rectangles. Adapted from Lehmann et al. [21].
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Overall, about 10% of the genome is under circadian control [12], although recent studies in
mice suggest that up to 50% of all genes show circadian oscillations in at least one tissue [23].
The circadian control of gene expression is highly tissue specific and only a small number of
oscillating genes is present in different tissues of an organism [13]. Based on the large number
of oscillating genes, it comes as no surprise that the circadian clock is involved in the regulation
of a large number of processes such as the immune system [24], the metabolism of several
metabolites [25], bone formation [26], sleep-awake cycles [27], memory consolidation [28],
blood pressure, body temperature, cell division and proliferation [29], hormone regulation [30],
apoptosis and senescence [31]. Therefore, in consequence of a deregulated clock several
pathologies may arise.
1.2 The circadian clock in disease
As described above, the circadian clock regulates several biological pathways and processes.
Unsurprisingly, a deregulated clock is involved in the onset of many diseases. Although it is
still not completely understood how the circadian clock gets disrupted, night shift work,
melatonin release, artificial light, diet and molecular deregulations or genetic disorders based
on clock genes and clock-regulated genes have been identified as potential causes [32]. Altered
circadian rhythms induced by clock gene knockdown (KD) lead to perturbations that have
effects on the cellular and the organismic level [33], [34]. Pathologies that were already shown
to be related with disrupted circadian rhythms include sleeping disorders (familial advanced
sleep-phase syndrome (FASPS), sleep problems in the elderly) [18], [27], neuropsychiatric
disturbances (seasonal affective disorder (SAD), bipolar disorders) [3], [18], metabolic diseases
(diabetes and obesity) [35], [36], cardiovascular disorders [32] and cancer development [37].
Nonetheless, the mechanisms by which a disrupted clock leads to disease remain poorly
understood. Furthermore, in many cases it is difficult to discriminate between direct effects of
circadian clock disruption and a deregulated clock as a result of a certain disease.
1.2.1 The circadian clock in cancer
One connection under intensive study is the interplay between the circadian clock and cancer.
The link between a disrupted clock and cancer was strengthened by several publications [37],
[38] and shift work that involves circadian disruption was listed as a probable carcinogen by
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the World Health Organization’s International Agency for Research on Cancer (IARC) in 2007
[39]. Cancer types that were connected to night shift work by epidemiological studies include
colorectal cancer [40], breast cancer [41], prostate cancer [42], endometrial cancer [43] and
non-Hodgkin`s lymphoma [44]. The reason for increased cancer risk among night shift workers
might be disrupted neuroendocrine function due to frequent phase shifts of external cues. This
is supported by the fact that blind people display a lower cancer risk, probably because they are
dependent on the endogenous clock without environmental light stimuli [39].
The dysregulation of core-clock genes can occur on different levels, including promoter
methylation-induced epigenetic silencing, transcriptional and post-transcriptional
modifications and structural variations of clock proteins [39]. Clock gene mutations were
observed in different cancer types and as the circadian clock regulates cell cycle, DNA damage
response and metabolism, disrupted circadian rhythms may lead to a deregulation of the
beforementioned processes, eventually leading to tumourigenesis [37]. As an example, a study
found the expression of Per genes to be disrupted in 95% of the examined female patients with
breast cancer [45]. Various in vitro studies point to a tumour suppressor role of the Per family,
as its overexpression leads to growth inhibition and apoptosis in different cancer types
[45]-[47]. Furthermore, Per2 expression levels are downregulated in lymphoma and acute
myeloid leukaemia cell lines [49]. Moreover, low levels of Per1 and Per2 expression are linked
to poor prognosis in gastric cancer [50]. Other core-clock genes that were shown to be disrupted
in different cancer types include Bmal1, Clock, Npas2 and Cry genes [37], [39]. Clock was
shown to be involved in colorectal cancer, glioma and breast cancer [50]. These findings suggest
a role of the circadian clock in cancer development and progression and point to a tumour
suppressor role for several core-clock genes. Various studies suggest the possibility that not
only one but several members of the circadian clock might be deregulated in different cancer
types [39]. Depending on the experimental model used, the results gained from studies on the
circadian clock and tumourigenesis are diverse. Furthermore, it partly remains unclear whether
the impact of the circadian clock disruption in cancer development is directly due to the
disruption of circadian rhythms itself or indirectly due to other regulatory features of core-clock
genes such as regulation of the cell cycle, DNA damage responses and cellular metabolism [37].
Clock gene disruption leads to an activation of numerous oncogenic signalling pathways by
activation of NF-κB, c-MYC, p53 and other elements. Additionally, a disrupted clock affects
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several pathways involved in carcinogenesis. These include cell proliferation, metabolism,
senescence, apoptosis, DNA damage response, DNA repair and replication and drug resistance
[39]. This is underlined by the fact that a disrupted clock particularly increases the risk for
tumours in systems that need constant cell proliferation for proper function, namely the immune
system, the reproductive system and the digestive system [39], [51]. Another way by which the
circadian clock is involved in tumourigenesis is via the regulation of the cell cycle. The
circadian clock regulates the cell cycle at the G1/S and the G2/M checkpoints. Furthermore,
several cell cycle-regulating genes are under circadian control, for example Wee1, c-Myc,
Cyclin-D1, p20 and p21 [50], [52].
Although many studies connect the circadian clock to cancer, it is still debatable if a deregulated
clock rather acts as a cause or consequence of cancer development. Furthermore, when studying
the role of the circadian clock in cancer development and progression, it needs to be taken into
account that in vitro experiments are not able to completely represent the complexity of
circadian rhythms in animals [53].
1.2.1.1 The circadian clock in colorectal cancer
Different processes in the gastrointestinal tract display circadian rhythms, including motility,
activity of mucosal enzymes and proliferation rate of different cell types. Therefore, disrupted
circadian rhythms and gastrointestinal diseases such as cancer are likely to be tightly connected
and a deregulated clock has been implicated in colorectal cancer (CRC)[54]. Colorectal cancer
is the third most common cancer and a main cause of death in western societies [55]. The major
cause of death related with CRC is the development of lung and liver metastases. Most of the
patients with metastatic CRC remain incurable and have a median survival of two years [55].
The results of multiple studies suggest a role for the circadian clock in CRC. A study with
colorectal cancer cell lines showed that Bmal1 overexpression inhibits cell proliferation and
improves oxaliplatin sensitivity in colorectal cancer [56]. Bmal1-knockdown studies in murine
colon cancer cells revealed reduced expression levels of Per1, Per2, Per3, Wee1 and tp53,
decreased apoptosis and decreased cisplatin-induced DNA damage leading to enhanced tumour
growth [54]. The circadian rhythmicity in the expression profiles of Per1, Per2, Rev-erbα and
Dbp were reduced in chemically induced primary colorectal tumours as compared to normal
colon and rhythmicity in Bmal1 expression was completely abolished. While Bmal1
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rhythmicity was also abolished in the surrounding colon tissue, the circadian expression profiles
of Per1, Per2, Rev-erbα and Dbp were still existent [57]. Per1, Per2, Per3 and Cry2 were
shown to be significantly downregulated in colorectal tumours and lower survival rates could
be observed for colorectal cancers with low Per1 and Per3 expression [58]. A recent study using
droplet digital PCR to study the expression of clock genes in human colorectal cancer reports
that abnormal expression levels of Per1 and Per3 may be used as diagnostic and prognostic
markers for colorectal cancer. Decreased levels of Per1 and Per3 were reported, however
Bmal1, Per2 and Clock expression were not changed [59]. Apart from that, other contradicting
studies regarding the expression of clock genes exist that report upregulated clock gene
expression in colorectal cancer, namely Clock1 and Bmal1 and Cry [60].
In summary, findings to date point to a role of the circadian clock in tumour suppression and
the deregulation of the circadian system seems to play a role in cancer development and
progression, as well as in treatment response and tolerability [3]. Nevertheless, it is difficult to
interpret the partially contradicting results gained from animal models, human cell lines and
patient samples, because the effects of a deregulated clock depend on the experimental model
used. Additionally, as already mentioned, it is still controversial whether the impact of the
circadian clock disruption in cancer development is due to the disruption of circadian rhythms
itself or due to other regulatory features of core-clock genes such as regulation of the cell cycle,
DNA damage responses and cellular metabolism [37].
1.2.1.2 Fundamentals of cancer metabolism
Metabolism includes all biochemical reactions that convert molecules to generate energy and
structural building blocks [61]. Metabolic activity is adapted to respond to external cues which
is crucial in a constantly changing environment. Discrepancies between metabolic requirements
and the metabolic capacity of an organism are linked to a wide variety of pathologies, including
metabolic syndrome, type 2 diabetes and cancer [61]. Cancer cells must fulfil a certain number
of requirements that are essential for cell survival and proliferation. These include the
generation of energy for biochemical reactions, the generation of biochemical components via
biosynthetic pathways that are essential for cell division and growth and the maintenance of
biochemical homeostasis. Besides the well-known hallmarks of cancer [62], cells need to fulfil
these requirements to develop into malignant tumour cells [63].
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In addition to the above described connection between the circadian clock and cancer,
tumourigenesis is also linked to imbalanced metabolic homeostasis and to the deregulation of
different metabolic pathways and specialised altered metabolic pathways may contribute to
tumourigenesis [64]. Cancer cells show a vast number of metabolic alterations and specific
metabolic pathways are likely to play a role in cell transformation. Metabolic alterations
associated with tumourigenesis occur on all stages of cell-metabolite interaction. Consequently,
the metabolic influx is affected, and allows the acquisition of necessary nutrients. The way that
nutrients are allocated to different metabolic pathways contributing to tumourigenesis is altered.
Metabolic alterations lead to long-term effects on cellular fate, for example changes in tumour
cell differentiation or components of the tumour microenvironment [64].
Figure 5: The emerging hallmarks of cancer metabolism
Based on metabolic alterations that occur in cancer cells, six hallmarks of cancer metabolism were defined.
Namely, a deregulated uptake of glucose and amino acids, use of opportunistic modes of nutrient acquisition, use
of glycolysis/TCA cycle intermediates for biosynthesis and NADPH production, increased demand for nitrogen,
alterations in metabolite-driven gene regulation and metabolic interactions with the microenvironment Adapted
from Pavlova and Thompson [64].
As a continuation of the well-known hallmarks of cancer [62], six metabolic alterations in
cancer cells have been recently defined as the emerging hallmarks of cancer metabolism [64].
A deregulated uptake of glucose and amino acids, the use of opportunistic modes of nutrient
acquisition, the use of glycolysis and the tricarboxylic acid (TCA) cycle intermediates for
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biosynthesis and NADPH production, an increased demand for nitrogen, alterations in
metabolite-driven gene regulation, and metabolic interactions with the microenvironment [64]
(Figure 5). Tumours might show all six hallmarks or only some of them. These hallmarks can
be used to better classify individual tumour and improve treatment [64].
One metabolic characteristic of many cancer cells is the preservation of high rates of glycolysis
and concurrent oxidative phosphorylation to supply other pathways that generate
macromolecules to fulfil metabolic demands of proliferating cells [65], [66]. In the glycolytic
pathway, glucose enters the cell and is converted into pyruvate through a cascade of enzymatic
reactions. Pyruvate can then either enter the TCA cycle or be processed to lactate. The TCA
cycle is the link between glycolysis and oxidative phosphorylation. In normal cells, most of the
pyruvate is processed to acetyl coenzyme A (acetyl-CoA) which enters the TCA cycle and is
used for ATP production via the electron transport chain [67]. In cancer, an altered glucose
metabolism is required to fulfil the anabolic demands of tumour cells [65]. Although enhanced
aerobic glycolysis has been used as a marker to distinguish cancer cells from normal cells
already decades ago, an elevated glucose metabolism has only very recently been defined as
one of the hallmarks of cancer [64]. Aerobic glycolysis also known as the Warburg effect is an
adaptation of cancer cells to the nutrient-poor tumour microenvironment and helps cancer cells
to optimise nutrient uptake and metabolisation to macromolecules needed for cell growth and
proliferation [68]. Already in 1956, Otto Warburg observed that cells process glucose to CO2
and H2O via low rates of glycolysis and subsequent oxidation of pyruvate in the TCA cycle in
mitochondria. Though, cancer cells mainly use glucose for energy production by high rates of
glycolysis and subsequently by lactic acid fermentation in the cytosol even in the presence of
oxygen. Latter studies discovered that cancer cells show a variety of metabolic abnormalities
and that oncoproteins as well as tumour suppressors influence the switch between aerobic
glycolysis and the use of the TCA cycle to generate ATP. Still, the question remains, why cells
use glycolysis as the preferred process which brings less energy instead of oxidative
phosphorylation. Processing glucose via glycolysis produces two ATP molecules, whereas the
processing by oxidative phosphorylation produces up to 36 ATP molecules [67]. The high rates
of aerobic glycolysis lead to high levels of reactive oxygen species (ROS), a major cause of
DNA damage promoting cancer and aging [39], but on the other hand glucose supplies other
metabolic pathways with building blocks that are needed for the synthesis of lipids, nucleic
acids, proteins and complex sugars, all needed for fast growing and dividing tumour cells [67].
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Many members of the glycolytic pathway are associated with cancer, including glucose
transporters, hexokinase 2 (HK2) and the pyruvate kinase PKM2 [67] (Figure 6). Furthermore,
many oncogenic signalling pathways target metabolic pathways, thereby influencing tumour
cell metabolism. For example, the oncogenic transcription factor MYC regulates the expression
of several metabolic genes including PKM2, the predominant pyruvate kinase in cancer, the
glucose transporter GLUT1, and the hexokinase HK2 [67]. Another example is the PI3K/AKT
pathway. AKT leads to an upregulation of glucose transporter expression and induces glycolytic
enzyme activity by phosphorylation of HK2, thereby promoting a glycolytic phenotype in
cancer cells [67]. Besides the characteristic elevated use and uptake of glucose of many tumour
cells, the uptake and use of acetate was described more recently as well. Acetate can be used
for energy production and as a component for lipid biosynthesis. Additionally, glutamine as a
substrate for energy production and glutathione synthesis came into focus very recently as
elevated glutamine metabolism was shown in cancer cells [63].
Figure 6: Targeting cancer metabolism
Metabolic pathways, key pathway interactions and enzymes (blue boxes) are shown together with key metabolic
endpoints (purple boxes) necessary for proliferation and survival (biosynthetic intermediates and NADPH) as well
as compounds targeting cancer metabolism (red circles). Adapted from Jones and Schulze [67].
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1.2.2 Targeting cancer metabolism
Altered metabolic demands of proliferating tumour cells provide potential targets for new
treatment strategies. Targeting metabolism in general is difficult and likely to cause severe side
effects in patients because of the targeting of other fast-dividing cells in the bone marrow, hair
follicles or intestinal crypts [69]. Although metabolic alterations of tumour cells were already
observed a century ago, studies on cancer metabolism only came into renewed focus again
during the last years. Concomitant, different molecular targets within metabolic pathways were
tested with respect to their anticancer effects but to date most of them are still in preclinical
development [70], [71]. The use of huge amounts of glucose and the metabolisation into lactate
even in the presence of oxygen, known as aerobic glycolysis or Warburg effect, is a
characteristic that distinguishes cancer cells from normal cells. Therefore, targeting enhanced
glycolysis is a potential target for cancer therapy and research is made in this direction as well
as the attempt to inhibit lactate production and excretion [69]. An example for targeting
glycolysis in cancer therapy is the use of 2-deoxyglucose (2-DG), which is phosphorylated by
hexokinase to 2-deoxyglucose-6-phosphate and cannot be further metabolised. Consequently,
it accumulates and competitively inhibits hexokinase, therefore slowing down glucose uptake
[69]. Although anti-proliferative effects of 2-DG were shown by several studies, its use in
cancer therapy is limited due to severe side effects when used in effective doses [69]. Other
agents tested include 3-Bromopyruvate (3-BrPa) that blocks the glycolytic flux by targeting
HK2 [67]. 3-BrPa diminishes ATP reserves in the cell which is seen as a key factor for
chemoresistance in cancer cells [70]. Another tested metabolism-targeting anticancer drug is
oxythiamine that blocks the non-oxidative pentose phosphate pathway by targeting
Transketolase[67]. Other potential targets are glucose transporters as the first rate-limiting step
in glucose metabolism. WZB117 is a GLUT1 inhibitor which blocks glucose uptake and
consequently decreases ATP levels and glycolytic enzyme leading to reduced glycolysis and
cellular growth [70], [72]. Furthermore WZB117 has been found to repress tumour growth in
nude mice [72]. WZB117 was also used in combination with 5-Fluorouracil (5-Fu) in colon
cells to overcome 5-Fu resistance [73] (Figure 6).
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1.3 Circadian regulation of metabolism – an impact in cancer?
The circadian clock regulates metabolic homeostasis and tight links between the circadian clock
and the regulation of metabolism have been described previously. Time course microarray
studies on different mammalian tissues revealed that a large proportion of the transcriptome
(3%-20%) showed rhythmic expression in these tissues [74]. Many of the oscillating genes are
members of biosynthetic and metabolic processes, such as cholesterol and lipid metabolism,
glycolysis, gluconeogenesis, oxidative phosphorylation and detoxification, suggesting a tight
control of metabolic pathways by the circadian clock. Noteworthy, in many cases, the
rate-limiting enzymes were under circadian control [74], [75]. A publication from our group
revealed a connection between the circadian clock and metabolism as well as detoxification
pathways [76]. Furthermore, a reciprocal interplay of the circadian clock and mitochondrial
respiratory activity has been shown recently [77], [78]. One essential link between the circadian
clock and metabolism are feeding/fasting cycles. Peripheral clocks can be entrained by food
intake and feeding time changes have consequences on cell metabolism [79].
One way how the circadian clock regulates metabolic homeostasis is by targeting key metabolic
genes that have functions in nutrient uptake, energy storage, mitochondria biosynthesis and
intracellular redox levels, including genes that are associated with the Warburg effect, namely
glucose-6-phosphatase, pyruvate kinase and glucose transporter 2 [39]. Several
metabolism-associated genes show circadian expression patterns, for example genes encoding
for the glucagon receptor, glucokinase, glucagon, glucose transporter 2, glucose-6-phosphatase,
pyruvate kinase, pyruvate dehydrogenase and HMG-CoA reductase [37], [80]. Furthermore,
numerous metabolites have been shown to oscillate in a circadian manner including glucose,
lipids and fatty acids with peaking levels during wakefulness and activity [61], [80], [81]. In
nocturnal rodents, amino acid and xenobiotic metabolites peak during the night, while
carbohydrate, lipid and nucleotide metabolites peak during the daily resting period [82]. These
observations strengthen the role of the circadian clock as a regulator of metabolism.
While the circadian clock regulates multiple metabolic pathways, in turn, metabolite
availability and feeding behaviour regulate the circadian clock, indicating a bidirectional
interaction [37]. This reciprocal interplay provides the circadian clock with the required
flexibility to adjust physiology to the metabolic requirements of cells, tissues and the whole
organism [61]. Interactions between small metabolites and their cellular binding partners seem
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to be one way how the feedback regulation works. So-called metabolic sensor proteins perceive
fluctuations in nutrient, energy and redox levels and consequently adjust gene expression.
Furthermore, systemic metabolite levels act as peripheral Zeitgebers. Circadian-regulated
metabolites such as glucose [83], amino acids [84], insulin [85], glucagon [86] and
glucocorticoids [87] also have Zeitgeber capacity. Different feedback mechanisms exist to
adjust the circadian clock to the metabolic state of a cell, including various metabolic genes
such as members of insulin and folate metabolism that affect the core-clock oscillator [61]. The
strong interconnection between the circadian clock and metabolism is reinforced by the
observation that circadian disruption due to environmental factors as well as genetic aberrations
can lead to metabolic disorders [80]. As an example, night shift work is associated with
cardiovascular disease, increased body mass, and elevated plasma glucose and lipid levels [80].
Animal experiments were performed to better understand the mechanisms of internal
synchronisation and revealed that plasma glucose rhythmicity was lost in rodents that “worked”
during their sleep phase and the levels of serum triglycerides was reversed with peaks during
the sleep phase [88]. Furthermore, evidence suggests that a deregulated clock can promote the
development of metabolic disorders, including hyperlipidaemia, fatty liver, obesity, type 2
diabetes mellitus and some types of cancer [89]. For example, animals with Clock or Bmal1
knockout have been shown to develop hyperglycaemia, glucose intolerance and ultimately
obesity and metabolic syndrome [61].
Besides their direct role in the core-clock network, several core-clock genes also have reported
functions associated with metabolic processes. PER2 does not only bind to REV-ERBα but also
to the nuclear receptors PPARα and PPARγ, thereby controlling metabolic processes in white
adipose and liver tissue [80]. Bmal1 knockout mice do not only show complete abolishment of
circadian rhythms, they also display a severe metabolic phenotype, namely impaired glucose
metabolism as well as insulin hypersensitivity [90]. Furthermore, several tissues in these
animals show an age-dependent size reduction in accordance with elevated ROS levels [91].
Additionally, glucose and triglyceride levels are not oscillating, and gluconeogenesis is
impaired in Bmal1-deficient mice [92]. Although Clock- and Per2-mutant mice show metabolic
alterations in several studies, inconsistent findings were reported probably based on differences
in the specific type of  mutation and the genetic background [90].
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The interplay between the circadian clock and cell metabolism has already thoroughly been
studied and the connection between the circadian clock, metabolism and cancer came more and
more into focus during the last years. However, the role of the circadian clock in cancer
metabolism is still an area of active investigation. Studies in mice have shown that carrying
mutations in individual clock genes lead to a higher susceptibility to lymphoma. Additionally,
these mutant mice have increased rates of lymphoma and hepatocellular carcinoma after
irradiation [93]. Furthermore, the MYC oncogene was reported to be involved in the regulation
of rhythmic metabolism in cultured U2OS cells, further strengthening the connection between
metabolism, cancer and the circadian clock [93]. Based on the knowledge gained so far and
given the fundamental role of the circadian clock in regulating metabolism, it is very likely that
the circadian clock is involved in the regulation of metabolic processes also in the context of
cancer. Hence, tumourigenesis, the circadian clock and metabolism seem to be tightly
interconnected. Although the reasons and the role for metabolic disruption in tumourigenesis
are not fully understood, there is increasing evidence, that the circadian clock plays a crucial
role [37]. Findings to date point to a role for the circadian clock in energy homeostasis and
metabolism. As cancer cells consume high rates of energy, the loss of circadian metabolic
regulation may lead to uncontrolled proliferation in cancer cells [50]. However detailed
knowledge about the mechanisms by which the circadian clock regulates cellular metabolism
in cancer is still missing. In addition to the influence of the circadian clock on metabolic
pathways, drug response pathways that influence pharmacokinetics and pharmacodynamics are
under circadian control as well [94]. Consequently, improved treatment response and
tolerability could be achieved by chronomodulated chemotherapy [95] and time-dependent
radiotherapy scheduling [96]–[99].
1.4 Chronotherapy
In addition to the promotion of tumourigenesis, weak response to anticancer treatments and
early mortality were reported in cancer patients with disturbed circadian rhythms, as compared
to patients with a normal circadian phenotype [39]. Daily rhythms in cancer cell proliferation,
drug metabolism, toxicity and treatment efficacy are the basis for the scheduled timing of drug
administration over a 24 h period, the so-called chronotherapy [54]. Based on the current
knowledge about the circadian clock and its role in cancer development and progression,
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chronotherapy was established as a new treatment strategy which considers the patient’s
circadian clock and the timing for treatment. The administration of anticancer drugs in a defined
circadian time window has been postulated to achieve optimal pharmacokinetic and therapeutic
effects [100]. Chronopharmacology considers the dependency of drugs on circadian rhythms
and investigates the circadian variation of chronotoxicity, chronopharmacokinetics and
chronopharmacodynamics of a drug [101]. Time-dependent drug administration should
improve the efficacy and tolerability of a drug, while toxicity and side effects should be
decreased. These effects may be mostly due to the circadian control of metabolic processes,
which strongly influence the pharmacokinetics and pharmacodynamics of anticancer drugs
[11]. Due to the metabolic control, the circadian clock impacts the optimal dosing time of many
drugs and oscillations in drug absorption, distribution, metabolism, and excretion (ADME)
account for dosing-time dependent efficacy and safety of anticancer drugs [101].
Chronotherapy schedules were already applied in radiotherapy as well as in chemotherapy.
A chronomodulated chemotherapy protocol prolonged the survival of men with colorectal
cancer by 3.3 months [95]. However, this effect could not be observed in women, showing the
need for patient and gender specific chronotherapeutic protocols [95]. Additionally,
chronotherapy increased the survival time of children with acute lymphoblastic leukaemia
(ALL) [102]. The timing of radiotherapy was tested in mouse experiments where morning
radiation caused more hair loss than evening radiation [96]. Secondary effects of radiotherapy
in humans seem to be day-time dependent as well, but only very few rather contradictory studies
exist to date [97], [98].
Another approach that considers the patient’s circadian clock is the determination of different
circadian biomarkers such as melatonin and cortisol levels, body temperature and rest-activity
rhythms. These are often disrupted in cancer patients and can have effects like fatigue, sleep
problems and decreased overall survival [103]. Therapeutic approaches in this direction have
the aim to stabilise the disrupted circadian timing system of the patient. These include the
regulation of the sleep-wake cycle, physical activity, light therapy, timed meals and
synchronisation through chronobiotic drugs [103]. Although some studies already exist, clear
results regarding the effects of chronotherapy are still rare, probably because of the
heterogeneity of different tumour types and the individual circadian profile of the patients.
Studies in mice showed that tolerability and efficacy of a given drug are affected by the
circadian time, therefore temporal coupling of drug administration and host circadian rhythm
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may lead to best therapy results [39]. Chronotherapy is more beneficial for patients with an
intact circadian clock, as can be seen by less drug toxicity, better tumour response and decreased
frequency of tumour metastasis [39].
Most chemotherapeutics are toxic for all proliferating cells, independent of whether they are
healthy cells or cancer cells. Optimal timing for anticancer treatment therefore considers
differences in the circadian phase between normal and cancer cells in order to define the best
treatment time. For a variety of anticancer drugs, including 5-fluorouracil, oxaliplatin and
irinotecan time-dependent effects on treatment efficacy, tolerability and pharmacokinetics have
been shown [101], [104]. It seems as though the clock can affect both the efficacy of cancer
treatment by modulating the pharmacokinetics and pharmacodynamics of chemotherapeutic
drugs as well as the activity of the DNA repair enzymes that repair the DNA damage caused by
anticancer drugs [105]. A recent study on clock gene and circadian phenotype alterations in
different human cancers revealed strong connections between clock genes and clinically
actionable genes, highlighting the clinical value of circadian timing in cancer chronotherapy
[106].
Besides the role of the circadian clock in treatment of cancer, anticancer drugs can likewise
interfere with the circadian clock and may induce disruption of rest-activity cycles, body
temperature or the circadian clock itself [104]. During the last years, effort has been made to
identify small molecules that act as modulators of the circadian clock by affecting the period,
phase or amplitude of circadian oscillations. Possible targets for these small-molecules are core-
clock proteins, nuclear hormone receptors, and clock-related kinases [100]. Small molecules
are either identified by phenotype-based circadian screenings or they are developed against
known clock proteins [107]. The use of small molecules can modify circadian drug metabolism
and the response to existing therapeutics and might potentially be used in chronotherapy to
modulate the patient´s circadian clock prior to anticancer treatment [100]. Although
chronotherapy and the use of clock modulators represent a new generation of anticancer
treatment, the research field of chronotherapy is still at its beginning and needs further
improvement, partly shown by the fact that long-term survival is not increased in patients with
metastasising cancer [39]. Detailed insights into the mechanisms of chronotherapy and its
effects on tumour biology and host physiology may contribute to improved chronotherapeutic
anticancer treatment.
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1.5 Aims of this thesis
Studies on the circadian regulation of metabolic and cancer-related pathways came into
increased focus during the last years. Still, mechanisms by which the circadian clock regulates
metabolism in cancer remain subject of ongoing research. The general aim of this project was
to better understand the role of circadian clock in the control of tumour metabolism and drug
response. SW480 and SW620 cells, derived from a primary tumour and a metastasis of the same
patient, were used as a cellular model for colorectal cancer progression. The disruption of a
core-clock gene should help to investigate time-dependent metabolic phenotype rewiring in
both cell lines, as well as changes in treatment response. Results of this project should
contribute to elucidate the interplay between metabolic genes and the circadian clock and
identify novel connections between both systems that may play a pivotal role in colorectal
cancer progression and response to therapy. The hypothesis underlying this project was that
tumour stage-specific alterations of the circadian clock exist, leading to a more metastatic
phenotype, and that these alterations have impact on cancer cell metabolism and treatment
response. An overview of the workflow of this study is represented in Figure 7.
Figure 7: Experimental workflow
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The specific aims of this project were:
1. Evaluation of the diversity of clock phenotypes in cancer cell lines and primary cell
models by using several colorectal cancer cell lines as well as primary fibroblasts
isolated from normal colon and colon adenocarcinoma of the same patient and non-
cancerous human fallopian tube organoids
2. Analysis of the consequences of a deregulated clock on the transcriptome level by using
SW480 and SW620 cells as a model of colorectal cancer progression. Based on the
results, circadian-regulated metabolic pathways and putative clock-regulated metabolic
candidate genes should be identified and used for further experiments.
3. Investigation of the effects of a deregulated clock on tumour metabolism by introducing
a knockdown of the core-clock gene Bmal1 in SW480 and SW620 cells. Additionally,
NFs, CAFs and organoids should be used for supporting experiments.
4. Analysis of the effect of metabolic changes on the circadian clock by introducing a
knockdown of the glycolytic gene Hkdc1 in SW480 and SW620 cells.
5. Evaluation of the consequences of a deregulated clock on treatment response by treating
SW480 and SW620 control and shBmal1 cells with the glycolysis inhibitor WZB117.
Materials and methods
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Materials and methods
2.1 Materials
Table 2: Reagents, chemicals and media
Reagent Company
100% ethanol absolute pure Applichem
2-Mercaptoethanol Sigma-Aldrich
2-Propanol VWR
Activated charcoal Sigma-Aldrich
Agarose Thermo Fisher scientific
Ampicillin Carl Roth
Antibiotic-Antimycotic (100x) Gibco
Aquabator clean Applichem
Blasticidin S HCL, powder Life technologies
Bromopyruvic acid Sigma-Aldrich
Calciumchlorid Dihydrat Carl Roth
Carbenicillin Applichem
CellMask Orange Plasma Membrane Stain Thermo Fisher
D-(+)-Glucose Sigma
Dexamethasone Sigma-Aldrich
D-Luciferin PJK
DMEM high glucose with L-Glutamine Life technologies
DMEM high glucose, no phenol red Gibco/Life technologies
DMEM low glucose without L-Glutamine Lonza
DMEM/F12 Invitrogen
DMSO Applichem
dNTP mix 10mM Thermo scientific
FBS standard Life technologies
Forskolin Sigma
G418 (Geneticin) Gibco
Gelatin Sigma-Aldrich
GelRed Nucleic Acid Gel Stain, 10,000X in water Biotium
Glucose Carl Roth
GlutaMAX Invitrogen
Glycerol Applichem
HEPES, 1M, pH 7.2-7.5 Life technologies
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HiPerFect transfection reagent Qiagen
Human EGF Invitrogen
Human FGF-10 Reprotech
Human noggin Reprotech
Hyclone FBS GE Healthcare
Hydrochloric acid solution Sigma
Hygromycin B Gibco
LB Agar Carl Roth
LB Medium Carl Roth
L-Glutamine (200mM) Thermo Fisher scientific
Lipofectamine R 2000 Transfection Reagent Thermo Fisher scientific
Matrigel Corning
MEM Non-Essential Amino Acids Solution Gibco
MEM α without nucleosides Gibco
MEM α, nucleosides, no phenol red Gibco
M-MLV reverse transcriptase Life technologies
M-MLV reverse transcriptase buffer Life technologies
MycoAlert Plus buffer Lonza
N2 Invitrogen
Nicotinamide Sigma
Opti-MEM R I reduced serum medium Gibco
Oxaliplatin Cayman Chemical
PBS 10x Life technologies
Penicillin-Streptomycin 100x Life technologies
Polybrene (Hexadimethrine bromide) Sigma
Potassium cyanide Sigma-Aldrich
Propidium iodide Sigma
Protamine sulfate salt from salmon Sigma
Puromycin Dihydrochloride Gibco
Random hexamers Eurofins MWG Operon
RiboLock RNase Inhibitor (40 U/µL) Thermo Fisher scientific
Ribonuclease A from bovine pancreas Sigma
ROCK inhibitor Sigma
RPMI without L-Glutamine Biochrom
RPMI, no phenol red Gibco
RSPO1 Housemade stocks
Seahorse XF Base Medium Agilent
SiR-DNA labeling Spirochrome
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Table 3: Instruments and software
Instrument/software Company
CFX connect Real-time PCR detection system Biorad
CFX manager Biorad
Chronostar [108]
ConsensusPathDB http://cpdb.molgen.mpg.de
CSU-X spinning disc confocal microscope Nikon
GraphPad Prism 6 GraphPad software
ImageJ Fiji https://imagej.net
Lumicycle 32 Actimetrics
Lumicycle analysis Actimetrics
LUNA automated cell counter Logos Biosystems
NanoDrop 1000 Thermo Fisher scientific
R https://www.r-project.org/
Seahorse wave software Agilent
Seahorse XFe96 analyser Agilent
Victor multilabel plate reader PerkinElmer
Sodium pyruvate 100mM Gibco
SsoAdvanced Universal SYBR Green Bio-Rad
ssRNA Ladder NEB
TE Buffer, 1X, Molecular Biology Grade Promega
Technical ethanol Carl Roth
TGF-β RI Kinase Inhibitor IV Calbiochem
Triton X-100 Sigma
Trizol Thermo Fisher scientific
Trypan blue 0.4% solution Biozym
Tryple Express Gibco
Ultraglutamine I 200mM Lonza
Wnt3a Housemade stocks
WZB-117 Sigma-Aldrich
X-tremeGENE TM HP DNA Transfection Reagent Roche
Yeast extract Carl Roth
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Table 4: Consumables
Consumable Company
µ-Slide 8 Well Glass Bottom ibidi
0.1ml combitips advanced Eppendorf
0.2µm filter Sarstedt
0.2ml PCR tubes, individual attached caps Kisker
0.45µm filter Sarstedt
0.5ml combitips advanced Eppendorf
0.5ml tubes Sarstedt
1.5ml tubes Eppendorf
10µl filter tips Sarstedt
100µl filter tips Sarstedt
1000µl filter tips Sarstedt
10ml combitips advanced Eppendorf
10ml serological pipettes Sarstedt
10mm tissue culture dishes Falcon
12 well plates Sarstedt
15ml tubes Kisker
175cm2 cell culture flasks Sarstedt
20µl filter tips Sarstedt
200µl filter tips Sarstedt
22mm TC coverslips Sarstedt
24 well plates Sarstedt
25cm2 cell culture flasks Sarstedt
25ml combitips advanced Eppendorf
25ml serological pipettes Sarstedt
2ml cryo tubes Corning
2ml tubes Eppendorf
35mm cell culture dishes Falcon
35mm nunclon delta surface dishes Thermo scientific
50ml serological pipettes Sarstedt
50ml syringe BD
50ml tubes Kisker
5ml combitips advanced Eppendorf
5ml cryo tubes Thermo scientific
5ml serological pipettes Sarstedt
6 well plates Sarstedt
75cm2 cell culture flasks Sarstedt
96 well plates half area clear bottom black Corning
Cell counting slides Biozym
Hard-Shell® 96-Well PCR plates Bio-Rad
Microseal® PCR Plate Sealing Film, adhesive, optical Bio-Rad
Mr Frosty freezing container Sigma Aldrich
Reagent reservoirs Carl Roth
TC Coverslips 22mm Sarstedt
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Table 5: Cell lines, primary cells and bacteria
Cell line Company
CaCo2 ATCC
Cancer-associated primary fibroblasts Derived from patient material and kindly provided by Dr. MikkoLaukkanen, IRCCS SDN, Naples, Italy.  (see section 2.2.1.3)
Colo678 ATCC
DH5a bacteria ATCC
DLD1 ATCC
HCT116 ATCC
Hek293T ATCC
HepG2 ATCC
HT29 ATCC
Human fallopian tube organoids
Derived from patient material and kindly provided by Prof. Thomas
F. Meyer, Department of Molecular Biology, Max Planck Institute
for Infection Biology Berlin, Germany (see section 2.2.1.2)
LIM1215 ATCC
Normal primary fibroblasts Derived from patient material and kindly provided by Dr. MikkoLaukkanen, IRCCS SDN, Naples, Italy.  (see section 2.2.1.3)
RKO ATCC
SW480 ATCC
SW620 ATCC
U2OS ATCC
Table 6: Constructs and plasmids
Construct Company
REV-ERBα-VNP plasmid
Kindly provided by Ueli Schibler, Department of
Molecular Biology, Sciences III, University of
Geneva, iGE3, 1211 Geneva, Switzerland [109].
TRC Lentiviral pLKO.1 empty vector Dharmacon (Catalogue no: RHS4080)
TRC-ARNTL shRNA, glycerol set Dharmacon (Catalogue no: RHS3979-201750301)
TRC-HKDC1 shRNA, glycerol set Dharmacon (Catalogue no: RHS4533-EG80201)
pMD2G (envelope plasmid)
Kindly provided by Prof. Achim Kramer, Laboratory
of Chronobiology, Institute for Medical Immunology,
Charité University of Medicine, Berlin, Germany.
BLH (Bmal1-promoter-Luciferase-Hygromycin)
Kindly provided by Prof. Achim Kramer, Laboratory
of Chronobiology, Institute for Medical Immunology,
Charité University of Medicine, Berlin, Germany
[108], [110].
PLB (Per2-promoter-Luciferase-Blasticidin)
Kindly provided by Prof. Achim Kramer, Laboratory
of Chronobiology, Institute for Medical Immunology,
Charité University of Medicine, Berlin, Germany
[108], [110].
psPAX (packing plasmid)
Kindly provided by Prof. Achim Kramer, Laboratory
of Chronobiology, Institute for Medical Immunology,
Charité University of Medicine, Berlin, Germany.
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Table 7: Kits
Kit Company
AllPrep RNA/Protein Kit Qiagen
ApoTox-Glo TM Triplex Assay Promega
CalPhos mammalian transfection kit Clontech
CyQUANT Cell Proliferation Assay Kit Thermo Fisher scientific
CytoTox-Glo Cytotoxicity Assay Promega
GeneChip® Human Transcriptome Array 2.0 Affymetrix (Catalogue no: 902662)
MycoAlert Assay Control Set Lonza
MycoAlert Mycoplasma Detection Kit Lonza
PureLink HiPure Plasmid Midiprep Kit Invitrogen
RNase free Dnase set Qiagen
RNeasy 96 kit Qiagen
RNeasy Mini kit Qiagen
Seahorse XF Cell Mito Stress Test Kit Agilent
Seahorse XF Glycolysis Stress Test Kit Agilent
Seahorse XFe96 FluxPak mini Agilent
Table 8: Buffers and solutions
Buffer/solution Ingredients
SOB solution 0.5% yeast extract
2% tryptone
10mM NaCl
2.5mM KCl
10mM MgCl2
10mM MgSO4
SOC solution SOB solution + 20mM glucose
TB solution 10mM PIPES
15mM CaCl2
250mM KCl
55mM MnCl2
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Table 9: Primer
Primer Company/sequence
Hs_ALDH3A2_1_SG QuantiTect Primer Assay Qiagen
Hs_ALDOC_1_SG QuantiTect Primer Assay Qiagen
Hs_ARNTL_1_SG QuantiTect Primer Assay Qiagen
Hs_CRY1_1_SG QuantiTect Primer Assay Qiagen
Hs_CRY2_1_SG QuantiTect Primer Assay Qiagen
Hs_GAPDH_1_SG QuantiTect Primer Assay Qiagen
Hs_HKDC1_1_SG QuantiTect Primer Assay Qiagen
Hs_NR1D1_1_SG QuantiTect Primer Assay Qiagen
Hs_NR1D2_1_SG QuantiTect Primer Assay Qiagen
Hs_PCK2_1_SG QuantiTect Primer Assay Qiagen
Hs_PDHB_1_SG QuantiTect Primer Assay Qiagen
Hs_PER1_1_SG QuantiTect Primer Assay Qiagen
Hs_PER2_1_SG QuantiTect Primer Assay Qiagen
Hs_PER3_1_SG QuantiTect Primer Assay Qiagen
Hs_RORA_1_SG QuantiTect Primer Assay Qiagen
Hs_RORB_1_SG QuantiTect Primer Assay Qiagen
Hs_RORC_1_SG QuantiTect Primer Assay Qiagen
Hs_TBP_1_SG QuantiTect Primer Assay Qiagen
Hs_TP53_1_SG QuantiTect Primer Assay Qiagen
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2.2 Methods
2.2.1 Cell culture methods
2.2.1.1 Cultivation and subcultivation of cell lines
Cells were stored in liquid nitrogen until use. To take cells in culture, the vial was quickly
thawed, and cells were transferred into falcon tubes containing complete growth medium. Cells
were then centrifuged at 300 rpm for 5 minutes. The supernatant was discarded, and the cell
pellet was resolved in complete growth medium. Afterwards, the cell suspension was
transferred into a cell culture flask containing complete growth medium. Cells were incubated
in an incubator at 37 °C and 5 % CO2. Fresh medium was added the next day.
Table 10: Cell lines and growth medium
Cell line Medium composition
CaCo2 DMEM low glucose without L-Glutamine, 10 % FBS, 1 % penicillin-streptomycin,2 mM Ultraglutamine
Colo678 RPMI, 10 % FBS, 1 % penicillin-streptomycin, 1 mM sodium pyruvate, 2 mMUltraglutamine
DLD1 RPMI, 10 % FBS, 2 mM Ultraglutamine, 1 % penicillin-streptomycin
HCT116 DMEM low glucose without L-Glutamine, 10 % FBS, 1 % penicillin-streptomycin,2 mM Ultraglutamine
Hek293T DMEM, 10 % FBS, 1 % penicillin-streptomycin, 25 mM HEPES
HT29 DMEM low glucose without L-Glutamine, 10 % FBS, 1 % penicillin-streptomycin,2 mM Ultraglutamine
LIM1215 DMEM low glucose without L-Glutamine, 10 % FBS, 1 % penicillin-streptomycin,2 mM Ultraglutamine
RKO DMEM low glucose without L-Glutamine, 10 % FBS, 1 % penicillin-streptomycin,2 mM Ultraglutamine
SW480 DMEM low glucose without L-Glutamine, 10 % FBS, 1 % penicillin-streptomycin,2 mM Ultraglutamine
SW620 DMEM low glucose without L-Glutamine, 10 % FBS, 1 % penicillin-streptomycin,2 mM Ultraglutamine
U2OS DMEM, 10 % FBS, 1 % penicillin-streptomycin, 25 mM HEPES
Cells were cultured in complete growth medium as indicated in Table 10 and incubated at 37 °C
and 5 % CO2. Cells were subcultivated before they reached complete confluence (about 80 %).
Therefore, the culture medium was removed, and the cells were washed once with PBS and
detached from the flask bottom by using TrypLE Express (2 ml for T75) and an incubation at
37 °C for 5-10 minutes, depending on the cell line. After detachment of the cells, the reaction
was stopped by adding culture medium (8 ml for T75). The suspension was then transferred to
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a falcon tube and centrifuged for 5 minutes at 300 rpm, RT. The supernatant was discarded, and
the pellet was resolved in fresh medium. According to the subcultivation ratio, a proportion of
resuspended cells was transferred into a new cell culture flask. Cells were counted, and cell
viability was checked using a luna automated cell counter (Biozym) in a 1:1 trypan blue
dilution. All cells were incubated at 37 °C in a humidified atmosphere with 5 % CO2.
2.2.1.2 Cultivation of human fallopian tube organoids
Human fallopian tube samples were provided by the department of Gynaecology, Charité
Medical University of Berlin, Germany. Scientific usage of the samples for experimental
purposes was approved by the ethics commission of the Charité (EA1/002/07) and all subjects
gave informed consent to their tissues being used in scientific research. Fragments were sourced
from standard surgical procedures for benign gynaecological disease. Only anatomically
normal fallopian tubes were used. Tubes were transported and dissected within 2–3 h of
removal. Human fallopian tube organoids prepared for cell culture and all media and
supplements needed for organoid culture as well as technical supervision were provided by the
Group of Prof. Thomas F. Meyer, Department of Molecular Biology, Max Planck Institute for
Infection Biology Berlin, Germany. Human fallopian tube organoids were maintained in
Advanced DMEM/F12 supplemented with 12 mM HEPES, 1 % GlutaMAX, 2 % B27, 1 % N2,
10 ng/ml human EGF, 100 ng/ml human noggin, 100 ng/ml human FGF-10, 1 mM
nicotinamide, 9 µM ROCK inhibitor and 0.5 µM TGF-β RI Kinase Inhibitor IV, Wnt3a and
RSPO1 conditioned medium (housemade stocks) in Matrigel. Cells were isolated, maintained
and cultured as previously described [111]. Organoids were incubated at 37 °C in a humidified
atmosphere with 5 % CO2.
2.2.1.3 Cultivation and subcultivation of primary fibroblasts
Normal (NF) and cancer-associated (CAF) human primary fibroblasts were isolated, prepared
for cell culture and provided by the department of General, Laparoscopic and Robotic Surgery,
Azienda Ospedaliera Specialistica dei Colli, Monaldi Hospital, Via Leonardo Bianchi, 80131
Naples, Italy. Fibroblasts were derived from colorectal cancer patients. The protocol and the
scientific usage of the samples for experimental purposes was approved by IRCCS SDN
(Comitato Etico per la Sperimentazione Clinica Progetto N:ro 2013_01_02) and Monaldi
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Hospital ethical committees (Deliberazione del Direttore Generale n:o 1239). NFs were isolated
from a normal colon segment with a distance of approximately 20 cm from the tumour and
CAFs were isolated from the tumour of the same patient with moderately differentiated
adenocarcinoma and lymph node metastasis. Fibroblasts prepared for cultivation were provided
by Dr. Mikko Laukkanen, IRCCS SDN, Naples, Italy. Isolated fibroblasts were plated on gelatin
(1 g/l) pre-treated dishes in αMEM supplemented with 10% Hyclone FBS, 1× antibiotic-
antimycotic and 1× MEM Non-Essential Amino Acids Solution. The subcultivation protocol is
described in detail in chapter 2.2.1.1.
2.2.1.4 Freezing cells
Cells were frozen before they reached complete confluence (about 80 %). Therefore, the culture
medium was removed, and the cells were washed once with PBS and detached from the flask
bottom by using TrypLE Express (2 ml for T75) and an incubation at 37 °C for 5-10 minutes,
depending on the cell line. After detachment of the cells, the reaction was stopped by adding
culture medium (8 ml for T75). The suspension was then transferred to a falcon tube and
centrifuged for 5 minutes at 300 rpm, RT. The supernatant was discarded, and the pellet was
resolved in freezing medium (complete growth medium supplemented with 10% DMSO)
depending on the required concentration (normally 2x106 cells/ml). Cell suspension was
divided into cryovials. These were placed into a Mr. frosty freezing container at -80 °C
overnight and then transferred to liquid nitrogen for long-term storage.
2.2.2 Cell synchronisation
For the time-dependent analysis of glycolysis, mitochondrial respiration, cell viability,
cytotoxicity and apoptosis, cells were synchronised at three different timepoints prior to the
treatment. Synchronisation timepoints were 24 h, 21 h and 18 h before treatment. Timepoint
0 h was defined as the timepoint of treatment at which all cells were treated simultaneously
(Figure 8). Untreated control cells were treated in the same way, but with a vehicle control. For
bioluminescence measurements after time-dependent treatment, cells were synchronised as
described above in phenol-red free medium and the treatment was directly added to the dishes
at timepoint 0 h immediately before bioluminescence measurements were started.
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Figure 8: Treatment schedule for time-dependent treatment
Cells were synchronised 24 h, 21 h or 18 h before treatment. All cells were treated simultaneously at timepoint
0 h.
2.2.3 Proliferation curves
Cells were seeded at the same density and counted for four consecutive days 72 h – 144 h after
seeding. Cells were counted, and cell viability was checked using an automated cell counter in
a 1:1 trypan blue dilution.
2.2.4 Gene expression analysis
2.2.4.1 RNA purification
Total RNA was isolated using the RNeasy Mini kit (Qiagen) according to the manufacturer`s
manual. Prior to the purification procedure, medium was discarded, and cells were washed
twice with PBS and lysed in RLT buffer (Qiagen). To digest genomic DNA, an optional on
column DNase digestion was performed, using the RNase-free DNase Set (Qiagen). RNA was
eluted in 30-50 µl RNase-free water. The final RNA concentration was measured using the
Nanodrop 1000. RNA was then stored at -80 °C until use.
2.2.4.2 Reverse transcription
For qPCR analysis, the extracted RNA was reverse transcribed into cDNA using random
hexamers (Eurofins MWG Operon) and Reverse Transcriptase (Life technologies).
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2.2.4.3 Quantitative real-time PCR
qPCR was performed using human QuantiTect Primer assays (Qiagen) and SsoAdvanced
Universal SYBR Green Supermix (Biorad) in 96-well plates. The qPCR reaction and the
subsequent melting curve were performed using a CFX Connect Real-Time PCR Detection
System (Biorad). Briefly, after an initial denaturation at 95 °C for 10 min, the cDNA was
amplified by 40 cycles of PCR (95 °C, 15 s; 60 °C, 60 s). Subsequently, a melting curve analysis
was performed to detect potential unspecific amplification products. Relative gene expression
levels were normalised using Tbp or Gapdh as housekeeping gene and quantified by the 2-ΔΔCt
method [112].
2.2.5 Microbiological methods
2.2.5.1 Streaking and isolating bacteria on LB agar plates
Bacteria were plated on LB-agar plates containing the appropriate antibiotic
(100 µg/ml ampicillin). Using a sterile pipette tip, bacteria growing on top of a glycerol stock
were touched and bacteria were gently spread on the LB-agar plate in three different dilutions.
Plates were incubated overnight (12 – 18 h) at 37 °C. On the next day, single colonies could be
used for further experiments.
2.2.5.2 Bacterial transformation
For bacterial transformation, a standard heat-shock transformation protocol of chemically
component bacteria was used. Competent bacteria were taken out of -80 °C and thawed on ice
for 20 – 30 min. 1 - 5 μl of DNA (10 pg - 100 ng) were mixed into 50 μl of competent cells in
a microcentrifuge tube and gently mixed. The mixture was incubated on ice for 20 – 30 minutes.
Heat shock of the transformation mixture was performed by placing the bottom of the tube
1/2 to 2/3 into a 42 °C water bath for 45 seconds. Then tubes were put back on ice for 2 minutes.
500 µl LB medium without antibiotic was added to the bacteria and bacteria were grown in a
37 °C shaking incubator for 45 minutes. Transformation mixture was plated on LB-agar plates
containing the appropriate antibiotic and incubated overnight at 37 °C
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2.2.5.3 Inoculating liquid bacterial culture
25 ml LB-medium containing 100 µg/ml ampicillin/carbenicillin was prepared in a flask. Using
a sterile pipette tip, a single colony from the LB-agar plate was selected and the pipette tip was
directly dropped into the LB-medium. The flask was covered with sterile aluminium foil and
bacteria were incubated at 37 °C overnight in a shaking incubator at 180 rpm. After incubation
time, plasmid DNA from the bacterial culture was isolated by using the PureLink HiPure
Plasmid Midiprep Kit (Invitrogen).
2.2.5.4 Creating bacterial glycerol stocks
Bacterial glycerol stocks were prepared from liquid overnight cultures. 500 µl overnight culture
was added to 500 µl 50 % glycerol in a 2 ml cryovial and gently mixed. Glycerol stocks were
stored at -80 °C.
2.2.5.5 Preparing LB agar plates
LB-agar was autoclaved, and plates were labelled. Appropriate antibiotic was added to LB-agar
at around 60 °C and gently mixed. LB-agar was poured into plates air bubble-free. When
LB-agar in the plates was solidified, the plates were stored at 4 °C.
2.2.5.6 Preparation of ultra-competent E. coli for transformation
E. coli DH5a were cultured overnight at 37 °C and SOB-medium was prepared. Isolated
bacteria colonies were picked with a sterile pipette tip and cultured in 250 ml SOC-medium in
1 l flasks at 19 °C and vigorous shaking to an OD of 0.5 (24-36 hours). On the next day, the
flask was placed on ice for 10 minutes. Afterwards cells were pelleted by spinning at 4000 rpm
for 10 minutes at 4 °C. The pellet was gently resuspended in 80 ml ice-cold TB and stored on
ice for 10 minutes and again centrifuged at 4000 rpm for 10 minutes at 4 °C. The pellet was
gently resuspended in 20 ml ice-cold TB and 1.4 ml DMSO. The bacterial suspension was
aliquoted and stored at -80°C.
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2.2.6 Measurement of metabolic activity
2.2.6.1 Measurement of basal respiration
Basal respiration was measured in a Seahorse XFe96 Analyzer (Agilent). Cells were seeded in
seahorse assay plates one day prior to treatment. On the next day, cells were treated with the
appropriate compound or a vehicle control and incubated for 24 hours. After 24 hours, cells
were prepared according to the manual. The following medium composition was used: Seahorse
XF base medium supplemented with 2 mM Glutamine, 5.5 mM glucose and 1 mM sodium
pyruvate (for SW480 and SW620 cells). Extracellular acidification rate and oxygen
consumption rate were measured every 30 minutes for 12 hours.
2.2.6.2 Measurement of glycolytic activity
Glycolytic activity was determined using a Seahorse XFe96 Analyzer (Agilent) and the
Seahorse XF Glycolysis Stress Test Kit (Agilent). Glycolysis is, besides oxidative
phosphorylation the major energy-producing pathway in the cell. The ability to switch between
these two pathways, allows cells to adapt to their environment. During glycolysis, glucose is
converted to pyruvate, and then converted to lactate in the cytoplasm, or CO2 and water in the
mitochondria. The conversion of glucose to pyruvate, and subsequently lactate, results in a net
production and extrusion of protons into the extracellular medium, leading to an acidification
of the medium. The seahorse machine measures the extracellular acidification rate (ECAR).
When using the glycolysis stress test kit, the assay procedure is as follows. First, cells are
incubated in glycolysis stress test medium without glucose or pyruvate and the ECAR is
measured. Subsequently, three successive chemical injections are carried out (Figure 9).
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1. Injection of a saturating concentration of glucose. Glucose is catabolised through the
glycolytic pathway to pyruvate, producing ATP, NADH, water, and protons. The ECAR
increases due to proton extrusion. This glucose-induced response is reported as the rate
of glycolysis under basal conditions.
2. The ATP synthase inhibitor oligomycin is injected and inhibits mitochondrial ATP
production, and shifts the energy production to glycolysis. The increase in ECAR
reveals the cellular maximum glycolytic capacity.
3. The last injection is 2-deoxy-glucose (2-DG), a glucose analogue, that inhibits
glycolysis through competitive binding to hexokinase, the first enzyme in the glycolytic
pathway. The resulting decrease in ECAR confirms that the ECAR produced in the
experiment is due to glycolysis. The difference between glycolytic capacity and
glycolysis rate defines glycolytic reserve. ECAR, prior to glucose injection, is referred
to as non-glycolytic acidification which is caused by processes in the cell other than
glycolysis.
Figure 9: Glycolysis Stress Test
(A) Agilent Seahorse XF Glycolysis Stress Test profile of the key parameters of glycolytic function. Successive
compound injections measure glycolysis and glycolytic capacity. Based on these parameters glycolytic reserve
and non-glycolytic acidification can be calculated. (B) Schematic representation of the glycolytic pathway and the
sites of action of the kit components. Glucose fuels glycolysis. Oligomycin inhibits ATP synthase in the
mitochondria resulting in an increased dependence on glycolysis. 2-DG is a competitive inhibitor of glucose, and
functions to shut down glycolysis. Adapted from Agilent (www.agilent.com).
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Cells were seeded one day prior to the assay in 96-well seahorse plates. The assay was
performed according to the manufacturer`s instructions. For the Glycolysis stress test seahorse
XF base medium (Agilent) supplemented with 2 mM L-Glutamine was used and 10 mM
glucose, 1 µM oligomycin and 50 mM 2-DG was used for the injections. Subsequently, plates
were normalised based on the DNA content using the CyQuant kit (Thermo Fisher scientific)
according to the manufacturer`s instructions. Data was analysed using the wave software
(Agilent).
2.2.6.3 Measurement of mitochondrial respiration
Mitochondrial respiration was determined using a Seahorse XFe96 Analyzer (Agilent) and the
Seahorse XF Cell Mito Stress Test Kit (Agilent). The kit measures key parameters of
mitochondrial function by directly measuring the oxygen consumption rate (OCR) of cells.
Different modulators of cellular respiration (oligomycin, FCCP, and a mix of rotenone and
antimycin A) are serially injected into the medium to target components of the electron transport
chain (ETC) in mitochondria. ATP production, maximal respiration, and non-mitochondrial
respiration are measured. Each compound targets a specific component of the ETC (Figure 10).
1. Oligomycin inhibits ATP synthase (complex V) and the decrease in OCR following
injection of oligomycin correlates with the mitochondrial respiration associated with
cellular ATP production.
2. FCCP is an uncoupling agent that collapses the proton gradient and disrupts the
mitochondrial membrane potential. As a result, electron flow through the ETC is
uninhibited and oxygen is maximally consumed by complex IV (maximal respiration).
3. The third injection is a mix of rotenone, a complex I inhibitor, and antimycin A, a
complex III inhibitor. This combination shuts down mitochondrial respiration and
enables the calculation of non-mitochondrial respiration driven by processes outside the
mitochondria.
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Figure 10: Cell Mito Stress Test
(A) Test profile of the key parameters of mitochondrial respiration. Consecutive compound injections measure
basal respiration, ATP production, proton leak, maximal respiration, spare respiratory capacity, and
non-mitochondrial respiration. (B) Schematic representation of the complexes of the ETC and the target of action
of all test compounds. Oligomycin inhibits ATP synthase (complex V), FCCP uncouples oxygen consumption
from ATP production, and rotenone and antimycin A inhibit complexes I and III, respectively. Adapted from
Agilent (www.agilent.com).
Cells were seeded one day prior to the assay in 96-well seahorse plates. The assay was
performed according to the manufacturer`s instructions. For the cell mito stress test, seahorse
XF base medium (Agilent) supplemented with 2 mM L-Glutamine, 5.5 mM glucose and 1 mM
sodium pyruvate was used and 2 µM oligomycin, 0.5 µM FCCP and 0.5 µM rotenone/antimycin
A were used for the injections. Subsequently, plates were normalised based on the DNA content
using the CyQuant kit (Thermo Fisher scientific) according to the manufacturer`s instructions.
Data was analysed using the wave software (Agilent).
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2.2.7 Lentiviral methods
2.2.7.1 Lentivirus production
Figure 11: Lentivirus production and transduction of target cells
Hek293T cells were co-transfected with the packaging plasmid psPAX, the envelope plasmid pMD2G and the
expression plasmid. Harvested lentiviral particles were used to transduce target cells.
Lentiviral elements containing either a Bmal1-promoter-driven luciferase (BLH) or a
Per2-promoter-driven luciferase (PLB) were generated as previously described [110]. The
vector maps can be found in the supplements (Figure S 1 and Figure S 2). HEK293T cells were
seeded in 175 cm2 culture flasks and co-transfected with 12.5 µg packaging plasmid psPAX
(Figure S 3) 7.5 µg envelope plasmid pMD2G (Figure S 4) and 17.5 µg expression plasmid
using the CalPhos mammalian transfection kit (Clontech) according to the manufacturer’s
instruction (Figure 11). To harvest the lentiviral particles, the supernatant was centrifuged at
4100 x g for 15 min to remove cell debris and passed through a 45 µm filter. The lentiviral
particles were stored at -80 °C until use.
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2.2.7.2 Transduction with lentiviral vectors
For lentiviral transduction cells were seeded in 6-well plates. On the day of transduction, 1 ml
medium and 1 ml of lentiviral particles were added. 8 µg/ml protamine sulphate and 4 µg/ml
polybrene were used to enhance transduction efficiency. On the next day, the medium was
replaced, and selection medium was added one day later (complete growth medium containing
appropriate antibiotic) to obtain stable transduced cells and incubated at 37 °C with 5 % CO2
atmosphere. Untransduced cells treated with the same antibiotic concentration were used as
selection controls.
2.2.8 Bioluminescence measurements
Figure 12: Workflow for live-cell bioluminescence measurements
Cells were seeded and transduced with Bmal1:luc or Per2:luc reporter constructs. After selection, cells were
synchronised by medium change and live-cell bioluminescence was measured using a photomultiplier.
Period = the time for one cycle. Phase = the timing of each cycle relative to an external zeitgeber. Amplitude = the
ratio of max to min expression.
For live-cell bioluminescence recordings, cells were maintained in phenol red-free DMEM or
RPMI containing 10 % FBS, 1 % penicillin-streptomycin and 250 µM D-Luciferin. NFs and
CAFs were maintained in phenol red-free MEM-α medium supplemented with 10 % Hyclone
FBS, 1 x antibiotic-antimycotic and 1 x MEM Non-Essential Amino Acids Solution and
250 µM D-Luciferin. Human fallopian tube organoids were maintained in normal growth
medium supplemented with 250 µM D-Luciferin. Cells were synchronised by medium change
prior to measurement. Bmal1-promoter-(BLH)-reporter activity or Per2-promoter
(PLB)-reporter activity was measured using a LumiCycle instrument (Actimetrics) for five
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consecutive days (Figure 12). Bioluminescence data was analysed using the Chronostar
software [108]. Raw bioluminescence data was de-trended by the 24 hours running average and
a sine fit was fitted to the data. Based on the sine fit, circadian parameters were calculated.
2.2.9 Single live-cell microscopy
For single live-cell microscopy, SW480 and SW620 cells were transfected with a
REV-ERBα-VNP plasmid using the X-tremeGENE HP DNA Transfection reagent
(Sigma-Aldrich) according to the manufacturer's instructions. REV-ERBα-VNP positive cells
were sorted via fluorescence-activated cell sorting and cultured under normal growth conditions
until use. For the experiment, cells were plated in μ-Slide 8 Well Glass Bottom dishes (ibidi).
Time course live-cell microscopy was performed using a CSU-X spinning disc confocal
microscope (Nikon). Pictures were taken and fluorescence intensity was determined every
30 min for 38 h. Data processing was done using ImageJ Fiji [113], [114].
2.2.10 Measurement of cell viability, cytotoxicity and apoptosis
To determine cell viability, cytotoxicity and apoptosis, the ApoTox-Glo Triplex Assay
(Promega) was used. The test measures live-cell protease activity using a fluorogenic, cell-
permeant peptide substrate (GF-AFC Substrate), dead-cell protease activity using a cell-
impermeant, fluorogenic peptide substrate (bis-AAF-R110 Substrate) and caspase-3/7
activation as a key indicator of apoptosis. Cells were seeded in black 96-well half-area plates
with clear bottom. The assay was performed according to the manufacturer`s instructions.
Subsequently, plates were normalised based on the DNA content using the CyQuant kit
(Thermo Fisher scientific) according to the manufacturer`s instructions.
2.2.11 shRNA-mediated knockdown
For the knockdown of Bmal1 and Hkdc1, a TRC lentiviral shRNA glycerol set (Dharmacon)
specific for each gene was used consisting of five individual shRNAs. The construct that gave
best knockdown efficiency was determined by gene expression analysis and used for further
experiments. The empty pLKO.1 vector was used as a control (Figure S 5). The transduction
was performed as described in chapter 2.2.7.2.
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2.2.12 Treatment with WZB117 and oxaliplatin
Treatment concentrations were determined based on the experimentally determined IC50 value
(Figure 43) or based on literature search [115]. For the experimental determination of WZB117
treatment concentration, cells were seeded in 96 well plates one day prior to treatment. Cells
were treated with 1.25 μM, 2.5 μM, 5 μM, 10 μM, 20 μM, 40 μM, 80 μM, 160 μM, 320 μM or
640 μM WZB117 for 48 h. The cytotoxicity was determined using the CytoTox-Glo
Cytotoxicity Assay (Promega) following the manufacturer's manual. The following treatment
concentrations were used: WZB117: 80 μM, oxaliplatin: 5 μM. Treatment duration was 24 h.
The structure of WZB117 (CAS number 1223397–11-2) as well as oxaliplatin (CAS number
61825–94-3) is already published.
2.2.13 Sample preparation for 24 h time course microarray studies
Cells were seeded in triplicates in 6-well plates one day prior to the experiment. On the next
day, cells were synchronised by medium change and samples were taken every 3 h for 24 h and
prepared for RNA extraction. RNA extraction was carried out as described above (2.2.4.1).
Microarray hybridisation was carried out by the Labor für funktionelle Genomforschung
(LFGC, Charité - Universitätsmedizin Berlin) using Affymetrix GeneChip Human
Transcriptome Array 2.0. The microarray dataset has been deposited in the ArrayExpress
database at EMBL-EBI (www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-5876.
2.2.14 Co-culture
One day prior to start of the co-culture, cells were seeded at the appropriate density dependent
on the cells used. Untransduced cells were seeded in 35 mm dishes and transduced cells
(Bmal1-promoter-(BLH)-reporter) were seeded on 22 mm coverslips. The next day, cells on
coverslips were added to the appropriate untransduced cells. From this timepoint on, all cells
were maintained in MEMα complete growth medium. Co-culture was maintained for 48 hours.
For bioluminescence measurements, cells were synchronised by serum shock with medium
containing 50 % FBS for 2 hours. Next, cells were washed once with 1x PBS and
phenol-red-free MEMα supplemented with 250 µM D-Luciferin was added. Bioluminescence
measurements and data analysis were performed as described above (2.2.8).
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2.2.15 Bioinformatics methods
2.2.15.1 Microarray analysis
The microarray analysis was conducted in R version 3.4.1 [116] using the oligo package [117].
Gene expression data was pre-processed for all samples as one batch using the Robust Multichip
Average (RMA) methodology [118], [119]. The R package arrayQualityMetrics [120] was used
for quality control and statistical testing of the array data. Top differentially expressed genes
with a log fold change (lfc) > 2 and p < 0.001 were identified using the limma package in R
[121]. To detect genes exhibiting rhythmic behaviour with a period of 24 h in their expression
intensities, the R package RAIN [122] and the R package Harmonic regression [123] were
applied to identify robustly 24 h cycling transcripts with a p-value < 0.05. Since the algorithm
works optimally with periods that are a multiple of the sampling interval, a period of 24 h was
chosen which is the nearest approximation to the observed period of 24.59 h in SW480 cells.
Expression heatmaps were created using the R package gplots [124]. The colours blue, white
and red were assigned to the colourpanel (low, mid, high), meaning blue indicates low
expression, white indicates middle expression and red indicates high expression.
2.2.15.2 Over-representation analysis
For the over-representation analysis of 24 h oscillating genes, genes were grouped into three
sets: genes oscillating in both cell lines, genes oscillating only in SW480 cells and genes
oscillating only in SW620 cells. Over-representation analysis was performed using
ConsensusPathDB (http://cpdb.molgen.mpg.de/). p-values were computed by
ConsensusPathDB according to the hypergeometric test based on the number of physical
entities present in both the predefined set and user-specified list of physical entities. The
p-values were corrected for multiple testing using the false discovery rate method. All pathways
with a p-value < 0.01 and containing at least two overlapping members of the defined sets
(genes oscillating in both cell lines, genes oscillating only in SW480 cells, genes oscillating
only in SW620 cells) were taken into consideration for further analyses.
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2.2.16 Statistical Analysis
The experiments were carried out with at least three biological replicates for each condition.
All results are represented as mean ± SEM. Statistical analysis of the results was performed
using either one-way ANOVA followed by Tukey`s multiple comparisons test or by two-tailed
unpaired t-test, based on the experimental design. A p-value < 0.05 was considered as
statistically significant. (* = p < 0.05; ** = p < 0.01; *** = p < 0.001).
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Results
3.1 Colorectal cancer cell lines exhibit diverse circadian phenotypes
Cancer cell lines show a huge variety of circadian phenotypes [10]. Therefore, in a first step the 
circadian phenotype of different colorectal cancer cell lines was evaluated. To measure the 
circadian clock in living cells, cells were lentivirally transduced with a construct harbouring a 
luciferase under the control of the Bmal1 or Per2 promoter. Bioluminescence was measured in 
live cells over five consecutive days in a photomultiplier. 
Figure 13: Bmal1-promoter activity in U2OS cells
Cells were lentivirally transduced with a Bmal1-luciferase construct (BLH) and synchronised with 1µM
dexamethasone for 30 minutes. Bioluminescence was measured over five days. Displayed is one representative
replicate.
The osteosarcoma cell line U2OS was used as a reference cell line as it is a commonly used 
cellular model for circadian research with stable and robust oscillations of about 24 h. Figure 13 
shows bioluminescence measurements of U2OS cells over five consecutive days. As expected, 
U2OS cells had a period of 24.7 h (SEM = 0.13, n = 3) and exhibited robust oscillations in 
Bmal1-promoter activity.
It has already been shown before that human colorectal cancer cell lines exhibit large 
phenotypic variations in circadian rhythms [10]. These differences in clock phenotypes were 
confirmed as well as extended for more cell lines. Overall, nine colorectal cancer cell lines were 
tested for their clock phenotype (CaCo2, Colo678, HCT116, HT29, LIM1215, RKO, SW480 
and SW620).
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Figure 14: Clock phenotypes of different colorectal cancer cell lines
Bioluminescence measurements of Caco2 (A), Colo678 (B), DLD1 (C), HCT116 (D), HT29 (E), LIM1215 (F),
RKO (G), SW480 (H) and SW620 (I) cells. Cells were lentivirally transduced with a Bmal1-luciferase construct
(BLH) and synchronised with 1µM dexamethasone for 30 minutes. Bioluminescence was measured over five days.
Displayed is one representative replicate per cell line.
A comparison of the oscillatory profile of all tested cell lines revealed differences between the
tested cell lines with respect to their Bmal1-promoter activity (Figure 14). While DLD1,
HCT116, and SW480 showed robust oscillations, CaCo2, HT29, LIM1215, RKO and SW620
cells showed only very weak or no oscillations at all. The calculated periods of all cell lines,
independent from their observed clock phenotype are displayed in Table S 1. These results once
more demonstrate that colorectal cancer cell lines show diverse and distinct clock phenotypes.
However, due to the lack of information about the cancer stage for many cell lines, it was not
possible to correlate the tumour stage and the clock phenotype.
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3.2 Determination of a synchronisation method
To study the circadian clock in a cell population, it is necessary to synchronise the cells so that
they are in the same circadian phase. For cell synchronisation, different methods exist, including
the glucocorticoid dexamethasone, forskolin that elevates cAMP levels and a simple
serum-containing medium change [87], [125], [126].
Figure 15: Comparison of different synchronisation methods in selected colorectal cancer cell lines
Bioluminescence measurements of Colo678 (A), DLD1 (B), HCT116 (C), SW480 (D) and SW620 (E) cells after
synchronisation with forskolin, dexamethasone or medium change. Cells were lentivirally transduced with a
Bmal1-luciferase construct (BLH) and synchronised with 1µM dexamethasone (Dex), 40µM forskolin (Fors) or
medium (Med) for 30 minutes. Bioluminescence was measured over five days. Displayed is one representative
replicate for each synchronisation method and cell line.
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All beforementioned synchronisation methods reset the circadian clock by inducing circadian
gene expression. The abovementioned chemicals dexamethasone and forskolin as well as a
normal medium change were tested for their capability to synchronise cells and generate robust
oscillations. Figure 15 shows bioluminescence measurements in different colorectal cancer cell
lines after synchronisation with dexamethasone, forskolin or medium change. In SW480 cells,
forskolin synchronisation led to a significantly longer period when compared to medium change
and dexamethasone treatment. Apart from that, no significant changes regarding the period
length were observed and oscillations were very similar, independent from the synchronisation
method used. Overall the results indicate that the synchronisation method only has minor effects
on cell oscillations. Based on these results, cells were synchronised by a simple medium change
for further experiments as this method does not include the use of additional chemicals that
might influence the results.
3.3 SW480 and SW620 cells as a model for tumour progression
3.3.1 Detailed analysis of the core-clock in SW480 and SW620 cells
For further experiments, a pair of cell lines was selected that can be used as a model for
circadian studies in the context of colorectal cancer progression. Based on the comparison of
different colorectal cancer cell lines, SW480 and SW620 cells were chosen as an experimental
model to investigate the interplay of a dysregulated circadian clock and the resultant metabolic
output in colorectal cancer progression. Both cell lines are originally derived from the same
patient but from different sites and at different times, representing two stages of cancer
progression. The SW480 cell line is derived from a primary Duke's stage B colorectal
adenocarcinoma, and the SW620 cell line is derived from a mesenteric lymph node metastasis.
In a first attempt the circadian phenotype of both cell lines was evaluated in greater detail by
measuring the circadian clock on the population level via bioluminescence measurements, on
the single cell level by the use of live-cell microscopy and on the gene expression level via
qPCR.
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3.3.1.1 Bioluminescence measurements
Figure 16: Bioluminescence measurements of Bmal1- and Per2-promoter activity in SW480 and SW620 cells
To investigate circadian clock activity, SW480 (A) and SW620 (B) cells were lentivirally transduced with a
Bmal1-promoter (blue) or Per2-promoter (pink) driven luciferase construct. Bioluminescence was measured for
five consecutive days. Shown is one representative replicate for each condition. Adapted from
Fuhr et al., 2018 [1].
Bioluminescence measurements of Bmal1- and Per2-promoter activity in SW480 and SW620
cells revealed that both cell lines exhibit different clock phenotypes (Figure 16). SW480 cells
showed robust oscillations (T= 24.59 h ± 0.34, n = 3) with Bmal1 and Per2 oscillating in
antiphase, as expected [127], [128]. In contrast, the oscillations in SW620 cells were less robust
and had a delayed phase of around 12 h for both Bmal1 and Per2, as compared to SW480 cells.
3.3.1.2 Single-cell clock measurements
Bioluminescence measurements in live cells using a photomultiplier always display the
behaviour of a bulk of synchronised cells. To find out whether different clock phenotypes in
SW480 and SW620 cells are truly based on differences in the molecular clock on the single cell
level and do not only occur because of synchronisation problems of SW620 cell populations,
the circadian clock on the single cell level was evaluated. Thus, cells were transfected with a
REV-ERBα-VNP fluorescence fusion protein and time course single live-cell fluorescence
microscopy was performed to determine the clock phenotype on the single cell level.
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Figure 17: Time course single-cell microscopy
Single-cell time-series measurements of REV-ERBα protein abundance in SW480 and SW620 cells. The
fluorescence intensity of a REV-ERBα-VNP fusion protein was measured for 36 h in SW480 (A) and SW620 (B)
single live-cells. A fourth-grade polynomial fit was applied. Adapted from El-Athman, Fuhr, et al., 2018 [2].
The analysis of time course microscopy for 36 h revealed different oscillation patterns in
SW480 and SW620 cells in (Figure 17). The oscillations in SW620 cells seemed to be weaker,
as the curve was rather flat, as compared to SW480 cells. These results confirm the assumption,
that the differences in the circadian clock of both cell lines are due to changes within the
molecular clock rather than due to a different ability of cell synchronisation within the
population.
3.3.1.3 qPCR
The lumicycle analysis as well as the live-cell microscopy revealed profound changes in the
core-clock between SW480 and SW620 cells. To confirm and extend these observations, a 45 h
time course qPCR experiment was carried out and the expression of selected core-clock genes
was analysed. The analysis of 45 h time course qPCR data confirmed the results gained from
the bioluminescence measurements. In particular, the observed phase shift in Bmal1 expression
between SW480 and SW620 cells was confirmed via qPCR (Figure 18). Furthermore, the
analysis of oscillating genes approved that the oscillations of Bmal1 and Per2 expression were
more robust in SW480 cells as compared to SW620, as indicated by lower p-values in the RAIN
analysis (Table S 2). Minor discrepancies regarding the circadian parameters between
bioluminescence measurements and qPCR experiments occur due to the different methods used
and different sampling intervals. While bioluminescence measurements in live cells measure
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the promoter activity of Bmal1 and Per2 every 10 minutes, mRNA levels of Bmal1 and Per2
(as well as other clock genes) were determined every three hours via qPCR.
Figure 18: Time course gene expression analysis of core-clock genes in SW480 and SW620 cells
45 h time course qPCR measurements of selected core-clock genes (Bmal1, Per2, Cry1 and Rev-erbα) in SW480
(dark red) and SW620 (dark blue) cells. Data are expressed as mean ± SEM, n = 3. See also Table S 2. Adapted
from Fuhr et al., 2018 [1].
A detailed analysis of clock phenotypes in SW480 and SW620 cells revealed changes in the
core-clock between both cell lines that are likely to affect genome-wide circadian expression of
clock-regulated genes. Hence, in a next step, the consequences of different clock phenotypes
on the transcriptome level were investigated. For this purpose, a 24 h time course microarray
analysis for both cell lines was performed with a sampling interval of 3 h. This set of data
represents the first 24 h time course microarray study for SW480 and SW620 cells and can be
found in the ArrayExpress database at EMBL-EBI (www.ebi.ac.uk/arrayexpress) under
accession number E-MTAB-5876.
3.3.2  Changes in the core-clock have consequences on the transcriptome level
In a first step, the expression profiles of 14 core-clock genes were evaluated to further analyse
differences in the core-clock between SW480 and SW620 cells. Furthermore, these genes were
tested for oscillations in gene expression.
The time course analysis of 14 core-clock genes revealed different expression patterns of
core-clock genes between both cell lines, as can be seen in the phase-ordered heatmap of
core-clock genes in Figure 19. The ordering of the genes was based on their peak phases of
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expression in SW480 cells and the same ordering was used to represent the temporal expression
profiles of the same set of genes in SW620 cells. Furthermore, a RAIN analysis was performed
to define 24 h oscillating genes. Out of 14 tested core-clock genes, 8 were identified to be
oscillating in SW480 cells with a period of around 24 h (p < 0.05), but only 4 in SW620 cells
(Table S 3). These results are in line with the observations made from bioluminescence
measurements, single live-cell microscopy and time course qPCR of SW480 and SW620 cells.
Figure 19: Heatmap of core-clock genes in SW480 and SW620 cells
Phase-ordered, median-normalised heatmap of core-clock genes in SW480 and SW620 cells. Phase-ordering was
performed based on SW480 expression data and the same ordering of genes was used for SW620 cells. See also
Table S 3. Adapted from Fuhr et al., 2018 [1].
These results showed that SW480 and SW620 cells display very diverse phenotypes, which
could be confirmed on different levels of gene expression and promoter activity. To analyse
changes in gene expression between both cell lines on the transcriptome level, an analysis of
the top differentially expressed genes was performed.
Figure 20 shows a heatmap of differentially expressed genes in SW480 and SW620 cells. A
subsequent over-representation analysis of this set of genes revealed different cancer-associated
pathways to be over-represented. These included, among others, the KEGG pathways pathways
in cancer (p = 0.001) and p53 signalling pathway (p = 0.0005) as well as the GO terms apoptotic
process (p = 4.73E-07), positive regulation of cellular metabolic process (p = 4.29E-06) and
positive regulation of cell death (p = 1.80E-06). These results show that the different cancer
stages of the two tested cell lines are represented by transcriptomic changes especially with
respect to cancer-associated gene expression.
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Figure 20:Top differentially expressed genes between SW480 and SW620 cells
Top differentially expressed genes with a lfc > 2 and p < 0.001 were defined using the limma package in R.
3.3.2.1 A deregulated clock induces a shift in oscillating gene expression
As the circadian clock regulates a huge number of target genes, a deregulated clock is very
likely to induce changes in the oscillations of target gene expression. Consequently, in a next
step, all oscillating genes with a period of 24 h were determined and compared between both
cell lines to see whether changes in the core-clock induce global changes in oscillating gene
expression.
Figure 21: Phase-ordered heatmap of 24 h oscillating genes in SW480 and SW620 cells
Phase-ordered heatmap of all oscillating genes in SW480 (left panel) and SW620 cells (right panel). P < 0.05.
Adapted from El-Athman, Fuhr, et al., 2018 [2].
The analysis of all 24 h oscillating genes revealed a slight phase-shift between both cell lines
(Figure 21). In total, a similar number of oscillating genes was found in both cell lines when
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analysing the oscillations independently in each cell line. Namely 16.0% (3998) of all genes
were oscillating in SW480 cells and 14.8% (3693) were oscillating in SW620 cells. However,
only 5.5% (1385) of all genes were oscillating in both cell lines, which points to a
reprogramming in the 24 h oscillating genetic landscape of these cells. When analysing only
genes that oscillate in at least one of the two cell lines, 22 % (1385) of these genes were found
to be oscillating in both cell lines, 41.4 % (2613) were oscillating only in SW480 cells and
36.6 % (2308) were only oscillating in SW620 cells (Figure 22).
Figure 22: Venn diagram of 24 h oscillating genes in SW480 and SW620 cells
In total 3998 genes were oscillating in SW480 cells and 3693 genes were oscillating in SW620 cells. An intersect
of 1385 genes was oscillating in both cell lines with a period of 24 h.
3.3.2.2 Metabolic pathways are over-represented in distinct sets of oscillating genes
To analyse the sets of oscillating genes in greater detail, an over-representation analysis of these
genes was performed. For this purpose, all 24 h oscillating genes were grouped into three sets
of genes: Genes oscillating only in SW480 cells, genes oscillating only in SW620 cells and
genes oscillating in both cell lines. Interestingly, the over-representation analysis revealed
several metabolic pathways to be overrepresented (Figure 23). The KEGG pathways glucose
metabolism (p = 1.06E-05) and glycolysis (p = 3E-03) were over-represented in the set of genes
oscillating in both cell lines. Genes oscillating only in SW620 cells showed over-represented
pathways involved in mitochondrial respiration, including the tricarboxylic acid (TCA) cycle
(p = 5.85E-04), mitochondrial electron transport chain (p = 7.66E-05), and the Warburg effect
(p = 1.04E-06).
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Figure 23: Over-representation analysis of 24 h oscillating genes
All 24 h oscillating genes were divided into sets of genes oscillating in both cell lines, oscillating only in SW480
cells and oscillating only in SW620 cells and an over-representation analysis was performed. The figure displays
a curated list of KEGG pathways. Relevant metabolic pathways are marked with a red arrow. See also
Table S 4 - S 8.
The expression patterns of 24 h oscillating genes involved in the pathways glycolysis, oxidative
phosphorylation and Warburg effect are displayed as heatmaps in Figure 24. Genes were
ordered based on their phase in SW480 cells and the same ordering was used for SW620 cells.
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A comparison of the heatmaps between both cell lines revealed visible differences regarding
the temporal expression patterns in all three pathways, further supporting the metabolic
differences between both cell lines, especially with respect to oscillating genes in metabolic
pathways.
Figure 24: 24 h oscillating genes belonging to different metabolic pathways in SW480 and SW620 cells
Phase-ordered, median-normalised heatmaps of the pathways glycolysis (A), Warburg effect (B) and oxidative
phosphorylation (C). Only genes are displayed that oscillate with a 24 h period in at least one of the two tested cell
lines. Phase-ordering was performed based on SW480 expression data and the same ordering of genes was used
for SW620 cells. Adapted from Fuhr et al., 2018 [1].
3.3.2.3 Metabolic candidate genes show different time-dependent expression patterns
Based on the results gained from the analysis of oscillating genes and the over-representation
analysis, metabolic candidate genes were defined within over-represented metabolic pathways
for further experiments. Therefore, the 24 h microarray expression data of all genes included in
the pathways glycolysis, oxidative phosphorylation and Warburg effect were evaluated and five
putatively clock-controlled candidate genes were selected based on differences in the temporal
mRNA expression profiles of these genes between both cell lines (Figure S 6).
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Five genes were selected that all belong to the KEGG pathway glycolysis and gluconeogenesis.
Aldh3a2 is involved in oxidative stress response [129], Aldoc catalyses the conversion of
fructose-1,6-bisphosphate to glyceraldehyde-3-phosphate and dihydroxyacetone phosphate
[130], Hkdc1 catalyses the phosphorylation of glucose [131], Pck2 catalyses the conversion of
oxaloacetate to phosphoenolpyruvate [132] and Pdhb catalyses the overall conversion of
pyruvate to acetyl-CoA and carbon dioxide and provides the primary link between glycolysis
and the TCA cycle [133].
Figure 25: Time course gene expression analysis of metabolic genes in SW480 and SW620 cells
45 h time course qPCR measurements of selected metabolic genes (Aldh3a2, Aldoc, Hkdc1, Pck2, Pdhb) in SW480
(dark red) and SW620 (dark blue) cells. Data are expressed as mean ± SEM, n = 3. See also Figure S 6. Adapted
from Fuhr et al., 2018 [1].
The expression profiles of the five candidate genes Aldh3a2, Aldoc, Hkdc1, Pck2 and Pdhb
were evaluated via qPCR (Figure 25). Based on 45 h time course qPCR data, all candidate
genes had higher fold changes over time in SW480 cells. Especially Hkdc1 showed a
phase-shift of around 13 h in its peak expression between both cell lines. This is consistent with
the observed phase shift in Bmal1 expression between SW480 and SW620 cells (Figure 16)
and might be a hint for a circadian regulation of Hkdc1 expression via Bmal1, though further
targeted studies will be needed to test this hypothesis in future work. Among the top candidates,
Hkdc1 showed 24 h oscillations with the lowest p-value (p = 5.7E-04, SW480; p = 1.6E-05,
SW620) and the highest relative amplitude (0.562 in SW480; 0.353 in SW620) for both cell
lines, as estimated by harmonic regression analysis and was thus chosen for further
investigation (Table S 2). Furthermore, an inhibitory effect of intracellular glucose on the
expression of the core-clock genes Bmal1, Per1 and Per2 was reported before, pointing to an
interplay between glycolysis and the circadian clock [83]. As Hkdc1 is a central gene in the
glycolytic pathway, it seemed to be an appropriate candidate gene for further experiments.
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A detailed analysis of SW480 and SW620 cells with respect to their clock phenotypes and
metabolic gene expression confirmed that these two cell lines are a good model for circadian
studies in tumour progression. Particularly metabolic changes between both cell lines could be
observed on the transcriptome level and a detailed analysis of metabolic genes expression
revealed Hkdc1 as a potential clock-regulated metabolic candidate gene that drives metabolic
alterations between the tumour stages of both cell line.
Before the consequences of a deregulated clock on metabolic changes during tumour
progression were analysed by introducing a knockdown of the core-clock gene Bmal1, the
circadian clock was evaluated in primary cellular models.
3.4 The circadian clock in non-cancerous cellular models
Apart from the investigation of circadian phenotypes in colorectal cancer cell lines, the
circadian clock was also evaluated in primary cellular models that served as a comparison for
the results gained in cell lines. For this purpose, human normal and cancer-associated fibroblasts
isolated from colorectal cancer patients were used as well as non-cancerous human fallopian
tube organoids.
3.4.1 Human normal and cancer-associated fibroblasts
Cancer cells are under continuous bidirectional communication with tumour stroma that
nurtures and supports tumour progression. Stroma modifies proliferation, local migration,
metastasis, metabolism, and drug resistance responding to the needs of cancer cells [134]. To
compare the results gained from the colorectal cancer cell lines SW480 and SW620 with a pair
of patient-derived primary stromal cells, normal fibroblasts (NFs) and cancer-associated
fibroblasts (CAFs) derived from the same colorectal cancer patient were used. In total NFs and
CAFs from three patients were evaluated with respect to their circadian phenotype.
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Figure 26: Bioluminescence measurements of NFs and CAFs from individual patients
NFs and CAFs from three patients were lentivirally transduced and the Bmal1-promoter activity was measured
over five consecutive days. Shown is one representative replicate for each cell type.
Bioluminescence measurements of NFs and CAFs derived from three different patients
revealed that NFs as well as CAFs showed robust oscillations even though the amplitudes were
low for patient 10 and patient 7, most likely due to relatively low cell numbers (Figure 26).
Periods ranged between 24.74 h and 27.31 h, but no significant differences were observed
between NFs and CAFs or between different patients. Regarding the period and the oscillation
profile, the clock phenotype, especially in patient 8 seemed to be very similar to the circadian
model cell line U2OS.
3.4.2 Human fallopian tube organoids
As a second non-cancerous model system, human fallopian tube organoids derived from
females without cancer were used to study the circadian clock in normal tissue in comparison
to cancer cell lines. These cells form an organ-like 3D structure consisting of different cell types
and therefore represent the structure of normal tissue quite well. Organoids mimic the
physiology and anatomy of the donor-tissue very closely [111], [135]. Hence, this cellular
model system allows for the analysis of the circadian clock in healthy cells in an organ-like
context.
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Figure 27: The circadian clock in human fallopian tube organoids
(A) Bioluminescence measurements of human fallopian tube organoids transduced with a Bmal1-promoter driven
luciferase construct. Bioluminescence was measured for 14 consecutive days. High peaks indicate medium
changes. Shown is one representative replicate. 24 h time course qPCR measurements of Bmal1 (B) and Hkdc1
(C) in human fallopian tube organoids. Data are expressed as mean ± SEM, n = 3. Adapted from
Fuhr et al., 2018 [1].
Figure 27 shows bioluminescence measurements of fallopian tube organoids over 14
consecutive days. Human fallopian tube organoids showed very robust oscillations even for
longer time frames with a period of 24.64 ± 0.10 h which was similar to the period measured in
SW480 cells (T = 24.59 h ± 0.34, n = 3, Figure 16). In contrast to all tested colorectal cancer
cell lines, no typical damping of oscillations was observed over time, probably due to the
communication between different cell types within the organoids.
The metabolic gene Hkdc1 was identified as a potential clock-regulated candidate gene in the
CRC cell line model. Hkdc1 is known to catalyse the phosphorylation of glucose in the
glycolytic pathway, but its role in cancer remains largely unknown [131]. In the cellular model
system of colorectal cancer progression, Hkdc1 showed time-dependent changes in its mRNA
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expression levels that differed between SW480 and SW620 cells. In order to compare the
expression of the core-clock gene Bmal1 and Hkdc1 in a normal scenario, a 24 h time course
gene expression analysis was performed in human organoids derived from normal fallopian
tubes. The comparison of SW480 and SW620 cells with organoids derived from non-cancer
tissues was used to evaluate the relative similarity of both cell lines to a normal tissue. In the
fallopian tube organoids, Bmal1 showed circadian oscillations with a phase at 8-12 h after
synchronisation, as also observed in SW480 cells (Figure 27 B and Figure 18 ). Therefore, the
time-dependent expression pattern of Bmal1 seems to be a characteristic that is shared between
normal cells and non-metastatic cancer cells. Moreover, the changes of Hkdc1 mRNA
expression over time in human fallopian tube organoids followed a very similar pattern to that
observed in SW480 cells with a trough of expression at around 12 h after synchronisation, in
antiphase to Bmal1 (Figure 27 B and Figure 25). Thus, it seems that the hypothesised interplay
between Bmal1 and Hkdc1 expression in SW480 cells is different from that of the metastatic
cell line SW620, despite their common genetic origin, and instead resembles more closely the
phenotype observed in organoids derived from non-cancerous tissue.
3.5 Core-clock gene disruption induces a metastatic phenotype in SW480 cells
The global analysis of different clock phenotypes on the transcriptomic level revealed metabolic
changes between SW480 and SW620 cells. To further investigate the connection between
altered circadian rhythms and possible effects on cell metabolism, a stable knockdown of the
core-clock gene Bmal1 was performed using lentivirus-based shRNA constructs (see 2.2.11)
and the output on gene expression and metabolic activity was evaluated. Although the
knockdown was carried out at a specific time-point in synchronised cells, the gene is from then
on constantly lower expressed in KD-cells than in control cells.
3.5.1 Bmal1-knockdown in SW480 and SW620
The knockdown efficiency of different shRNA-constructs was tested via qPCR and the
construct that gave the best knockdown efficiency was used for further experiments.
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Figure 28: Knockdown efficiency after shRNA-mediated KD of Bmal1
Gene expression analysis of Bmal1 in SW480 (A) and SW620 (B) cells after shRNA-mediated Bmal1-KD. Gene
expression is shown compared to the corresponding control gene. Mean ± SEM, n = 3. KD efficiency in
SW480-shBmal1 cells: 0.317 ± 0.009 (68.3%). KD efficiency in SW620-shBmal1 cells: 0.313 ± 0.03 (68.7%).
Bioluminescence measurements in SW480 (C) and SW620 (D) cells. Cells were lentivirally transduced either with
an empty vector (ctrl) or with a shBmal1-construct. Additionally, cells were lentivirally transduced with a
Bmal1-promoter driven luciferase construct. Bioluminescence was measured for five consecutive days. Shown is
one representative replicate for each condition. Adapted from Fuhr et al., 2018 [1].
Figure 28 shows the expression of Bmal1 in SW480 (A) and SW620 (B) cells after
shRNA-mediated Bmal1-KD. The knockdown efficiency was very similar in both cell lines,
with 68.3 % in SW480 cells and 68.7 % in SW620 cells. Additionally, the effect of Bmal1-KD
on Bmal1-promoter activity was tested via bioluminescence measurements (Figure 28 C and
D). The knockdown led to a complete loss of oscillations in Bmal1-promoter activity, further
confirming the temporal stability of the knockdown.
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Additionally, a 24 h time course qPCR analysis was carried out to examine the effect of
Bmal1-KD on temporal Hkdc1 expression (Figure 29, Figure 18 and Figure 25), as a possible
interplay between both genes was supposed based on the results gained so far. In both cell lines,
the Hkdc1 expression profile changed upon Bmal1-KD, further supporting the assumption that
Bmal1 and Hkdc1 expression are correlated. These results further reinforce a connection
between the core-clock and clock-controlled metabolic genes with possible consequences on
metabolic activity.
Figure 29: Time-dependent gene expression after Bmal1-KD in SW480 and SW620 cells
24 h qPCR measurements of Bmal1 and Hkdc1 in SW480-shBmal1 (A and B) and SW620-shBmal1 (C and D)
cells. Data are shown compared to the mean expression. Mean ± SEM, n = 3. Adapted from Fuhr et al., 2018 [1].
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3.5.2 Bmal1-KD induces alterations in core-clock and metabolic gene expression
After having confirmed the efficiency and stability of Bmal1-KD, the consequences of
Bmal1-KD on the expression of other core-clock genes as well as on the previously selected
metabolic candidate genes were tested via qPCR (Figure 30).
Figure 30: Gene expression analysis of selected core-clock and metabolic genes
Gene expression of selected core-clock (Bmal1, Cry1, Rev-erbα, Per2) and metabolic genes (Aldoc, Aldh3a2,
Hkdc1, Pck2 and Pdhb) was measured in (A) SW480 and (B) SW620 cells after Bmal1-KD. Gene expression is
shown compared to the corresponding control-gene. Mean ± SEM, n = 3. * = p < 0.05, ** = p < 0.01,
*** = p < 0.001. Adapted from Fuhr et al., 2018 [1].
In SW480 cells, Hkdc1 expression was significantly upregulated after Bmal1-KD (p < 0.001),
whereas Rev-erbα (p < 0.01), Aldoc (p < 0.001), Pck2 (p < 0.01) and Pdhb (p < 0.01) were
significantly downregulated (Figure 30 A). Interestingly, Bmal1-KD led to different effects in
SW620 cells. While Per2 (p < 0.05) and Pck2 (p < 0.001) were significantly upregulated,
Aldh3a2 (p < 0.05) was significantly downregulated (Figure 30 B). These results show that the
knockdown of the core-clock gene Bmal1 does not only affect other core-clock genes, but also
influences the expression of metabolic genes in both cell lines. However, the effect on metabolic
gene expression was stronger in SW480 cells. Especially the effect of Bmal1-KD on Hkdc1
expression in SW480 cells further supports the hypothesised interplay between both genes.
SW620 cells represent the metastatic counterpart to primary tumour-derived SW480 cells.
Additionally, the circadian clock in SW620 cells is deregulated when compared to SW480 cells.
Consequently, in a next step it was tested whether Bmal1-KD in SW480 cells resembles the
metastatic phenotype of SW620 cells. Therefore, relative expression changes of
SW480-shBmal1 and SW620-ctrl cells were compared to SW480-ctrl cells and analysed for
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their similarity. Remarkably, the expression profile of SW620-ctrl cells closely resembled the
expression profile of SW480-shBmal1 cells (Figure 31). Namely Hkdc1 was also significantly
upregulated and Aldoc and Pck2 also significantly downregulated (comparison of Figure 30 A
and Figure 31). These results support the hypothesis that SW480-shBmal1 cells have a
phenotype similar to SW620-ctrl cells and therefore resemble a phenotype of tumour
progression or metastasis.
Figure 31: Gene expression analysis of selected genes in SW620 cells compared to SW480 cells
Gene expression analysis of selected core-clock (Bmal1, Cry1, Rev-erbα, Per2) and metabolic genes (Aldoc,
Aldh3a2, Hkdc1, Pck2 and Pdhb) in SW620 cells compared to SW480 cells. Gene expression is shown compared
to SW480 cells. Mean ± SEM, n = 3. * = p < 0.05, ** = p < 0.01. Adapted from Fuhr et al., 2018 [1].
3.5.3 Bmal1-KD induces changes in cell proliferation and apoptosis
A knockdown of the core-clock gene Bmal1 induced expression changes in other core-clock
and metabolic genes. In SW480 cells, Bmal1-KD induced a gene expression phenotype similar
to the metastatic cell line SW620. Consequently, the effects of Bmal1-KD were further
evaluated and the consequences on proliferation, viability, cytotoxicity and apoptosis were
evaluated in SW480 and SW620 cells.
As shown in Figure 32, SW480-shBmal1 cells proliferated faster than SW480-ctrl cells
(p < 0.05 for all timepoints), and their proliferation profile resembled that of metastatic
SW620 ctrl cells (p < 0.05 for the last two timepoints). These findings support published data
regarding the role of the biological clock as a tumour suppressor [22], [56], [136]–[141] and
support the assumption that a deregulated clock promotes a more metastatic phenotype.
Results
Core-clock gene disruption induces a metastatic phenotype in SW480 cells
 ___________________________________________________________________________
67
Figure 32: Proliferation curves of SW480 and SW620 cells
The proliferation of SW480-ctrl, SW480-shBmal1, SW620-ctrl and SW620-shBmal1 cells was measured for four
days. Adapted from Fuhr et al., 2018 [1].
Furthermore, the impact of Bmal1-KD on cell viability, cytotoxicity and apoptosis was
evaluated at three different timepoints after cell synchronisation (18 h, 21 h and 24 h)
(Figure 33). Cell viability and cytotoxicity tendentially decreased with later synchronisation
timepoints in SW480-ctrl and SW620-ctrl cells. After Bmal1-KD, the time-dependent profile
was inverted as compared to the normal scenario in both cell lines and viability and cytotoxicity
increased with time. The apoptotic profile of the cells was not dependent on the synchronisation
timepoint. However, Bmal1-KD led to significantly lower apoptosis rates in SW480 (p < 0.001)
as well as in SW620 (p < 0.001) cells. Therefore, Bmal1-KD may protect cells from apoptosis
and support cell survival and consequently progression towards malignant phenotypes. These
results are in agreement with recent findings in a model system of mouse embryonic fibroblasts
published by our group [52].
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Figure 33: Viability, cytotoxicity and apoptosis in SW480 and SW620 cells
Viability (A, B), cytotoxicity (C, D) and apoptosis (E, F) in SW480 and SW620 control and shBmal1 cells
synchronised at different timepoints. Mean ± SEM, n = 3. Significant changes (p < 0.05) between different
synchronisation timepoints of the same condition are marked with *. Adapted from Fuhr et al., 2018 [1].
Results
Core-clock gene disruption induces a metastatic phenotype in SW480 cells
 ___________________________________________________________________________
69
3.5.4 Bmal1-knockdown induces metabolic changes in SW480 and SW620 cells
The knockdown of Bmal1 in SW480 and SW620 cells induced changes in metabolic gene
expression. Hence, in a next step it was tested if these changes also lead to alterations in
metabolic activity. The metabolic profiles were investigated in control cells as well as in
shBmal1 cells and an energy map was created based on the extracellular acidification rate
(ECAR) and the oxygen consumption rate (OCR) of the cells.
Figure 34: Energy map of SW480 and SW620 cells
Energy map of SW480 (A) and SW620 (B) control and shBmal1 cells. The mean of three treatment timepoints
after synchronisation is shown (18 h, 21 h, 24 h). Mean ± SEM, n = 16. Adapted from Fuhr et al., 2018 [1].
The energy maps of SW480 and SW620 cells revealed that the knockdown of Bmal1 induced
a more energetic phenotype in SW480 cells (Figure 34 A), while for SW620 cells, no change
upon Bmal1-KD was observed (Figure 34 B). Remarkably, the energy phenotype of
SW480 shBmal1 cells closely resembled the energy phenotype of SW620 cells. These findings
further support the hypothesis that clock gene disruption leads to a more metastatic phenotype,
reinforcing the role of the circadian clock as a tumour suppressor.
As a deregulated circadian clock changed the metabolic profile of SW480 cells and induced a
more energetic metabolic phenotype, in a next step, it was tested whether a deregulated clock
also changes the time-dependent metabolic profile of SW480 and SW620 cells. Therefore,
ECAR and OCR were measured for 12 h in SW480 and SW620 control and shBmal1 cells.
SW480-ctrl cells showed distinct time-dependent fluctuations in the ECAR rates, which were
diminished upon Bmal1-KD (Figure 35 A). Remarkably, as already observed before for
proliferation and energy phenotype, the time-dependent metabolic profile of SW480-shBmal1
Results
Hkdc1-knockdown alters clock and metabolic gene expression
 ___________________________________________________________________________
70
cells resembled that of SW620 cells, again supporting the hypothesis that a deregulated clock
induces a more metastatic phenotype. The time-dependent fluctuations in the OCR were also
reduced in SW480 cells after Bmal1-KD but in the opposite direction as the ECAR
(Figure 35 B). The OCR profile in SW620 cells did not change upon Bmal1-KD and was
generally higher than in SW480 cells (Figure 35 B).
Figure 35: Time-dependent metabolic activity in SW480 and SW620 cells
Extracellular acidification rate (A) and oxygen consumption rate (B) of SW480 and SW620 control and shBmal1
cells measured using a seahorse machine for 12 h. Mean ± SEM, n = 8.
In summary, a knockdown of the core-clock gene Bmal1 leads to time-dependent metabolic
changes in SW480 and SW620 cells and the results shown above again support the hypothesis
that a deregulated clock may induce a more metastatic phenotype probably through metabolic
phenotype rewiring.
3.6 Hkdc1-knockdown alters clock and metabolic gene expression
The results gained so far showed that a deregulated clock induces metabolic changes in tumour
cells evoking a more metastatic phenotype. The glycolytic gene Hkdc1 was identified as a
possible mediator of clock-dependent metabolic changes. Especially in SW480 cells, the
expression of Bmal1 and Hkdc1 seemed to be connected and Hkdc1 was found to be upregulated
in SW480-shBmal1 cells. Furthermore, the expression of Hkdc1 differed between SW480 and
SW620 cells. Therefore, out of the five metabolic candidate genes, Hkdc1 was chosen for
further experiments. To gain further insights into the interplay between the circadian clock and
Results
Hkdc1-knockdown alters clock and metabolic gene expression
 ___________________________________________________________________________
71
cellular metabolism, a knockdown of Hkdc1 was carried out in SW480 and SW620 cells and
the output on the circadian clock and metabolic activity were evaluated.
Figure 36: Knockdown efficiency after shRNA-mediated KD of Hkdc1
Gene expression analysis of Hkdc1 in SW480 (A) and SW620 (B) cells after shRNA-mediated Hkdc1-KD. Gene
expression is shown compared to the corresponding control gene. Mean ± SEM, n = 3. KD efficiency in
SW480-shHkdc1: 0.03 ± 0.006 (97%). KD efficiency in SW620-shHkdc1: 0.13 ± 0.013 (87%). Bioluminescence
measurements in SW480 (C) and SW620 (D) cells. Cells were lentivirally transduced either with an empty vector
(ctrl) or with a shHkdc1-construct. Additionally, cells were lentivirally transduced with a Bmal1-promoter driven
luciferase construct. Bioluminescence was measured for five consecutive days. Shown is one representative
replicate for each condition.
A stable knockdown of Hkdc1 was performed using lentivirus-based shRNA constructs
(see 2.2.11) and the consequences on core-clock and metabolic gene expression were evaluated.
The knockdown efficiency of different shRNA-constructs was tested via qPCR and the
construct that gave the best knockdown efficiency was used for further experiments. Figure 36
shows the expression of Hkdc1 in SW480 (A) and SW620 (B) cells after shRNA-mediated
Hkdc1-KD. The knockdown efficiency was high in both cell lines with 97 % in SW480 cells
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and 87 % in SW620 cells. Bioluminescence measurements of the Bmal1-promoter activity after
Hkdc1-KD showed that Hkdc1-KD had only minor effects on circadian oscillations in SW480
(C) and SW620 (D) cells.
Figure 37: Gene expression analysis of selected core-clock and metabolic genes in SW480 and SW620 cells
after Hkdc1-KD
The expression of core-clock (Bmal1, Cry1, Rev-erbα, Per2) and metabolic genes (Aldoc, Aldh3a2, Hkdc1, Pck2
and Pdhb) was measured in (A) SW480 and (B) SW620 cells after Hkdc1-KD. Gene expression is shown compared
to the corresponding control-gene. Mean ± SEM, n = 3. Significant changes (p < 0.05) are marked with *.
* = p < 0.05, ** = p < 0.01, *** = p < 0.001. Adapted from Fuhr et al., 2018 [1].
Subsequently, the effect of Hkdc1-KD on core-clock and metabolic gene expression was tested
via qPCR. As also seen for the Bmal1-KD, the knockdown of Hkdc1 had effects on the
expression of several core-clock and clock-regulated metabolic candidate genes. In SW480
cells, Hkdc1-KD led to a significant upregulation of Bmal1 (p < 0.001) and Rev-erbα
(p < 0.001), whereas Per2 (p < 0.01), Pck2 (p < 0.001) and Pdhb (p < 0.05) were significantly
downregulated (Figure 37 A). In SW620 cells, Bmal1 (p < 0.01), Pck2 (p < 0.001) and Pdhb
(p < 0.01) were significantly downregulated upon Hkdc1-KD (Figure 37 B). Interestingly, in
WT cells, the expression of Hkdc1 in SW620 cells was higher as compared to SW480 cells,
whereas Bmal1 expression was lower (Figure 31).
Summarising, the results gained so far point to a reciprocal interplay between Bmal1 and Hkdc1.
A low expression of Bmal1 leads to a higher expression of Hkdc1, as seen for SW620 vs SW480
cells and for SW480-shBmal1 vs SW480-ctrl cells. On the other hand, low Hkdc1 expression
led to upregulated Bmal1 expression, as seen for SW480-shHkdc1 vs SW480-ctrl cells.
However, this effect could not be observed in SW620 cells, most likely due to the initial gene
expression levels of both genes in these cells.
Results
Bmal1-KD and Hkdc1-KD alter metabolic activity in colorectal cancer cells
 ___________________________________________________________________________
73
3.7 Bmal1-KD and Hkdc1-KD alter metabolic activity in colorectal cancer cells
The results gained so far indicate an influence of Bmal1 on metabolic activity most likely in
coherence with Hkdc1. Consequently, the following step was to evaluate the effects of
Bmal1- and Hkdc1-KD on the metabolic activity in SW480 and SW620 cells. The glycolytic
and mitochondrial activity of the cells were compared between control, shBmal1 and shHkdc1
cells in a time-dependent manner at three different timepoints after synchronisation (18 h, 21 h
and 24 h).
3.7.1 Effects of Bmal1- and Hkdc1-KD on glycolysis
The use of high rates if glycolysis even in the presence of oxygen, known as the Warburg effect,
is a characteristic of many cancer cells. The altered glucose metabolism is required to fulfil the
anabolic demands of tumour cells [65]. An elevated glucose metabolism was only very recently
defined as one of the hallmarks of cancer [64].
To investigate the effects of Bmal1- and Hkdc1-KD on glycolytic activity, SW480 and SW620
cells were synchronised at three different timepoints (see 2.2.2) and the glycolytic activity was
measured using the glycolysis stress test kit (Agilent) as described in chapter 2.2.6.2. Glycolysis
and glycolytic capacity were compared between control, shBmal1 and shHkdc1 cells.
Figure 38 shows glycolysis (A, B) and glycolytic capacity (C, D) in SW480 and SW620 cells.
Both, glycolysis and glycolytic capacity showed significant time-dependent alterations in
SW480-ctrl cells. Remarkably, these time-dependent alterations were diminished in
SW480-shBmal1 cells. Although SW620-ctrl cells also showed time-dependent changes in
glycolytic activity, these changes were not significant. When all timepoints were taken together
as replicates, glycolysis was significantly increased (p < 0.05) after Bmal1-KD in SW480 cells
whereas Bmal1-KD led to a significant decrease of glycolysis (p < 0.05) in SW620 cells. As
expected, given its upstream role in the glycolytic pathway, a Hkdc1-KD led to a significant
decrease of glycolysis in both cell lines (p < 0.05) (Figure 38 A and B), whereas only in SW480
cells, the glycolytic capacity increased after Hkdc1-KD (Figure 38 C and D). As also seen for
shBmal1 cells, no significant time-dependent changes between different synchronisation
timepoints were observed after Hkdc1-KD.
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Figure 38: Glycolysis and glycolytic capacity in SW480 and SW620 cells
Glycolysis (A, B) and glycolytic capacity (C, D) in SW480 and SW620 control, shBmal1 and shHkdc1 cells at
different timepoints after synchronisation. Mean ± SEM, n = 5. Significant changes (p < 0.05) between different
timepoints of the same condition are marked with *. * = p < 0.05, ** = p < 0.01. Adapted from Fuhr et al., 2018
[1].
Taken together, these results indicate a general control of glycolytic activity by the circadian
clock. Additionally, the loss of time-dependent variations in glycolytic activity upon Bmal1-KD
might be a hint for a circadian control of the timing of glycolytic activity in CRC cells.
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3.7.2 Effect of Bmal1- and Hkdc1-KD on mitochondrial respiration
In addition to the glycolytic activity, the mitochondrial function plays an important role in
tumour growth and metastasis as well [66]. Highly metastatic tumours increase mitochondrial
NADPH and undergo further metabolic changes to fight stress caused by ROS [142]. To
investigate the effects of Bmal1 and Hkdc1-knockdown on mitochondrial respiration, SW480
and SW620 cells were synchronised at three different timepoints and the mitochondrial activity
was measured using the cell mito stress test kit (Agilent) as described in chapter 2.2.6.3. Basal
respiration, ATP production and maximum respiration were compared between control,
shBmal1 and shHkdc1 cells.
Figure 39 shows the mitochondrial activity in SW480 and SW620 cells. In general, similar
time-dependent effects on the mitochondrial activity were observed, although not as strong as
for the glycolytic activity. Especially in SW480-shHkdc1 cells, basal respiration, ATP
production and maximum respiration showed time-dependent effects and increased in earlier
timepoints after synchronisation, whereas no significant time-dependent changes were
observed in SW480-ctrl and SW480-shBmal1 cells. In SW620-shHkdc1 cells, only maximum
respiration showed synchronisation time-dependent effects, whereas ATP production and basal
respiration remained unaffected in SW620 cells. As already observed for the glycolytic activity,
Bmal1-KD led to a general increase of mitochondrial activity in SW480 cells, whereas in
SW620 cells, the mitochondrial activity slightly decreased.
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Figure 39: Basal respiration, maximum respiration and ATP production in SW480 and SW620 cells
Basal respiration (A, B), maximum respiration (C, D) and ATP production (E, F) in SW480 and SW620 control,
shBmal1 and shHkdc1 cells at different timepoints after synchronisation. Mean ± SEM, n = 5. Significant changes
(p < 0.05) between different timepoints of the same condition are marked with *. * = p < 0.05, ** = p < 0.01.
Adapted from Fuhr et al., 2018 [1].
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Summarising, the results gained from knockdown studies in SW480 and SW620 cells point to
an interplay between Hkdc1 and the circadian clock, particularly in SW480 cells, since the KD
of Bmal1 led to a higher Hkdc1 expression and consequently to a higher metabolic activity in
these cells. Additionally, a KD of Hkdc1 led to higher Bmal1 expression and slightly lower
glycolytic activity. In general, a KD of Bmal1 led to a slight increase in metabolic activity in
SW480 cells, but to the opposite change in SW620 cells. Upon Bmal1-KD, Hkdc1 expression
was upregulated in SW480 cells, but not in SW620 cells. This is likely a result of the overall
increased metabolic activity of SW480-shBmal1 cells. Thus, Hkdc1 might be a mediator of
time-dependent effects on energy producing metabolic pathways. Overall, the data shows that
a deregulated biological clock leads to alterations in the expression of metabolic genes, as well
as in metabolic activity that could be pivotal in colorectal cancer progression.
3.8 Clock gene knockdown in primary cell models
As already mentioned above, in addition to experiments carried out in colorectal cancer cell
lines, primary cellular models were used to compare the results gained in cell lines, namely
normal and cancer-associated primary fibroblasts and human fallopian tube organoids. To study
the effects of a deregulated clock in a primary cell model, a Bmal1-KD was carried out in NFs
and CAFs isolated from colorectal cancer patients. However, due to unresolved technical
reasons, a Bmal1-KD could not be performed in organoids, as cells died upon transduction with
shBmal1. As an alternative, a p53-KD was carried out in organoids and the effects on core-clock
and metabolic gene expression were evaluated.
3.8.1 Clock gene knockdown in primary fibroblasts
To compare the results gained from cancer cell lines with patient-derived primary stromal cells,
NFs and CAFs derived from the same colon cancer patient were used. Each pair of NFs and
CAFs from one patient represents a single unique model system reflecting the status of the
patient. The stromal cells were derived from a patient with lymph node metastasis, but without
other distant organ metastasis observed. Therefore, this patient best represents the epithelial
cancer cell model system used in this study (SW480 vs SW620). Bioluminescence
measurements, gene expression analysis of selected core-clock and metabolic candidate genes
and the glycolytic activity of WT and shBmal1 NFs and CAFs were evaluated.
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Figure 40: The circadian clock in primary fibroblasts
(A) Normal fibroblasts (NFs) and cancer associated fibroblasts (CAFs) were lentivirally transduced with either an
empty vector (ctrl) or with a shBmal1-construct. Additionally, cells were lentivirally transduced with a
Bmal1-promoter driven luciferase construct. Bioluminescence was measured for five consecutive days. Shown is
one representative replicate for each condition. (B-D) Gene expression analysis of selected core-clock (Bmal1,
Cry1, Rev-erbα, and Per2) and metabolic genes (Aldoc, Hkdc1, Pck2 and Pdhb) in control (B) and shBmal1 NFs
(C) and CAFs (D). Gene expression is shown compared to the corresponding control-gene. KD efficiency in
NF-shBmal1 cells: 0.328 ± 0.028 (67.2 %). KD efficiency in CAF-shBmal1 cells: 0.347 ± 0.022 (65.3 %).
Mean ± SEM, n = 3. * = p < 0.05, ** = p < 0.01, *** = p < 0.001. Adapted from Fuhr et al., 2018 [1].
Bioluminescence measurements of NFs and CAFs revealed the same peak phase of rhythmic
Bmal1-expression as already observed in SW480 cells (Figure 40 A and Figure 28 C). The
oscillatory profile of NFs and CAFs was very similar and in both cell types a Bmal1-KD led to
a complete loss of oscillations. An analysis of clock gene and metabolic gene expression in
CAFs compared to NFs showed a significant upregulation of Pck2 expression (p < 0.001) and
a downregulation of Hkdc1 (Figure 40 B). In a next step, the effect of Bmal1-KD on core-clock
and metabolic gene expression was tested. In NFs as well as in CAFs, Per2 was upregulated
(p < 0.001) and Rev-erbα was downregulated (p < 0.001) upon Bmal1-KD (Figure 40 C and D).
The same tendency was also observed in SW480-shBmal cells. Furthermore, Bmal1-KD led to
the down- regulation of Aldoc (NF, p < 0.05; CAF, p < 0.001), Hkdc1 (NF, p < 0.05; 
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CAF, p < 0.001) and Pck2 (NF, p < 0.01; CAF, p < 0.001). In CAFs, Bmal1-KD additionally
led to the downregulation of Pdhb (p < 0.01). These results gained in primary fibroblasts
reinforce the observations made in CRC cell lines regarding the impact of Bmal1 on the
expression of metabolic genes.
Figure 41: Glycolytic activity in primary fibroblasts
Glycolysis (A) and glycolytic capacity (B) of control and shBmal1 NFs and CAFs at three different timepoints
after synchronisation (18 h, 21h, 24h). Mean ± SEM, n = 5. Significant changes (p < 0.05) between different
synchronisation timepoints of the same condition are marked with *. Adapted from Fuhr et al., 2018 [1].
Figure 41 shows glycolysis and glycolytic capacity in WT NFs and CAFs and after Bmal1-KD.
NFs showed time-dependent glycolytic activity, where glycolysis decreased at later
synchronisation timepoints. The same tendency was observed in CAFs but with weaker
time-dependent effects. The knockdown of Bmal1 led to a decrease of glycolysis and glycolytic
capacity in NFs, as well as in CAFs and an omission of time-dependent variations in glycolytic
activity. These results support the hypothesis that the circadian clock influences the timing of
metabolism and is able to reprogram metabolic activity in general. However, the specific effects
of Bmal1-KD on metabolic activity seem to be dependent on the initial genetic conditions of a
given cell, as Bmal1-KD induced higher glycolytic activity in SW480 cells, while glycolytic
activity was decreased upon Bmal1-KD in primary fibroblasts.
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3.8.2 P53 knockdown in human fallopian tube organoids
As already mentioned above (see 3.4.2), human fallopian tube organoids were used as a model
for non-cancerous tissue. In this case WT organoids and p53-knockdown (KD-efficiency: 96 %,
Figure S 7) organoids were tested for their circadian phenotype. The knockdown of the tumour
suppressor p53 should serve as a simulation of a more cancerous stadium when compared to
the WT organoids. Due to technical issues, a knockdown of Bmal1 was not performed in
organoids. During the time of this project, it was not possible to optimise the transduction and
selection protocol for human organoids. In addition to bioluminescence measurements, gene
expression analysis of selected core-clock and metabolic genes was performed, and the
expression was compared between WT and p53-KD organoids.
Figure 42: Bmal1-promoter analysis and gene expression analysis in WT and p53-KD organoids
(A) Cells were lentivirally transduced with a Bmal1-reporter construct and Bmal1-promoter activity was measured
over 14 consecutive days. Shown is one representative replicate per condition. (B) The expression of selected core-
clock and metabolic genes (Bmal1, Cry1, Cry2, Per1, Per2, Per3, Rev-erbα, Rev-erbβ, Aldh3a2, Aldoc, Hkdc1,
Pdhb) was measured using qPCR in p53-KD organoids compared to WT organoids. Data are expressed as
mean ± SEM, n = 2.
The Bmal1-promoter activity was measured over 14 consecutive days in WT and p53-KD
organoids (Figure 42). WT as well as p53-KD organoids showed very robust circadian
oscillations even for longer time frames. No significant difference in period length between
both conditions was observed (WT: 24.64 ± 0.10, p53-KD: 24.34 ± 0.08). The gene expression
analysis of several core-clock and metabolic genes in p53-KD organoids compared to WT
organoids revealed strong effects of p53-KD on core-clock and metabolic gene expression.
While core-clock genes were downregulated upon p53-KD, metabolic candidate genes were
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upregulated after p53-KD (Figure 42 B). Although due to the lack of replicates, no assumptions
about the statistical significance of the results could be made, the knockdown of the tumour
suppressor p53 seemed to induce metabolic gene expression and inhibited core-clock activity.
These results support the assumptions made so far that a more cancerous phenotype is linked
to a deregulated clock and enhanced metabolic activity.
3.9 A deregulated clock induces metabolic phenotype rewiring after treatment
By the experiments made so far, Bmal1- as well as Hkdc1-KD have been shown to induce
metabolic changes in SW480 and SW620 cells. Consequently, in a next step, it was tested
whether these metabolic changes also induce differential effects on treatment response. To
answer this question, a metabolism-targeting anticancer treatment was applied to ctrl, shBmal1
and shHkdc1 cells. SW480 and SW620 cells were treated with WZB117, a glucose transporter
(GLUT1) inhibitor, and its effect on gene expression, as well as on metabolic activity was
evaluated.
Figure 43: Determination of treatment concentration for WZB117 treatment.
To determine the appropriate treatment concentration, SW480-ctrl, SW480-shBmal1, SW620-ctrl and
SW620-shBmal1 cells were treated with different concentrations of WZB117 and the IC50 value was calculated
based on the cytotoxicity. Adapted from Fuhr et al., 2018 [1].
To determine the appropriate treatment concentration, cells were treated with different WZB117
concentrations and the cytotoxicity was measured (Figure 43). Based on the experimentally
defined and calculated IC50 value, a treatment concentration of 80 µM was determined.
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3.9.1 WZB117 treatment induces gene expression changes in SW480 and SW620 cells
In a first approach, SW480- and SW620-ctrl, shBmal1 and shHkdc1 cells were treated with
WZB117 at a single timepoint and the effects on core-clock and metabolic gene expression
were measured via qPCR.
Figure 44: Consequences of Bmal1- and Hkdc1-KD on core-clock gene expression after WZB117 treatment
Gene expression analysis of selected core-clock genes (Bmal1, Cry1, Per2 and Rev-erbα) in SW480 (A) and
SW620 (B) control, shBmal1 and shHkdc1 cells after treatment with WZB117. Data are shown compared to
untreated control cells. Mean ± SEM, n = 3. * = p < 0.05, ** = p < 0.01, *** = p < 0.001 compared to the
corresponding untreated sample of the same condition (control, shBmal1, shHkdc1). Adapted from
Fuhr et al., 2018 [1].
Figure 44 shows the expression of selected core-clock genes in SW480 and SW620 cells after
treatment with WZB117. In SW480-ctrl cells, WZB117 treatment led to a significant
upregulation of all tested core-clock genes (Bmal1 (p < 0.05), Cry1 (p < 0.01), Per2 (p < 0.01),
Rev-erbα (p < 0.001)) (Figure 44 A). This result fits with the observed increase of glycolysis
upon Bmal1-KD in untreated SW480 cells. Furthermore, these results are in concordance with
the reported inhibitory effect of intracellular glucose on the expression of the core-clock genes
Bmal1, Per1 and Per2 [83]. In SW480-shBmal1 cells, Bmal1 (p < 0.001) and Rev-erbα
(p < 0.001) were upregulated after treatment with WZB117. This upregulation of core-clock
genes was also observed for SW480-shHkdc1 cells after WZB117 treatment where Per2 was
additionally upregulated (p < 0.01). In contrast to these observations, Rev-erbα was the only
tested core-clock gene whose expression was significantly upregulated (p < 0.05) after
treatment in SW620 cells in all conditions (Figure 44 B). Additionally, Bmal1 (p < 0.05) and
Cry1 (p < 0.05) were downregulated in SW620-shBmal1 cells, whereas Bmal1 (p < 0.01) was
upregulated in SW620-shHKkdc1 cells upon treatment. Overall, the effect of WZB117
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treatment on core-clock gene expression was weaker in SW620 cells when compared to SW480
cells.
Figure 45: Consequences of Bmal1- and Hkdc1-KD on metabolic gene expression after WZB117 treatment
Gene expression analysis of selected metabolic genes (Aldoc, Aldh3a2, Hkdc1, Pck2 and Pdhb) in SW480 (A) and
SW620 (B) control, shBmal1 and shHkdc1 cells after treatment with WZB117. Data are shown compared to
untreated control cells. Mean ± SEM, n = 3. * = p < 0.05, ** = p < 0.01, *** = p < 0.001 compared to the
corresponding untreated sample of the same condition (control, shBmal1, shHkdc1). Adapted from
Fuhr et al., 2018 [1].
Moreover, the outcome of WZB117 treatment on the expression of metabolic genes was
analysed. In this case, the effects were very diverse for the different ctrl and KD conditions
(Figure 45). Upon WZB117 treatment, Pck2 expression was significantly downregulated in
SW480 and SW480-shBmal1 cells (p < 0.05) but upregulated in SW480-shHkdc1 cells
(p < 0.01). The same effect could be observed in SW620 cells. While Hkdc1 expression was
not affected in SW480- and SW620-ctrl cells, it was upregulated in both cell lines after
Hkdc1-KD, as well as in SW480-shBmal1 cells (p < 0.001). Interestingly, no significant effect
on Pdhb expression was observed in any of the SW480 conditions but a downregulation of
Pdhb was measured after treatment in SW620 ctrl and -shBmal1 cells (p < 0.01). Additionally,
Aldh3a2 expression was downregulated upon treatment in SW620-ctrl and SW620-shHkdc1
cells and Aldoc was downregulated upon treatment in SW480-shBmal1 and SW620-shBmal1
cells. The diverse treatment effects on metabolic gene expression based on different cellular
conditions led to the conclusion that the initial genetic status of the cell affects treatment
response.
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3.9.2 WZB117 treatment affects Bmal1-promoter activity
As WZB117 treatment induced changes in core-clock gene expression, live-cell
bioluminescence measurements were carried out to evaluate if these changes can also be
observed in the Bmal1-promoter activity. For this purpose, SW480-ctrl and SW480-shBmal1
cells were synchronised at three different timepoints (18 h, 21 h, 24 h before treatment) and
treated with 80 µM WZB117. Subsequently, Bmal1-promoter activity was measured for five
consecutive days to evaluate the effects of WZB117 on the core-clock and to see if these effects
are dependent on the time of treatment. Only SW480 and not SW620 cells were used for this
experiment, as SW480 cells were previously defined as the more robust oscillators, allowing
for a more reliable interpretation of the results.
In ctrl as well as in Bmal1-KD cells, WZB117 treatment induced changes in Bmal1-promoter
activity until cells died after approximately 48 h (Figure 46). Interestingly, in SW480-ctrl cells,
cells synchronised 24 h before treatment showed a different oscillatory profile when compared
to the other synchronisation timepoints (Figure 46 A). In SW480-shBmal1 cells however, cells
synchronised 21 h before treatment showed a different oscillatory profile than cells
synchronised 18 h and 24 h before treatment (Figure 46 B). These results indicate that WZB117
treatment has time-dependent effects on core-clock activity in SW480 cells.
Figure 46: Bioluminescence measurements in SW480 cells after treatment with WZB117
SW480 cells were lentivirally transduced with an empty vector (ctrl) or with a shBmal1-construct. Additionally,
cells were lentivirally transduced with a Bmal1-promoter driven luciferase construct. Cells were synchronised
18 h, 21 h or 24 h before treatment and then either untreated or treated with 80 µM WZB117. Bioluminescence
was measured for five consecutive days. Shown is one representative replicate for each condition.
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3.9.3 The energy phenotype is affected by WZB117 treatment
After having observed diverse effects after WZB117 treatment on gene expression and on the
circadian phenotype, in a next step, the energy phenotype was evaluated in SW480 and SW620
cells after treatment with the glycolysis inhibitor WZB117.
The energy phenotypes in untreated cells have been described above (3.5.4). WZB117 treatment
induced a shift from an energetic towards a more quiescent phenotype in ctrl as well as in
shBmal1 cells for both cell lines (Figure 47). However, untreated SW480-shBmal1 cells
exhibited a more energetic phenotype than SW480-ctrl cells and this difference was still present
after WZB117 treatment (Figure 47 A). More precisely, the energy phenotype in
SW480-shBmal1 cells upon WZB117 treatment corresponded to the energy phenotype of
untreated SW480-ctrl cells. Likewise, in SW620 cells, WZB117 treatment led to a shift from a
more energetic to a more quiescent phenotype. In this case, untreated ctrl and shBmal1 cells
showed a very similar energy phenotype. Consequently, the shift upon WZB117 treatment
regarding the energy phenotype was very similar in both conditions (Figure 47 B).
Summarising, the energy phenotype after WZB117 treatment was dependent on the initial
condition of the cells. Especially in highly energetic SW480-shBmal1 cells, the resulting
phenotype upon WZB117 treatment was still more energetic than in all other tested conditions.
Figure 47: Energy map of SW480 and SW620 cells after WZB117 treatment
Energy map of SW480 (A) and SW620 (B) control and shBmal1 cells untreated or after treatment with WZB117.
The mean of three treatment timepoints after synchronisation is shown (18 h, 21 h, 24 h). Mean ± SEM, n = 16.
Adapted from Fuhr et al., 2018 [1].
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3.9.4 A deregulated clock affects time-dependent treatment response
Following the evaluation of the energy phenotype, it was analysed if a deregulated clock
influences the time-dependent effect of WZB117 treatment on metabolic activity in SW480 and
SW620 cells. Therefore, ECAR and OCR were measured for 12 h in SW480 and SW620 ctrl
and shBmal1 cells either untreated or treated with WZB117.
The time-dependent metabolic activity of SW480 and SW620 ctrl cells was already described
above and shown in Figure 35. WZB117 treatment induced changes in the distinct time-
dependent ECAR profile in SW480 and SW620 cells (Figure 48). After a short increase in
glycolytic activity, glycolysis rapidly decreased in ctrl as well as in shBmal1 cells. The oxygen
consumption rate also decreased after WZB117 treatment in all tested cells. Overall, the
treatment with WZB117 affected the metabolic activity of SW480 and SW620 cells, but in the
same direction for ctrl and shBmal1 cells.
Figure 48: Time-dependent metabolic activity in SW480 and SW620 cells after WZB117 treatment
Extracellular acidification rate (A, B) and oxygen consumption rate (C, D) of SW480 and SW620 control and
shBmal1 cells untreated or after treatment with WZB117 measured using a seahorse machine for 12h.
Mean ± SEM, n = 8.
As described above, the time-dependent pattern of glycolytic activity changed upon Bmal1-KD,
especially in SW480 cells. To investigate the dependence of the time of treatment on subsequent
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effects on metabolism in greater detail, ctrl, shBmal1 and shHkdc1 cells were synchronised
18 h, 21 h and 24 h before treatment. After treatment with WZB117, glycolytic and
mitochondrial activity of the cells were determined.
Figure 49: Glycolysis and glycolytic activity in SW480 and SW620 cells after WZB117 treatment
Glycolysis (A, B) and glycolytic activity (C, D) of SW480 and SW620 control, shBmal1 and shHkdc1 cells at
three different timepoints after synchronisation. Cells were either untreated or treated with WZB117.
Mean ± SEM, n = 5. Significant changes (p < 0.05) between different timepoints of the same condition are marked
with *. * = p < 0.05, ** = p < 0.01. Adapted from Fuhr et al., 2018 [1].
Figure 49 shows glycolysis and glycolytic capacity in SW480 and SW620 ctrl, shBmal1 and
shHkdc1 cells. Cells were either untreated or treated with WZB117. Untreated conditions were
already described in chapter 3.7.1. Treatment with the GLUT1 inhibitor WZB117 led to the
inhibition of glycolysis in SW480-ctrl, as well as in SW480-shBmal1 cells, but with differential
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time-dependent effects (Figure 49 A and C). In SW480-ctrl cells, WZB117 treatment induced
a significant inhibition of glycolysis, as well as of glycolytic capacity independently of the
treatment timepoint. In contrast to that, upon Bmal1-KD, glycolysis was only inhibited when
cells were either synchronised 24 h or 21 h before treatment and glycolytic capacity was only
found to be significantly lower for cells synchronised 24 h before treatment. Interestingly, when
all synchronisation timepoints were taken together, the inhibiting effect of WZB117 treatment
on glycolysis was stronger in SW480 and SW620 ctrl cells as compared to shBmal1 cells.
WZB117 treatment did neither lead to lower glycolysis, nor to lower glycolytic capacity in
SW480-shHkdc1 cells, independent from the time of treatment. In SW620 cells, the glycolysis
rate was lower when treated at timepoint 21 h or 18 h after synchronisation, whereas glycolytic
capacity was downregulated for all treatment timepoints (Figure 49 B and D). Comparable
results were obtained after Bmal1-KD. In contrast to the observation in SW480 cells, WZB117
treatment led to a slight inhibition of glycolysis and glycolytic capacity in SW620-shHkdc1
cells. These results led to the hypothesis that not only glycolysis itself is time-dependent but
also the effect of glycolysis-targeting treatment.
The mitochondrial activity represented by basal respiration, maximum respiration and ATP
production, was not affected upon WZB117 treatment in SW480-ctrl cells but in
SW480-shBmal1 cells, independent from the time of treatment (Figure 50 A, C, E). For
shHkdc1 cells, while basal respiration and ATP production were not affected, maximum
respiration was inhibited independent from the time of treatment. This might result from a
weaker input into the glycolytic pathway that subsequently impacts on the mitochondrial
respiration pathway, leading to an overall inhibition of maximum respiration. WZB117
treatment in SW620 cells led to differing results when compared to the untreated scenario as
compared to SW480 cells (Figure 50 B, D, F). In SW620 cells basal respiration, maximum
respiration and ATP production were inhibited in ctrl cells after WZB117 treatment,
independent from the treatment time. The results for shBmal1 and shHkdc1 cells, however, were
the same in both cell lines. While basal respiration, ATP production and maximum respiration
were affected in shBmal1 cells, only maximum respiration was inhibited in shHkdc1 cells.
Interestingly, while the effect of WZB117 treatment on glycolysis was stronger in ctrl cells,
mitochondrial respiration was affected to a higher extend in shBmal1 cells.
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Figure 50: Basal respiration, maximum respiration and ATP production in SW480 and SW620 cells after
WZB117 treatment
Basal respiration (A, B), maximum respiration (C, D) and ATP production (E. F) of SW480 and SW620 control,
shBmal1 and shHkdc1 cells at different timepoints after synchronisation. Cells were either untreated or treated
with WZB117. Mean ± SEM, n = 5. Significant changes (p < 0.05) between different timepoints of the same
condition are marked with *. * = p < 0.05, ** = p < 0.01. Adapted from Fuhr et al., 2018 [1].
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Although the selection of a temporal window of six hours is too short to draw conclusions
concerning detailed chronopharmacology profiles, the results show that the efficiency of
WZB117 treatment on metabolic activity appears to change depending on the time of treatment.
Furthermore, a deregulated clock, as represented by shBmal1 cells influences response to
treatment.
3.9.5 Effect of oxaliplatin treatment on metabolic activity
The observed effect of WZB117 treatment on metabolic activity in ctrl, shBmal1 and shHkdc1
cells was further compared to the effect after treatment with the classical chemotherapeutic
oxaliplatin, a platinum complex that is used effectively for CRC treatment and exerts its
cytotoxic effect mostly through DNA damage [94].
Figure 51: Energy map of SW480 and SW620 cells after oxaliplatin treatment
Energy map of SW480 (A) and SW620 (B) control and shBmal1 cells untreated or after treatment with oxaliplatin.
The mean of three treatment timepoints after synchronisation is shown (18 h, 21 h, 24 h). Mean ± SEM, n = 16.
The results gained from WZB117 and oxaliplatin treatment were used to evaluate whether the
metabolic effects of WZB117 treatment are due to the treatment with a GLUT1 inhibitor itself
or whether these effects on metabolism can be generally observed after anticancer treatment
even when applying a drug with a different mechanism of action. Regarding the energy
phenotype, oxaliplatin treatment did not induce any changes in SW480 and SW620 ctrl or
shBmal1 cells (Figure 51).
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Figure 52: Glycolytic activity of SW480 and SW620 control and shBmal1 cells after oxaliplatin treatment
Glycolysis of SW480 (A) and SW620 (B) control and shBmal1 cells at three different timepoints after
synchronisation (18 h, 21 h, 24 h). Cells were either untreated or treated with oxaliplatin. Mean ± SEM, n = 5.
Glycolytic capacity of SW480 (C) and SW620 (D) control and shBmal1 cells at different timepoints. Cells were
either untreated or treated with oxaliplatin. Mean ± SEM, n = 5. Significant changes (p < 0.05) between different
timepoints of the same condition are marked with *. * = p < 0.05, ** = p < 0.01. Adapted from Fuhr et al., 2018 [1].
Regarding the glycolytic activity, oxaliplatin treatment did not induce changes in SW480 or
SW620 cells, neither in ctrl nor in shBmal1 cells (Figure 52). Although oxaliplatin treatment
did induce slight changes in time-dependent mitochondrial activity especially in
SW480-shBmal1 cells, overall, no significant effects could be observed after oxaliplatin
treatment (Figure 53).
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Figure 53: Basal respiration, maximum respiration and ATP production in SW480 and SW620 cells after
oxaliplatin treatment
Basal respiration of SW480 (A) and SW620 (B) control and shBmal1 cells at different timepoints (18 h, 21 h,
24 h). Cells were either untreated or treated with oxaliplatin. Mean ± SEM, n = 5. Maximum respiration of SW480
(C) and SW620 (D) control and shBmal1 cells at three different timepoints. Cells were either untreated or treated
with oxaliplatin. Mean ± SEM, n = 5. ATP production of SW480 (E) and SW620 (F) control and shBmal1 cells at
three different timepoints. Cells were either untreated or treated with oxaliplatin. Mean ± SEM, n = 5.  Adapted
from Fuhr et al., 2018 [1].
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In summary, oxaliplatin treatment did not induce significant metabolic changes in SW480 and
SW620 cells. Hence, the metabolic alterations observed after WZB117 treatment seem to be
specific to anticancer treatment aiming at the tumour`s metabolism.
3.9.6 Effect of WZB117 treatment on viability, cytotoxicity and apoptosis
Besides the effect of WZB117 treatment on metabolic activity, in a next step, its consequences
on cell viability, cytotoxicity and apoptosis were evaluated in SW480 and SW620 ctrl, shBmal1
and shHkdc1 cells. For this purpose, WT and shBmal1 as well as shHkdc1 cells were
synchronised at three different timepoints and treated with the glycolysis inhibitor WZB117
and as a comparison with the classical chemotherapeutic oxaliplatin.
Figure 54 shows cell viability, cytotoxicity and apoptosis in ctrl and shBmal1 cells after
treatment with either WZB117 or oxaliplatin. Viability and cytotoxicity were not affected by
WZB117 treatment in SW480-ctrl and -shBmal1 cells, as they still showed the same
synchronisation time-dependent pattern as without treatment. Interestingly, after WZB117
treatment, a lower apoptosis rate was observed in SW480-ctrl as well as in -shBmal1 cells. In
SW620 cells, this effect was not present. Furthermore, oxaliplatin treatment did not affect
viability, cytotoxicity or apoptosis. This might be due to the used treatment concentration or
treatment duration that was adjusted for WZB117 treatment. Cytotoxicity, viability and
apoptosis were also evaluated in shHkdc1 cells after treatment with WZB117 or oxaliplatin but
in both cases, no significant changes upon treatment were observed (Figure S 8).
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Figure 54: Viability, cytotoxicity and apoptosis in SW480 and SW620 cells after treatment
Viability (A, B), cytotoxicity (C, D) and apoptosis (E, F) in SW480 and SW620 control and shBmal1 cells
synchronised at different timepoints. Cells were either untreated or treated with WZB117 or oxaliplatin.
Mean ± SEM, n = 3. Significant changes (p < 0.05) between different synchronisation timepoints of the same
condition are marked with *. * = p < 0.05, ** = p < 0.01, *** = p < 0.001. Adapted from Fuhr et al., 2018 [1].
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3.10 Cell-to-cell communication impacts on the circadian phenotype
Apart from the use of human fallopian tube organoids, all experiments so far were carried out
in a cell model containing only a single cell type. However, a tumour does not consist of
homogenous cancer cells only but rather of a complex tissue that is composed of different cell
types mainly derived from the neighbouring stroma, thus making up the tumour
microenvironment. Interactions between these different cell types have positive as well as
negative effects on tumourigenesis [143]. In normal colonic mucosa, the stromal population
mainly consists of fibroblasts [144]. Through different pathways fibroblasts may differentiate
into cancer-associated fibroblasts which are then the main cellular component of tumour
stroma. [145]. CAFs secrete growth factors and support tumour growth and migration [134].
Because of the nowadays known importance of the tumour microenvironment and its
constituents, especially CAFs, they might be used as diagnostic and prognostic biomarkers and
should be considered as potential targets for anticancer therapy.
It is still unclear how the individual molecular clocks of different cell types influence each other,
especially in a cell culture model system. To further evaluate this question, different human cell
types were used for co-culture experiments and the effect on the clock phenotype was evaluated
via bioluminescence measurements. In a first attempt, the colorectal cancer cell line HCT116
and the human intestinal fibroblast cell line HIF were used as a co-culture model. The clock
phenotype was measured in cells without co-culture and in co-cultured cells, but with only one
cell type being transduced and measured. In a second attempt, HCT116 cells were co-cultured
with CAFs or NFs. In this case, all cells were measured individually and in co-culture, where
the clock phenotype of HCT116 cells was determined and it was evaluated if co-culture with
stromal cells changes the oscillation profile.
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Figure 55: Effect of co-culture on circadian rhythms in HCT116 and HIF cells
Cells were lentivirally transduced and the Bmal1-promoter activity was measured over five consecutive days. Cells
were either co-cultured with the same cell line (A) or with a different cell line (B and C). Shown is one
representative replicate per condition. The sample written in coloured letters was the one that was measured.
Period (D) und phase (E) were calculated in samples with and without co-culture. Data are expressed as
mean ± SEM, n = 3. Significant changes (p < 0.05) between different conditions are marked with *. Unpublished
data, paper in preparation.
Under control conditions, HCT116 and HIF cells showed significantly different periods
(p < 0.05) (Figure 55 A and D). Although co-culture of both cell lines did not lead to significant
changes in period length or phase, the oscillatory patterns changed in HIF cells upon co-culture
with HCT116 cells. In particular, the oscillations were more robust when cells were measured
in co-culture (Figure 55 B). This influence could not be observed the other way around, when
HCT116 cells were measured in co-culture with HIF cells (Figure 55 C).
In a next step, HCT116 cells were co-cultured with NFs or CAFs from two patients and the
effect on the circadian phenotype was evaluated. The results for patient 7 and patient 10 are
displayed in Figure 56 and Figure 57, respectively.
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Figure 56: Effect of cell-to-cell communication on circadian rhythms
(A) HCT116, NF7 and CAF7 cells were lentivirally transduced and the Bmal1-promoter activity was measured
over five consecutive days. Shown is one representative replicate per condition. Period (B) und phase (C) were
calculated. Data are expressed as mean ± SEM, n = 3. Significant changes (p < 0.05) between different cells are
marked with *. (D) HCT116, NF7 and CAF7 cells were lentivirally transduced and the Bmal1-promoter activity
was measured over five consecutive days. HCT116 cells were either co-cultured with themselves or with NFs or
CAFs. Shown is one representative replicate per condition. The sample written in coloured letters was the one that
was measured. Period (E) und phase (F) were calculated. Data are expressed as mean ± SEM, n = 3. Significant
changes (p < 0.05) between different conditions are marked with *. Unpublished data, paper in preparation.
The oscillatory profile and the circadian parameters period and phase were first determined
without co-culture in all tested cells. While NFs and CAFs from patient 7 did not have a
different period as compared to HCT116 cells (Figure 56 A and B), the period of NFs and CAFs
from patient 10 was significantly longer. (Figure 57 A and B). The phase was significantly
different in NFs and CAFs from both patients as compared to HCT116 cells. When HCT116
were co-cultured with primary NFs and CAFs, a phase shift was observed as compared to the
normal HCT116 oscillatory profile without co-culture. For patient 10 this effect was present for
NFs and CAFs (Figure 57 D and F), whereas in patient 7 this effect was only present when
HCT116 cells were co-cultured with CAFs (Figure 56 D and F). Co-culture with primary
fibroblasts also had effects on the period in HCT116 cells, especially with cells from patient 10,
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where co-culture led to a significantly longer period in HCT116 cells (Figure 57 E).
Interestingly, the longer period was very similar to the period observed for NFs and CAFs.
Figure 57: Cell-to-cell communication impacts on the circadian phenotype
(A) HCT116, NF10 and CAF10 cells were lentivirally transduced and the Bmal1-promoter activity was measured
over five consecutive days. Shown is one representative replicate per condition. Period (B) und phase (C) were
calculated. Data are expressed as mean ± SEM, n = 3. Significant changes (p < 0.05) between different cells are
marked with *. (D) HCT116, NF10 and CAF10 cells were lentivirally transduced and the Bmal1-promoter activity
was measured over five consecutive days. HCT116 cells were either co-cultured with themselves or with NFs or
CAFs. Shown is one representative replicate per condition. The sample written in coloured letters was the one that
was measured. Period (E) und phase (F) were calculated. Data are expressed as mean ± SEM, n = 3. Significant
changes (p < 0.05) between different conditions are marked with *. Unpublished data, paper in preparation.
As co-culture with primary fibroblasts induced changes in the circadian phenotype of HCT116
cells, in a next step it was tested whether co-culture also influences metabolic activity as well
as cell viability, cytotoxicity and apoptosis.
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Figure 58: Cell-to-cell communication impacts on cell metabolism
(A) Glycolysis and (B) glycolytic capacity in HCT116 cells cultivated alone or after co-culture with NFs or CAFs.
Only HCT116 cells were measured. Data are represented as mean ± SEM (n = 8). (C) Basal respiration, (D)
maximum respiration and (E) ATP production in HCT116 cells cultivated alone or after co-culture with NF or
CAF. Only HCT116 cells were measured. Data are represented as mean ± SEM (n = 8). (F) Viability, (G)
cytotoxicity and (H) apoptosis in HCT116 cells cultivated alone or after co-culture wit NF or CAF. Only HCT116
cells were measured. Data are represented as mean ± SEM (n = 5). Statistically significant values (p < 0.05) are
indicated with *. Unpublished data, paper in preparation.
Co-culture with NFs or CAFs did not induce changes regarding the glycolytic activity
(Figure 58 A and B) in HCT116 cells, whereas the mitochondrial activity was altered. Basal
respiration, maximum respiration and ATP production were significantly increased after co-
culture with NFs in HCT116 cells (Figure 58 C - E). On the other hand, co-culture with CAFs
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tendentially decreased the mitochondrial activity. While cell viability was not changed after
co-culture, cytotoxicity and apoptosis were both significantly decreased in HCT116 cells when
co-cultured with NFs or CAFs (Figure 58 F and H). Taken together the results gained from
co-culture experiments showed that cell-to-cell communication of primary fibroblasts and
HCT116 cells influences the circadian phenotype, changes mitochondrial respiration and
prevents cells from apoptosis and decreases cell cytotoxicity.
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Discussion
4.1 SW480 and SW620 cells - a model for circadian studies in tumour progression
Cancer cell lines show a wide diversity of circadian phenotypes, varying from robust 24 h 
oscillations of core-clock gene expression to a complete loss of oscillations in circadian gene 
expression [10]. These alterations in circadian clock function have impact on cell metabolism 
and proliferation that ultimately lead to different cancer phenotypes [37]. In the present project, 
the consequences of a deregulated clock on cancer progression were studied with a focus on the 
effects of clock disruption on cancer metabolism and the resulting effects on drug response in 
cancer cells. The diversity of clock phenotypes in cancer cell lines was confirmed in selected 
colorectal cancer cell lines. These cells displayed a range of oscillatory profiles, from robust to 
very weak oscillations and with different periods to no detectable oscillations in 
Bmal1-promoter activity at all. However, no correlation could be made between tumour stage 
and clock phenotype, indicating that deregulations of the core-clock in cancer cells are specific 
for a given cell line and might be associated to other factors such as the genetic and epigenetic 
signature of a cell as well as present mutations. 
To study the consequences of a deregulated clock on tumour progression and tumour 
metabolism in greater detail, SW480 and SW620 cells were used as a cellular model for 
colorectal cancer progression in which the consequences of clock gene disruption were tested 
in a time-dependent manner. Both cell lines are derived from the same patient with SW480 cells 
originating from a primary tumour and SW620 cells from a lymph node metastasis. The chosen 
cell model is a commonly used model to study and compare the behaviour of primary and 
metastatic tumours [146], [147]. However, other causes for different phenotypes of both cell 
lines must be considered, apart from their primary and metastatic origin. For example, do these 
cell lines also represent two clones from the same cancer with different features, not necessarily 
pointing toward metastatic versus non-metastatic behaviour. Therefore, a thorough comparison 
between both cell lines using different experimental methods was carried out to confirm the 
usability of this pair of cells as a model for cancer progression. Bioluminescence measurements 
confirmed different clock phenotypes for both cell lines. SW480 cells showed robust 
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oscillations with a period of around 24 h while SW620 showed rather weak oscillations in the
promoter activity of the core-clock genes Bmal1 and Per2. The same tendency was observed in
time course qPCR data of the same genes and other core-clock genes. In line with these
observations, a recently published study identified a large number of differentially expressed
clock genes among different tumour stages, supporting the hypothesised involvement of clock
genes in tumour progression [106]. To exclude the possibility that variations in clock
phenotypes only occur due to different capability to synchronise both cell lines, single-cell time
course microscopy of the core-clock protein REV-ERBα was performed. Higher
time-dependent expression changes in SW480 cells on the single cell level led to the assumption
that different clock phenotypes between SW480 and SW620 cells are indeed based on
differences in the molecular clock. Based on these results, SW480 and SW620 cells seem to be
a suitable model for circadian research in tumour progression.
4.2 A deregulated clock induces alterations on the transcriptome level
To study the consequences of a disrupted clock on the transcriptome level, a 24 h time course
microarray analysis was performed for both SW480 and SW620 cells. This study represents the
first set of time course microarray data for both cell lines and might help to understand how a
deregulated core-clock contributes to tumour progression and metastasis. The time course
microarray study of SW480 and SW620 cells confirmed different time-dependent expression
patterns of core-clock genes and revealed global gene expression changes between both cell
lines. An analysis of differentially expressed genes revealed diverse cancer-associated pathways
to be over-represented. Hence, it is very likely that differences between both cell lines occur
due to their different cancer progression stages and possibly also due to a deregulated clock
associated with different tumour stages. A global phase-shift of oscillating genes was observed
between both cell lines and although the total number of 24 h oscillating genes was very similar,
the intersect of genes that oscillate in both cell lines was rather small. This finding led to the
assumption that a deregulated clock induces a switch in the genetic landscape of
circadian-controlled genes, representing the progression from primary tumour to metastatic
cells. These results are in line with recently analysed time course transcriptome data of the
breast cancer cell line MCF7 and the non-tumourigenic epithelial cell line MCF10A [106]. The
oscillation patterns of several clock genes were disrupted in the cancer cell line, supporting the
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conclusion made in this thesis that core-clock alterations are a characteristic feature of cancer
development and progression. Furthermore, the authors also observed a shift in circadian gene
expression, in line with the results gained in this project, further supporting the hypothesis that
disrupted and reprogrammed circadian rhythms contribute to cancer development. Gene
expression changes on the transcriptome level induced by a deregulated core-clock and a global
phase-shift in the expression of circadian-regulated genes might represent an important step in
tumour progression from a primary tumour towards a metastatic cell line.
An over-representation analysis of all 24 h oscillating genes identified different metabolic
pathways, including glycolysis, Warburg effect and mitochondrial respiration. While the
pathway glycolysis was over-represented in the set of genes oscillating in both cell lines,
metabolic pathways such as the TCA cycle and the Warburg effect were over-represented in the
set of genes oscillating only in SW620 cells. Based on changes in the core-clock between both
cell lines, these metabolic pathways showed different oscillation patterns. Thus, changes in the
core-clock seem to induce a reprogramming of the circadian system in the metastatic cell line
SW620 and appear to contribute to a shift in the metabolic gene expression profile between
both cell lines which consequently leads to metabolic modifications during tumourigenesis and
metastasis. The differential temporal expression between both cell lines led to the hypothesis
that these pathways are differentially regulated by the circadian clock dependent on the tumour
stage. A subsequent analysis of all metabolic genes from the over-represented pathways
revealed differences in their temporal expression patterns between both cell lines. Based on
these results, five putative clock-regulated metabolic candidate genes were identified. One of
these genes was Hkdc1 which encodes a recently identified member of the hexokinase family
that plays a role in glucose metabolism [148]. Furthermore, several studies revealed a potential
role for HKDC1 in tumourigenesis. A recent study points to HKDC1 as a potential therapeutic
target for lung cancer [149] and a high expression of Hkdc1 is associated with poor prognosis
and aggressive phenotype in hepatocarcinoma [131]. Concomitant with these findings,
metastatic SW620 cells showed higher Hkdc1 expression compared to SW480 cells. However,
the mechanisms by which HKDC1 influences cell proliferation and tumour progression are still
unknown, especially in CRC.
The results gained from the analysis of SW480 and SW620 cell lines were compared with data
from primary cells, including normal and cancer-associated human primary fibroblasts as well
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as non-cancerous human fallopian tube organoids. The circadian phenotype of NFs and CAFs
from three patients was evaluated. Although all tested NFs and CAFs exhibited robust
oscillations with similar periods, especially the amplitudes varied between the tested patients.
A time course analysis of Hkdc1 and Bmal1 in normal human fallopian tube organoids revealed
a gene expression profile which rather resembled the profile observed in the primary tumour
cell line SW480, indicating that SW480 cells are more similar to normal tissue than to their
metastatic counterpart SW620.
4.3 A deregulated clock induces metabolic phenotype rewiring
Following the identification of differential expressed metabolic pathways in both cell lines, the
impact of a deregulated clock on metabolic activity and drug response was further analysed. To
get better insights into the interplay between the core-clock and cancer metabolism, a
knockdown of the core-clock gene Bmal1 was carried out in SW480 and SW620 cells. A time
course gene expression analysis of Bmal1 and Hkdc1 confirmed a connection between both
genes, as Bmal1-KD did not only induce changes in the time-dependent expression of Bmal1,
but also of Hkdc1. The postulated connection between the circadian clock and cancer
metabolism could be further clarified after a gene expression analysis in shBmal1 cells. In
addition to its effects on other core-clock genes, Bmal1-KD induced alterations in metabolic
gene expression. Interestingly, in both cell lines most metabolic genes were tendentially
downregulated except for Hkdc1 in SW480-shBmal1 cells, further supporting the hypothesis of
an interplay between Bmal1 and Hkdc1. A study that compared normal and tumour cells
revealed Hk and Aldoc as upregulated, and Pdh as downregulated in most tumours [150]. In the
present study, the same tendency regarding Hkdc1 and Pdhb was observed, leading to the
assumption that these changes are important for both tumour onset and progression. However,
this tendency could not be observed after Bmal1-KD in metastatic SW620 cells, indicating that
the effect of a deregulated clock in cancer cells is dependent on the initial genetic condition of
the cell. Interestingly, the gene expression profile of SW480-shBmal1 and metastatic
SW620-ctrl cells was very similar, supporting the hypothesis that Bmal1-KD induces a
metastatic phenotype in SW480 cells. In line with these findings, the proliferation profile of
SW480-shBmal1 cells resembled that of SW620 cells and both cell types proliferated faster
than SW480 cells. These results support previous studies that point to a role of BMAL1 in
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tumorigenesis, through influencing the cell cycle [52], [151]. Furthermore, lower apoptosis
rates were observed in SW480 cells after Bmal1-KD, again resembling the apoptosis rate
observed for metastatic SW620 cells. Taken together, the induced changes upon Bmal1-KD in
SW480 cells closely resembled the phenotype of SW620 cells, leading to the assumption that a
deregulated clock induces a more metastatic phenotype in cancer cells. Remarkably the
induction of a more metastatic phenotype is also connected to metabolic phenotype rewiring as
shown by the observation that Bmal1-KD induced a more energetic phenotype in SW480 cells
and a change in time-dependent glycolytic activity, both resembling the energy phenotype of
SW620 WT cells.
The results described so far support the hypothesis that perturbations of the core-clock lead to
a more metastatic phenotype, measurable by fast proliferation and high metabolic activity.
Because of the hypothesised role of HKDC1 and BMAL1 in tumour progression and therapy,
the impact of Hkdc1-KD on gene expression and drug response in SW480 and SW620 cells
was evaluated. Bmal1-KD induced upregulation of Hkdc1 expression, while Hkdc1-KD
induced Bmal1 expression in SW480 cells, pointing to a reciprocal control between both genes.
In both CRC cell lines, Hkdc1-KD led to a strong decrease of Pck2 expression. PCK2 is a
mitochondrial enzyme that catalyses the conversion of oxaloacetate to phosphoenolpyruvate
(PEP). The functional role of the mitochondrial isoform PCK2 is likely linked to the provision
of precursor intermediates for the biosynthesis of phospholipids, amino acids and purines
thereby fulfilling the increased demand for biomass in rapidly proliferating cells [152]. This is
particularly relevant in cancer cells under restricted glucose where glutamine-derived
oxaloacetate is converted into PEP by PCK2. Additionally, Hkdc1-KD induced changes in
core-clock gene expression, mainly in SW480 cells, suggesting, that the interplay between the
core-clock and HKDC1 is stronger in SW480 cells than in SW620 cells. As mentioned above,
the reciprocal interplay between Bmal1 and Hkdc1 seems to be dependent from the initial
genetic condition of the particular cell line.
Cancer cells show a variety of metabolic alterations to fulfil the anabolic demands of tumour
cells, including glycolysis [65]. High rates of aerobic glycolysis are maintained, known as the
Warburg effect. Although enhanced aerobic glycolysis has been used as a marker to distinguish
cancer cells from normal cells already decades ago, an elevated glucose metabolism was only
very recently defined as one of the hallmarks of cancer [64]. Besides glycolytic activity,
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mitochondrial function also plays a role in tumour growth and metastasis [66]. Published data
show that highly metastatic tumours increase mitochondrial NADPH and undergo further
metabolic changes to fight stress caused by ROS [142]. To further evaluate the role of a
deregulated clock in metabolic phenotype rewiring during tumourigenesis, glycolysis and
mitochondrial respiration were measured under different conditions. While the metabolic
activity was similar in both WT cell lines, glycolysis as well as mitochondrial respiration were
increased in SW480 cells after Bmal1-KD. These results are in line with a reported inhibitory
effect of intracellular glucose on the expression of the core-clock genes Bmal1, Per1 and Per2,
pointing to an interplay between glycolysis and the circadian clock [83]. Furthermore, the
higher Hkdc1 expression observed in SW480-shBmal1 cells and the subsequent increase of
glycolytic activity agree with the reported reprogramming of metabolism in cancer cells [64],
[142], [153], which allows them to fulfil the enhanced energy demands of fast growing and
proliferating cells. However, the KD of Bmal1 led to a decrease in metabolic activity in SW620
cells, again indicating that the effect of a deregulated clock on tumour metabolism is dependent
on the initial genetic status of a cell. Remarkably, the time-dependent glycolytic activity
observed in SW480-ctrl cells was disrupted upon Bmal1-KD. These observations point to a
regulation of tumour metabolism by the circadian clock and a circadian regulation of temporal
patterns in metabolic activity that are lost upon clock disruption through Bmal1-KD. Upon
Hkdc1-KD, glycolysis decreased in both cell lines, while mitochondrial respiration was not
affected. On the one hand, a decrease in glycolytic activity was expected, as HKDC1 is a central
enzyme of the glycolytic pathway. On the other hand, other members of the HK family might
have compensated the effects Hkdc1-KD.
Taken together, these results point to a reciprocal interplay between Hkdc1 and the circadian
clock, in particular in SW480 cells, since the KD of Bmal1 led to a higher Hkdc1 expression
and consequently to a higher metabolic activity in these cells. Additionally, a KD of Hkdc1 led
to higher Bmal1 expression and slightly lower glycolytic activity. In general, a KD of Bmal1
led to a slight increase in metabolic activity in SW480 cells, but to the opposite change in
SW620 cells. Upon Bmal1-KD, Hkdc1 expression was upregulated in SW480 cells, but not in
SW620 cells. This is likely a result from the overall increased metabolic activity of
SW480-shBmal1 cells. Thus, Hkdc1 is a putative mediator of time-dependent effects on energy
producing metabolic pathways. Overall, the data shows that a dysregulation of the biological
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clock leads to alterations in expression of metabolic genes, as well as in metabolic activity that
could be pivotal in colorectal cancer progression.
Findings from the CRC cell lines regarding the circadian regulation of metabolic genes were
further validated in primary fibroblasts isolated from normal colon (NF) and colon
adenocarcinoma (CAF) of the same patient. In NFs, Bmal1-KD led to a downregulation of
Hkdc1 and a subsequent inhibition of glycolytic activity. These results suggest that clock
disruption via Bmal1-KD leads to changes in the expression levels of Hkdc1 with subsequent
effects on glycolysis. In normal cells, the inhibition of Hkdc1 and glycolysis is favoured, while
in primary tumour cells an upregulation of Hkdc1 and glycolysis is preferred, resulting in a
more cancerous phenotype. These results further support the above made conclusion, that the
initial genetic composition of a cell determines the effect of Bmal1-KD. As a second
non-cancerous cell model, human fallopian tube organoids were used. WT organoids and
p53-KD organoids were tested for their circadian phenotype. The knockdown of the tumour
suppressor p53 should serve as a more cancerous stadium as compared to the WT organoids.
P53-KD had strong effects on core-clock and metabolic gene expression. While core-clock
genes were downregulated upon p53-KD, metabolic candidate genes were upregulated,
supporting the assumptions made so far that a more cancerous phenotype is linked to a
deregulated clock and enhanced metabolic activity.
The results from the present study point to a tumour suppressor role of BMAL1. This is in line
with published data including recent work from our group [52], [154]. Furthermore, after
Bmal1-KD, SW480 cells proliferate faster and their proliferation profile resembles that of the
metastasis-derived SW620 cells. This leads to the assumption that a deregulated clock induces
a more metastatic phenotype which is further supported by the observation that
SW480-shBmal1 cells develop an active energy phenotype that is similar to that of SW620-ctrl
cells in order to fulfil the energetic demands of proliferating cells.
4.4 A deregulated clock impacts on response to anticancer treatment
The results discussed so far show that the circadian clock regulates tumour metabolism,
partially in a time-dependent manner. As a logical consequence, the following experiments on
the role of a deregulated clock on treatment response were not only performed at a single
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timepoint but at three different timepoints after cell synchronisation. In recent years, cancer
therapy approaches increasingly take the circadian timing of treatment administration into
account to improve tolerability of anti-cancer drugs and treatment efficacy. Chronotherapy
protocols have been used in chronomodulated chemotherapy [95] and time-dependent
radiotherapy scheduling [96]–[99]. Based on the idea of chronotherapeutic treatment strategies
SW480 and SW620 cells were treated with the GLUT1 inhibitor WZB117 at three different
timepoints after synchronisation to analyse putative time-dependent treatment effects. The
glucose transporter GLUT1 was shown to be upregulated in different cancer types and therefore
is a potential target for cancer therapy [155], [156]. WZB117 inhibits GLUT1 by binding at the
exofacial sugar binding site [157]. WZB117 was shown to inhibit cell growth in cancer cell
lines as well as in a nude mouse model. WZB117 treatment decreased GLUT1 levels,
intracellular ATP, and glycolytic enzymes finally resulting in cell-cycle arrest, senescence, and
necrosis [72]. Furthermore, a study showed that 5-Fu resistance, a commonly used drug in colon
cancer treatment, was associated with Glut1 overexpression in colon cancer cells and that
WZB117 treatment significantly increased the sensitivity of 5-Fu resistant cells to the drug,
providing new treatment options for patients with 5-Fu resistance [73]. In the present study,
WZB117 showed a strong impact on clock gene expression, in line with the described inhibitory
effect of intracellular glucose on clock gene expression [83]. Interestingly, Bmal1 and Rev-erbα
were upregulated in SW480 cells after WZB117 treatment in all conditions (ctrl, shBmal1,
shHkdc1). In SW620 cells, the effect of WZB117 on core-clock gene expression was weaker.
WZB117 also induced expression changes of Hkdc1. While Hkdc1 was upregulated upon
treatment in SW480-shBmal1 and SW480-shHkdc1 cells, in SW620 cells Hkdc1 was only
upregulated upon treatment in shHkdc1 cells. Taken together, the effects of WZB117 treatment
on core-clock and metabolic gene expression support the above made conclusion that the initial
genetic condition of a cell is responsible for the resulting treatment response. The effect of
WZB117 treatment on the circadian phenotype was further evaluated by treating ctrl and
shBmal1 cells at three different timepoints after synchronisation and measuring the
Bmal1-promoter activity. The effects of WZB117 treatment on the circadian phenotype differed
depending on the time of treatment. These results indicate that the circadian clock is affected
by anticancer treatment aiming at the cells metabolism and that the effect depends on the
treatment time. A chronotherapeutic approach might therefore not only be reasonable because
of the effect of a drug itself, but also because a certain treatment time might affect the clock to
a lesser extent than another treatment timepoint. Regarding metabolic effects, WZB117
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treatment induced a change towards a more quiescent energy phenotype in all conditions.
However, as the initial energy phenotype in SW480-shBmal1 cells was more energetic than in
ctrl cells, the resulting energy phenotype after WZB117 treatment was still more energetic than
in ctrl cells, meaning that the result of treatment is less effective in shBmal1 cells. The same
tendency could be observed regarding the glycolytic activity. Although WZB117 treatment
decreased glycolysis in ctrl as well as in shBmal1 cells, the effect was higher in ctrl than in
shBmal1 cells. In line with these results, high Bmal1 expression was reported to increase
sensitivity to cancer therapeutics in different cancer types [56], [136], [158]. A study using
Plasmodium-infected erythrocytes treated with WZB117 showed that WZB117 inhibited
glucose transporters and perturbed glycolysis. In consequence, glucose levels decreased, ROS
levels increased and apoptosis was induced [159]. However, in the present study glycolysis was
inhibited by WZB117 treatment while at the same time apoptosis was decreased, indicating a
different mechanism of action in CRC cell lines. Alternatively, the temporal treatment window
was too short to monitor the apoptotic effects of WZB117 treatment. Although WZB117 is a
specific GLUT1 inhibitor, mitochondrial respiration was also affected upon WZB117 treatment.
However, the results were different from those observed for glycolytic activity. The inhibitory
effect of WZB117 treatment on mitochondrial respiration was much stronger in shBmal1 cells.
Taken together, in WT cells, WZB117 treatment has strong effects on glycolytic activity but
minor effects on mitochondrial respiration. On the opposite, in Bmal1-KD and Hkdc1-KD cells,
WZB117 treatment has only minor effects on glycolytic activity but stronger effects on
mitochondrial respiration. In conclusion, after Bmal1-KD the efficacy of WZB117 treatment is
changed from glycolysis inhibition towards inhibition of mitochondrial respiration. Possible
reasons for the different effects might be due to a metabolic phenotype rewiring upon
Bmal1-KD that induces the glycolytic pathway and protects cells from treatment aiming at this
pathway but at the same time increases sensitivity at a different point of metabolism. The effects
of Bmal1- and Hkdc1-KD on cancer metabolism and treatment response are schematically
represented in Figure 59. Based on the results from this study, a deregulated clock might
decrease treatment sensitivity of cancer cells and might consequently lead to poor prognosis.
These results fit with published studies on the effect of clock gene expression on treatment
sensitivity. In a study in tongue squamous cells, Bmal1 inhibited tumourigenesis and increased
sensitivity to paclitaxel [158]. Furthermore, in CRC cell lines, overexpression of Bmal1
increased sensitivity to oxaliplatin treatment [56]. The results gained from WZB117 treatment
were compared to oxaliplatin treatment, a platinum-based antineoplastic agent that is widely
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used in chemotherapy for colorectal cancer [56], [160], [161]. Oxaliplatin exerts its cytotoxic
effects mainly through DNA damage. Apoptosis of cancer cells can be caused by different
mechanisms, including formation of DNA lesions, arrest of DNA synthesis and inhibition of
RNA synthesis [162]. A comparison of the results after WZB117 treatment with oxaliplatin
showed that oxaliplatin treatment did not have effects on cell metabolism measured by energy
phenotype, glycolysis and mitochondrial respiration. Thus, the results gained from WZB117
treatment are specific for a metabolism-targeting anticancer treatment.
Figure 59: The interplay between the biological clock and metabolism in tumorigenesis
In the primary tumour cell line (SW480), clock gene disruption (shBmal1) leads to the upregulation of Hkdc1 and
subsequent activation of metabolic activity (glycolysis and mitochondrial respiration). The downregulation of
Hkdc1 (shHkdc1) leads to the upregulation of Bmal1. Upon treatment with WZB117, metabolic activity is inhibited
in shBmal1 cells, and glycolytic activity is inhibited to a lesser extent than in SW480-ctrl cells, partially explained
by an increase of Hkdc1 expression in shBmal1 cells. In the metastatic cells (SW620) the effect of clock gene
disruption (shBmal1) on Hkdc1 expression is rather low and consequently Bmal1-KD leads to a slight inhibition
of metabolic activity (glycolysis and mitochondrial respiration). After treatment with WZB117, the glycolytic
activity is inhibited in shBmal1 cells, and mitochondrial respiration is inhibited to a much larger extent. The effect
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of WZB117 treatment is weaker in the shHkdc1 cells. The size of the ellipses represents the relative RNA quantity,
the width of the connecting lines represents the impact of the interaction. Adapted from Fuhr et al., 2018 [1].
Although the selection of a temporal window of six hours is too short to access detailed
chronopharmacology profiles, the results indicate that the relative efficacy of treatment on the
metabolic activity appears to change depending on the time of drug administration. This result
provides insights into the scheduling of chronotherapeutic protocols targeting cancer cell
metabolism and prompts to further deepen these studies in future work. The results further point
to a role for the circadian clock in tumourigenesis, indicating that the disruption of the biological
clock leads to a more metastatic phenotype. Metabolic alterations during tumorigenesis are a
relevant factor to be considered for drug resistance [66]. While expression changes in some
metabolic pathways including glycolysis are frequently observed during tumourigenesis,
alterations in other pathways such as oxidative phosphorylation are very heterogeneous [150].
Glycolysis is an attractive target for cancer therapy with promising therapeutic potential, since
many tumours increase glucose uptake and show elevated glycolysis rates. A possible
glycolysis-related target might be the hexokinase HK2 which is upregulated in different tumour
types and whose inhibition slows down tumour progression [66]. Although some isoforms of
glycolytic enzymes are only present in cancer cells and not in normal cells, such as the
hexokinase isoform HK2, the close similarity of different isoforms still makes them a difficult
target, thus complicating the use of glycolysis as a potential therapeutic target [65]. An
alternative candidate for targeting glycolysis might be the gene Hkdc1 that was identified in
this study as an important regulator via which the circadian clock influences metabolism in
colorectal cancer cells. Importantly, the effect of Bmal1 on metabolic function can be mediated
in different ways. Either by influencing the clock machinery, and altering circadian rhythms, or
by influencing the expression of genes that are direct targets of the CLOCK/BMAL1 complex.
This could also be the result of other potential, non-circadian functions of BMAL1. As such, in
order to differentiate between these two hypotheses and to better characterise the specific output
results of Bmal1-KD phenotypes, further studies are necessary.
Altogether, the results from this project show that the circadian clock regulates metabolism in
cancer cells with implications in metabolic phenotype rewiring observed during tumour
progression. Additionally, the data suggests a role for the circadian clock in fine-tuning both
drug efficiency and timing in cancer treatment, highlighting its crucial function as an elicitor of
treatment response.
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4.5 Cell-to-cell communication impacts on the circadian phenotype
It is common in oncological research to date to carry out experiments in human cancer cell
lines, representing only one type of tumour cells. However, a tumour consists of a complex
tissue, composed of different cell types mainly derived by the neighbouring stroma which make
up the tumour microenvironment [143]. In normal colonic mucosa, the stromal population
mainly consists of fibroblasts [144]. During tumourigenesis, fibroblasts may differentiate into
cancer-associated fibroblasts which are then the main cellular component of tumour stroma.
[145]. CAFs secrete growth factors and thereby support tumour growth and migration. They
promote survival and proliferation in primary tumours as well as in metastasis [134]. Insights
into the role of the tumour microenvironment show that cancer development is inseparably
connected to it [144]. Based on this knowledge, CAFs and NFs were co-cultured with HCT116
cells and the impact of cell-to-cell communication on the circadian phenotype of HCT116 cells
was evaluated. Co-culture induced both, a phase shift and a longer period in HCT116 cells.
Interestingly, the longer period of HCT116 cells after co-culture closely resembled the period
length of NFs and CAFs, suggesting that fibroblasts influence the cancer cell line`s period
length into the direction of their own period length. The results are in line with existing findings
that co-culture of fibroblasts and other cells has a profound impact on the expression of
circadian genes [163]. Other co-culture experiments in the context of circadian research include
experiments where the SCN was co-cultured with another cell type [164]. The observed effects
on the circadian phenotype could be extended to the metabolic activity, cytotoxicity and
apoptosis. While glycolysis was not affected in HCT116 cells upon co-culture, mitochondrial
activity was altered. Basal respiration, maximum respiration and ATP production were
significantly increased after co-culture with NFs in HCT116 cells. On the other hand, co-culture
with CAFs tendentially decreased the mitochondrial activity. These results suggest that the
surrounding stroma regulates metabolic activity in cancer cells and that the effects on cell
metabolism may differ based on the type of surrounding cells. Furthermore, cytotoxicity and
apoptosis were both significantly decreased in HCT116 cells when co-cultured with NFs or
CAFs, leading to the assumption that the surrounding stroma protects cancer cells from cell
death and promotes cell survival and growth. Taken together, the results gained from co-culture
experiments show that cancer cells are highly affected by surrounding cells not only with
respect to their circadian phenotype but also with respect to their metabolic activity and cell
survival. Results from this study should be considered for future experiments and when
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possible, co-culture experiments with different cell types should be preferred over experiments
with one cell type only.
4.6 Conclusions and future perspectives
The circadian clock is a powerful endogenous timing system that regulates many aspects of
human physiology. The role of the circadian clock in cancer and cancer-associated metabolic
alterations has already been proposed by various studies. The results gained in this project
further support the postulated interplay between the circadian clock and tumour metabolism
and identify new connections between both systems. The role of the core-clock gene Bmal1 as
a tumour suppressor was further affirmed, as Bmal1-KD induced a more metastatic phenotype
in SW480 cells. Moreover, Bmal1-KD induced metabolic phenotype rewiring by changing the
overall metabolic activity as well as the time-dependent metabolic profile of the cells. Finally,
Bmal1-KD led to changes in the response to treatment with the glycolysis inhibitor WZB117.
The consequences of a deregulated clock on cancer metabolism and treatment response in
colorectal cancer cell lines seem to be partly mediated by the glycolytic hexokinase HKDC1.
However, further experiments are necessary to overcome limitations and extend the insights
gained from the present study. The time course microarray experiment performed during this
project served as a starting point to identify over-represented pathways and candidate genes
between SW480 and SW620 cells. Due to financial reasons, it was not possible to have
replicates for each timepoint or to extend the timeframe to two full circadian cycles with smaller
sampling intervals. Therefore, candidate genes were validated via 45 h time course qPCR. In
future work, it will be beneficial to perform time course transcriptome studies with a longer
timeframe. In the present project, time course transcriptome data were only available for
SW480 and SW620 cells lines. In further studies, the additional use of a non-cancerous primary
cell model as well as transcriptome data from SW480-shBmal1 and SW620-shBmal1 cells will
be needed to generate a broader picture of the role of the circadian clock in tumourigenesis. To
address the question whether Bmal1 itself or the circadian clock in general is responsible for
the effects on cancer metabolism and treatment response in this project, knockdown studies
with another core-clock gene, for example Per2, will be needed. Due to time limits of this
project, a repetition of the experiments with Per2-KD cells was not possible. Moreover, the
timeframe of six hours used for time-dependent treatment in the present project gave hints that
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the timing indeed plays a role in treatment response to metabolism-targeting drugs but is too
short to generate reliable chronopharmacological profiles. Hence, in future work, a longer
timeframe should be considered. Furthermore, animal studies will be needed to test whether the
results gained from cell lines can be transferred to other model organisms in vivo. The treatment
with the glycolysis inhibitor WZB117 showed that the circadian phenotype influences the effect
of treatment on metabolic activity in colorectal cancer cells. To be able to make clear statements
about the anti-cancer effects of metabolism-targeting drugs, further experiments are needed to
investigate the effect on cell proliferation and cell survival. Furthermore, as described above,
the treatment with drugs that target cell metabolism is difficult, as these drugs should ideally
only target the metabolism of cancer cells and should not induce global metabolic effects. For
this purpose, the identification of metabolic targets that are preferably only expressed in cancer
cells is an important aim for future studies [67], [69], [70]. Although HK2 was identified as a
possible metabolic target, the close similarity of different isoforms of glycolytic enzymes makes
glycolysis still a difficult target in anti-cancer therapy [63], [65]. Likewise, antidiabetic drugs
have been explored with respect to their anti-cancer activity [165] while other studies explored
the Warburg effect as another potential target for anti-cancer therapy [71]. Furthermore,
glutamine metabolism is an additional potential target for anticancer drugs. Although studies
with inhibitors of glutamine metabolism have already been carried out, the toxicity of
metabolism-targeting drugs remains an issue and the potential therapeutic resistance of cancer
cells adds a new layer of complexity to this field of research [166]. Generally, different
metabolism-targeting drugs may potentially be used in cancer therapy, based on the metabolic
alterations a specific tumour has [167]. Another target that should be brought into focus is the
circadian clock itself. Several attempts have been made to identify modulators of the circadian
clock. These include small molecule clock modulators in general, REV-ERB agonists, ligand
modulators of ROR, CRY stabilizers and circadian clock modulators from existing drugs, such
as the period-shortening compound dehydroepiandrosterone (DHEA) [79], [168]–[172]. A
study in mice showed that the clock-modulating compound L-methyl selenocysteine (MSC)
elevates Bmal1 transcription and protects mice against toxicity induced by the
chemotherapeutic agent cyclophosphamide [173]. Although to date studies on this topic are
rare, modulators that target the circadian clock offer a new possibility to existing
chronotherapeutic approaches to cancer by providing pharmacological tools to actively adjust
the molecular clock and thereby improving treatment efficiency and tolerability of a given
anti-cancer agent.
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Taken together, the results gained in this study elucidate new ways by which the circadian clock
regulates metabolic phenotype rewiring during tumourigenesis and support the hypothesised
role of the circadian clock as a tumour suppressor. The study gives new insights into the
circadian regulation of cancer metabolism that may have implications on the development of
new drug targets for cancer therapy and the timing of chronotherapeutic treatment protocols.
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Supplementary information
Figure S 1: Vector map of the BLH vector
BLH (Bmal1-promoter-Luciferase-Hygromycin) vector. The luciferase is under the control of the Bmal1-promoter.
The selection marker is hygromycin.
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Figure S 2: Vector map of the PLB vector
PLB (Per2-promoter-Luciferase-Hygromycin) vector. The luciferase is under the control of the Per2-promoter.
The selection marker is blasticidin.
Figure S 3: Vector map of the psPAX2 packaging vector
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Figure S 4: Vector map of the pMD2.G envelope plasmid
Figure S 5: Vector map of the pLKO.1 plasmid
Table S 1: Mean period with SEM of different tested colorectal cancer cell lines
Cells were lentivirally transduced with a Bmal1-luciferase construct (BLH) and synchronised with 1µM
dexamethasone for 30 minutes. Bioluminescence was measured over five days. The mean period and SEM were
calculated based on three replicates.
Cell line Period (h) SEM
CaCo2 45.37 11.81
Colo678 26.70 0.09
DLD1 22.63 0.15
HCT116 23.18 0.31
HT29 26.57 5.12
LIM1215 22.01 0.63
RKO 35.85 1.63
SW480 23.79 0.70
SW620 28.31 1.77
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Table S 2: RAIN and harmonic regression analysis of core-clock and metabolic candidate genes.
Data are derived from 45 h time course qPCR. Adapted from Fuhr et al., 2018 [1].
Table S 3: Rain analysis of core-clock genes in SW480 and SW620 cells
Rain analysis was performed with 24 h time course microarray data. P-values < 0.05 are marked in green,
p-values > 0.05 are marked in red.
Gene SW480 p-value SW620 p-value
Bmal1 0.006111224 > 0.05
Bmal2 > 0.05 > 0.05
Cry1 0.012131716 > 0.05
Cry2 > 0.05 > 0.05
Clock > 0.05 > 0.05
Npas2 > 0.05 0.022373697
Rora 0.043383585 > 0.05
Rorb > 0.05 > 0.05
Rorc > 0.05 > 0.05
Rev-erba 0.011438475 > 0.05
Rev-erbb 0.008786381 0.002249272
Per1 0.004265529 0.028788217
Per2 0.031167244 0.004398827
Per3 0.006111224 > 0.05
SW480 SW620
Period p-value
Relative
Amplitude Phase Mesor Period p-value
Relative
Amplitude Phase Mesor p-value p-value
Bmal1 26.1 2.2E-05 0.385 8.0 1.11 21.2 3.9E-03 0.301 21.3 1.10 -13.3 9.8E-06 2.6E-02
Per2 20.2 2.5E-03 0.346 4.6 1.16 23.1 2.7E-01 0.129 21.4 1.09 -16.8 1.2E-09 3.7E-03
Cry1 28 1.3E-02 0.339 3.4 1.22 28 1.1E-03 0.365 1.0 1.12 2.4 1.8E-04 4.7E-06
Cry2 28 4.3E-01 0.315 8.6 1.53 27.3 2.0E-03 0.552 7.8 1.23 0.9 9.9E-01 6.3E-05
Reverba 20 6.9E-02 0.321 18.3 1.23 28 3.1E-04 0.576 20.8 1.25 -2.5 8.4E-01 3.6E-05
Pdhb 28 1.7E-03 0.465 2.7 1.31 20.1 1.8E-02 0.130 4.7 1.02 -2.1 2.8E-03 2.4E-03
Pck2 20 5.4E-02 0.347 2.7 1.36 21.7 4.2E-02 0.129 1.4 1.03 1.3 8.4E-02 6.4E-02
Aldoc 20.5 2.6E-01 0.297 4.1 1.63 28 1.0E-04 0.284 12.5 1.08 -8.4 1.9E-02 8.8E-04
Aldh3a2 28 1.2E-02 0.465 3.2 1.44 20 3.3E-03 0.228 3.1 1.06 0.1 7.5E-01 1.7E-02
Hkdc1 28 5.7E-04 0.562 3.7 1.48 28 1.6E-05 0.353 16.8 1.10 -13.1 8.3E-04 2.8E-08
RAIN
SW620SW480
RT-qPCR Data (Harmonic Regression)
Gene
Phase
shift
(SW480-
SW620)
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Table S 4: Over-representation analysis of top differentially expressed genes, pathway based
All differentially expressed genes between SW480 and SW620 cells were taken into account with lfc > 2 and
p < 0.001.
p-value pathway source
1.41E-05 Validated transcriptional targets of TAp63 isoforms PID
9.52E-05 Validated transcriptional targets of deltaNp63 isoforms PID
0.000187427 Extracellular vesicle-mediated signaling in recipient cells Wikipathways
0.000225801 Axon guidance - Homo sapiens (human) KEGG
0.000430668 Wnt Signaling Pathway and Pluripotency Wikipathways
0.000497315 p53 signaling pathway - Homo sapiens (human) KEGG
0.000724733 Hippo signaling pathway - Homo sapiens (human) KEGG
0.000910717 Transcriptional regulation of pluripotent stem cells Wikipathways
0.001235166 Signaling Pathways in Glioblastoma Wikipathways
0.001604464 Pathways in cancer - Homo sapiens (human) KEGG
0.001888413 Paclitaxel Action Pathway SMPDB
0.001888413 Docetaxel Action Pathway SMPDB
0.002439395 Direct p53 effectors PID
0.00267005 Cell-cell junction organization Reactome
0.003196557 retinoate biosynthesis I HumanCyc
0.003196557 Pravastatin Pathway, Pharmacokinetics PharmGKB
0.005415293 Adherens junction - Homo sapiens (human) KEGG
0.005415293 Primary Focal Segmental Glomerulosclerosis FSGS Wikipathways
0.006753106 il-10 anti-inflammatory signaling pathway BioCarta
0.006753106 Taxane Pathway, Pharmacokinetics PharmGKB
0.006753106 Methotrexate Pathway, Pharmacokinetics PharmGKB
0.007829117 Atorvastatin/Lovastatin/Simvastatin Pathway, Pharmacokinetics PharmGKB
0.008217788 Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling PID
0.009318316 a6b1 and a6b4 Integrin signaling PID
0.009603683 Cell junction organization Reactome
0.009993034 Hematopoietic cell lineage - Homo sapiens (human) KEGG
Table S 5: Over-representation analysis of top differentially expressed genes, GO terms
All differentially expressed genes between SW480 and SW620 cells were taken into account with lfc > 2 and
p < 0.001.
p-value term_category term_name
1.61E-08 b positive regulation of cell communication
2.67E-07 b regulation of programmed cell death
4.73E-07 b apoptotic process
7.14E-07 b positive regulation of macromolecule metabolic process
1.07E-06 b epithelial cell differentiation
1.80E-06 b positive regulation of cell death
1.99E-06 b positive regulation of signal transduction
4.29E-06 b positive regulation of cellular metabolic process
7.35E-06 b positive regulation of cell differentiation
1.60E-05 b neurogenesis
2.39E-05 b neuron differentiation
5.25E-05 b leukocyte differentiation
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5.79E-05 b positive regulation of biosynthetic process
6.57E-05 b axon guidance
7.66E-05 c apical dendrite
0.000100991 b mammary gland morphogenesis
0.000117053 b regulation of intracellular signal transduction
0.000218985 b cell morphogenesis involved in differentiation
0.000226766 b regulation of epithelial cell proliferation
0.00024409 b salivary gland morphogenesis
0.000252268 b kidney epithelium development
0.000274606 b axon development
0.000314784 b positive regulation of nervous system development
0.000338907 b eye morphogenesis
0.000405577 b stem cell differentiation
0.000430845 b homophilic cell adhesion via plasma membrane adhesion molecules
0.000477846 b regulation of cellular protein metabolic process
0.0006051 b negative regulation of cellular component movement
0.0007661 b morphogenesis of an epithelial sheet
0.00077592 b glial cell differentiation
0.00086486 m
transcriptional activator activity, RNA polymerase II core promoter
proximal region sequence-specific binding
0.000881994 b regulation of protein metabolic process
0.00115633 b regulation of cell development
0.001179953 b
calcium-independent cell-cell adhesion via plasma membrane cell-
adhesion molecules
0.001179953 b branching involved in salivary gland morphogenesis
0.001286036 b regulation of Wnt signaling pathway
0.001332245 b regulation of insulin-like growth factor receptor signaling pathway
0.001458414 b negative regulation of cell proliferation
0.001461174 b positive regulation of cell adhesion
0.001500647 b negative regulation of cell communication
0.001568083 b regulation of secondary metabolite biosynthetic process
0.001570582 b cell surface receptor signaling pathway
0.001614836 b negative regulation of leukocyte activation
0.001615225 b epidermis development
0.001690867 b regulation of interleukin-8 production
0.001692798 b negative regulation of response to external stimulus
0.001916087 m ubiquitin protein ligase binding
0.002075534 b myelination
0.002078709 b retinoic acid biosynthetic process
0.002078709 m axon guidance receptor activity
0.002130877 b mesenchymal cell development
0.002248714 b negative regulation of signal transduction
0.002471807 b epithelial cell migration
0.002679048 b positive regulation of nitrogen compound metabolic process
0.002850607 b negative regulation of cell activation
0.002894657 b positive regulation of cellular component organization
0.002971823 b negative regulation of cell adhesion
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0.003329158 b regulation of nervous system development
0.003910836 b intracellular signal transduction
0.003918285 b mammary gland epithelium development
0.004012977 b terpenoid biosynthetic process
0.004114258 b T cell mediated immunity
0.004166679 b embryonic axis specification
0.004186821 b regulation of lipid biosynthetic process
0.004186821 b regulation of epithelial cell differentiation
0.004316752 b central nervous system neuron development
0.0046561 b muscle cell differentiation
0.004787853 b myelin maintenance
0.005743005 b regulation of cell-cell adhesion
0.006465988 b negative regulation of cell death
0.006525736 b astrocyte development
0.006525736 b tripartite regional subdivision
0.006859973 b regulation of cytokine secretion
0.007016702 b cellular response to lipid
0.007229704 b cell differentiation involved in kidney development
0.008506827 b cardiac right ventricle morphogenesis
0.008506827 b renal filtration cell differentiation
0.008645037 b anterior/posterior axis specification
0.009585771 b pericardium development
0.009672498 b negative regulation of behavior
Table S 6: Over-representation analysis of genes oscillating in SW480 and SW620 cells
p-value pathway source
2.09E-30 S Phase Reactome
5.64E-28 Cell Cycle, Mitotic Reactome
2.47E-26 DNA Replication Reactome
3.56E-26 Cell Cycle Reactome
1.07E-25 Synthesis of DNA Reactome
1.32E-24 DNA strand elongation Reactome
8.85E-23 DNA replication - Homo sapiens (human) KEGG
5.80E-20 DNA Replication Wikipathways
8.18E-20 Chromosome Maintenance Reactome
7.64E-19 Telomere Maintenance Reactome
1.02E-17 G1/S Transition Reactome
2.09E-17 Retinoblastoma (RB) in Cancer Wikipathways
2.43E-16 Mitotic G1-G1/S phases Reactome
3.44E-16 DNA Replication Pre-Initiation Reactome
3.44E-16 M/G1 Transition Reactome
1.43E-15 Activation of the pre-replicative complex Reactome
1.21E-14 Extension of Telomeres Reactome
1.34E-14 Telomere C-strand (Lagging Strand) Synthesis Reactome
6.78E-14 Unwinding of DNA Reactome
3.86E-13 Cell Cycle Checkpoints Reactome
4.39E-13 Activation of ATR in response to replication stress Reactome
8.10E-13 G2/M Checkpoints Reactome
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1.16E-12 Lagging Strand Synthesis Reactome
3.36E-12 Resolution of AP sites via the multiple-nucleotide patch replacement pathway Reactome
3.98E-12 G1 to S cell cycle control Wikipathways
3.91E-11 M Phase Reactome
9.10E-11 Processive synthesis on the lagging strand Reactome
9.10E-11 Gap-filling DNA repair synthesis and ligation in GG-NER Reactome
9.10E-11 Gap-filling DNA repair synthesis and ligation in TC-NER Reactome
9.23E-11 PCNA-Dependent Long Patch Base Excision Repair Reactome
1.75E-10 Mismatch repair - Homo sapiens (human) KEGG
2.20E-10 DNA Repair Reactome
2.38E-10 Resolution of Abasic Sites (AP sites) Reactome
2.38E-10 Base Excision Repair Reactome
2.48E-10 Removal of the Flap Intermediate Reactome
2.48E-10 Cell Cycle Wikipathways
4.65E-10 Removal of licensing factors from origins Reactome
4.65E-10 Regulation of DNA replication Reactome
7.97E-10 cdk regulation of dna replication BioCarta
8.61E-10 Repair synthesis of patch ~27-30 bases long  by DNA polymerase Reactome
8.61E-10 Repair synthesis for gap-filling by DNA polymerase in TC-NER Reactome
1.02E-09 Parkin-Ubiquitin Proteasomal System pathway Wikipathways
1.95E-09 Proteasome Degradation Wikipathways
2.66E-09 Mitotic Prophase Reactome
4.65E-09 Assembly of the pre-replicative complex Reactome
6.81E-09 ATR signaling pathway PID
7.95E-09 Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) Reactome
7.95E-09 Polymerase switching on the C-strand of the telomere Reactome
7.95E-09 Polymerase switching Reactome
7.95E-09 Leading Strand Synthesis Reactome
2.07E-08 Orc1 removal from chromatin Reactome
2.07E-08 Switching of origins to a post-replicative state Reactome
2.21E-08 Mismatch Repair Reactome
2.37E-08 Processive synthesis on the C-strand of the telomere Reactome
3.69E-08 Processing of Capped Intron-Containing Pre-mRNA Reactome
5.83E-08
Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA
template Reactome
6.41E-08 Recognition of DNA damage by PCNA-containing replication complex Reactome
6.57E-08 Removal of the Flap Intermediate from the C-strand Reactome
8.15E-08 Base excision repair - Homo sapiens (human) KEGG
1.23E-07 Transcriptional regulation by small RNAs Reactome
1.29E-07 Proteasome - Homo sapiens (human) KEGG
1.52E-07 Pyrimidine metabolism - Homo sapiens (human) KEGG
1.86E-07 Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) Reactome
1.98E-07 Global Genomic NER (GG-NER) Reactome
2.63E-07 DNA Damage Bypass Reactome
2.81E-07 Cellular Senescence Reactome
3.11E-07 Packaging Of Telomere Ends Reactome
3.69E-07 Nucleotide excision repair - Homo sapiens (human) KEGG
3.69E-07 Transcription-coupled NER (TC-NER) Reactome
4.00E-07 Cellular responses to stress Reactome
4.05E-07 Cell cycle - Homo sapiens (human) KEGG
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4.58E-07 DNA methylation Reactome
5.05E-07 Translesion Synthesis by POLH Reactome
6.60E-07 Mismatch repair Wikipathways
7.99E-07 Cytosolic tRNA aminoacylation Reactome
8.06E-07 Regulatory RNA pathways Reactome
8.35E-07 Oxidative Stress Induced Senescence Reactome
9.68E-07 Viral carcinogenesis - Homo sapiens (human) KEGG
1.16E-06 E2F transcription factor network PID
1.50E-06 Termination of translesion DNA synthesis Reactome
1.53E-06 Disease Reactome
1.73E-06 Nucleotide Excision Repair Reactome
2.28E-06 RHO GTPase Effectors Reactome
2.40E-06 Gene Expression Reactome
3.19E-06 PRC2 methylates histones and DNA Reactome
3.53E-06
Activated PKN1 stimulates transcription of AR (androgen receptor) regulated
genes KLK2 and KLK3 Reactome
3.64E-06 Deposition of new CENPA-containing nucleosomes at the centromere Reactome
3.64E-06 Nucleosome assembly Reactome
3.98E-06 Condensation of Prophase Chromosomes Reactome
4.34E-06 tRNA charging HumanCyc
4.86E-06 Amyloids Reactome
4.86E-06 Meiotic recombination Reactome
4.93E-06 Meiosis Reactome
6.16E-06 TLR JNK INOH
6.16E-06 IL-1 JNK INOH
6.16E-06 RNA Polymerase I Promoter Opening Reactome
7.23E-06 mRNA Processing Wikipathways
7.61E-06 BARD1 signaling events PID
7.77E-06 TLR p38 INOH
7.99E-06 HATs acetylate histones Reactome
8.84E-06 Pyrimidine metabolism EHMN
9.74E-06 IL-1 NFkB INOH
9.74E-06 DroToll-like INOH
1.06E-05 Glucose metabolism Reactome
1.06E-05 RMTs methylate histone arginines Reactome
1.12E-05 RHO GTPases activate PKNs Reactome
1.12E-05 Mitotic Anaphase Reactome
1.15E-05 mRNA Splicing - Major Pathway Reactome
1.15E-05 mRNA Splicing Reactome
1.17E-05 Meiotic synapsis Reactome
1.22E-05 Senescence-Associated Secretory Phenotype (SASP) Reactome
1.30E-05 Mitotic Metaphase and Anaphase Reactome
1.44E-05 miR-targeted genes in epithelium - TarBase Wikipathways
1.51E-05 IL-1 p38 INOH
1.51E-05 TNF INOH
1.51E-05 tRNA Aminoacylation Reactome
1.63E-05 E2F mediated regulation of DNA replication Reactome
1.80E-05 Folding of actin by CCT/TriC Reactome
1.86E-05 Telomere C-strand synthesis initiation Reactome
1.86E-05 DNA replication initiation Reactome
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1.86E-05 Pyrimidine biosynthesis Reactome
1.86E-05 SIRT1 negatively regulates rRNA Expression Reactome
2.36E-05 Gemcitabine Action Pathway SMPDB
2.36E-05 Gemcitabine Metabolism Pathway SMPDB
2.53E-05 Chromatin modifying enzymes Reactome
2.53E-05 Chromatin organization Reactome
2.56E-05 Translation Factors Wikipathways
2.75E-05 RNA Polymerase I Chain Elongation Reactome
2.80E-05 TLR NFkB INOH
3.35E-05 NoRC negatively regulates rRNA expression Reactome
3.56E-05 Amino acid synthesis and interconversion (transamination) Reactome
3.91E-05 Pyrimidine Metabolism SMPDB
3.91E-05 UMP Synthase Deiciency (Orotic Aciduria) SMPDB
3.91E-05 MNGIE (Mitochondrial Neurogastrointestinal Encephalopathy) SMPDB
3.91E-05 Beta Ureidopropionase Deficiency SMPDB
3.91E-05 Dihydropyrimidinase Deficiency SMPDB
4.15E-05 Apoptotic execution phase Reactome
4.22E-05 Resolution of Sister Chromatid Cohesion Reactome
4.64E-05 Metabolism Reactome
4.67E-05 Transcription Reactome
5.20E-05 Homologous recombination - Homo sapiens (human) KEGG
5.23E-05 RNA Polymerase I Promoter Clearance Reactome
5.23E-05 Negative epigenetic regulation of rRNA expression Reactome
5.23E-05 Mitotic Prometaphase Reactome
5.71E-05 Nucleotide Metabolism Wikipathways
5.97E-05 Epstein-Barr virus infection - Homo sapiens (human) KEGG
6.24E-05 Separation of Sister Chromatids Reactome
6.35E-05 Epigenetic regulation of gene expression Reactome
6.40E-05 miR-targeted genes in lymphocytes - TarBase Wikipathways
6.63E-05 Validated targets of C-MYC transcriptional activation PID
6.95E-05 RNA Polymerase I Transcription Reactome
7.23E-05 CD4 T cell receptor signaling-NFkB cascade INOH
7.66E-05 SCF(Skp2)-mediated degradation of p27/p21 Reactome
0.000101 Transport of Mature Transcript to Cytoplasm Reactome
0.000127 Translesion synthesis by REV1 Reactome
0.000135 Cyclin D associated events in G1 Reactome
0.000135 G1 Phase Reactome
0.000143 Pyrimidine nucleotides nucleosides metabolism INOH
0.000144 HDACs deacetylate histones Reactome
0.000144 Metabolism of amino acids and derivatives Reactome
0.000149 Hedgehog INOH
0.000151 Recycling of eIF2:GDP Reactome
0.00016 Inhibition of replication initiation of damaged DNA by RB1/E2F1 Reactome
0.000167 AndrogenReceptor NetPath
0.000168 Regulation of HSF1-mediated heat shock response Reactome
0.000175 Signaling events mediated by HDAC Class III PID
0.000177 Transport of Mature mRNA derived from an Intron-Containing Transcript Reactome
0.000181 Protein processing in endoplasmic reticulum - Homo sapiens (human) KEGG
0.000194 pyrimidine deoxyribonucleosides salvage HumanCyc
0.000194 superpathway of pyrimidine deoxyribonucleotides <i>de novo</i> biosynthesis HumanCyc
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0.000194 Cyclin E associated events during G1/S transition Reactome
0.000201 Translesion synthesis by POLK Reactome
0.000201 Translesion synthesis by POLI Reactome
0.000202 Fanconi anemia pathway PID
0.000254 Cellular response to heat stress Reactome
0.00026 DNA Damage Response Wikipathways
0.000266 Mitochondrial protein import Reactome
0.000277 Antigen Presentation: Folding, assembly and peptide loading of class I MHC Reactome
0.000277 Cyclin A:Cdk2-associated events at S phase entry Reactome
0.000278 regulation of p27 phosphorylation during cell cycle progression BioCarta
0.000294 RHO GTPases Activate Formins Reactome
0.000317 Type I hemidesmosome assembly Reactome
0.000317 btg family proteins and cell cycle regulation BioCarta
0.000387 Pyrimidine metabolism Reactome
0.000392 Infectious disease Reactome
0.000433 B cell receptor signaling INOH
0.000453 CDT1 association with the CDC6:ORC:origin complex Reactome
0.00048 Purine metabolism EHMN
0.000529 IL-7 Signaling Pathway Wikipathways
0.000529 cell cycle: g1/s check point BioCarta
0.000533 Metabolism of nucleotides Reactome
0.000558
Urea cycle and metabolism of arginine, proline, glutamate, aspartate and
asparagine EHMN
0.000593 Gemcitabine Pathway, Pharmacodynamics PharmGKB
0.000631 Aminoacyl-tRNA biosynthesis - Homo sapiens (human) KEGG
0.000632 Apoptotic cleavage of cellular proteins Reactome
0.000632 Regulation of mRNA stability by proteins that bind AU-rich elements Reactome
0.000632 miRNA Regulation of DNA Damage Response Wikipathways
0.000645 Arginine biosynthesis - Homo sapiens (human) KEGG
0.000645 Urea cycle and metabolism of amino groups Wikipathways
0.000645 S-Adenosylhomocysteine (SAH) Hydrolase Deficiency SMPDB
0.000645 Methionine Metabolism SMPDB
0.000645 Methionine Adenosyltransferase Deficiency SMPDB
0.000645 Glycine N-methyltransferase Deficiency SMPDB
0.000645 Hypermethioninemia SMPDB
0.000645 Methylenetetrahydrofolate Reductase Deficiency (MTHFRD) SMPDB
0.000645
Homocystinuria-megaloblastic anemia due to defect in cobalamin metabolism,
cblG complementation type SMPDB
0.000645 Cystathionine Beta-Synthase Deficiency SMPDB
0.000646 Metabolism of proteins Reactome
0.000773 RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription Reactome
0.000787 Signaling by Rho GTPases Reactome
0.000823 Fanconi anemia pathway - Homo sapiens (human) KEGG
0.000823 Apoptosis-related network due to altered Notch3 in ovarian cancer Wikipathways
0.000824 formation of the beta-catenin:TCF transactivating complex Reactome
0.000886 Transport of the SLBP Dependant Mature mRNA Reactome
0.000901 Formation of tubulin folding intermediates by CCT/TriC Reactome
0.000912 HIV Life Cycle Reactome
0.00094 Prefoldin mediated transfer of substrate  to CCT/TriC Reactome
0.001003 Triglyceride Biosynthesis Reactome
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0.001015 Nucleotide Excision Repair SMPDB
0.001048 G2/M DNA damage checkpoint Reactome
0.00105 G1/S DNA Damage Checkpoints Reactome
0.001121 Interactions of Vpr with host cellular proteins Reactome
0.001166 Pathogenic Escherichia coli infection - Homo sapiens (human) KEGG
0.00119 POLB-Dependent Long Patch Base Excision Repair Reactome
0.00119 AUF1 (hnRNP D0) destabilizes mRNA Reactome
0.001201 Glycine Serine metabolism INOH
0.001203 Methionine and cysteine metabolism EHMN
0.001208 HDMs demethylate histones Reactome
0.001225 influence of ras and rho proteins on g1 to s transition BioCarta
0.001225 Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding Reactome
0.001362 HIV Infection Reactome
0.001377 Pathogenic Escherichia coli infection Wikipathways
0.001377 Notch INOH
0.001403 Alanine, aspartate and glutamate metabolism - Homo sapiens (human) KEGG
0.001465 FOXM1 transcription factor network PID
0.001489 Regulation of retinoblastoma protein PID
0.001547 CD4 T cell receptor signaling INOH
0.001574 Regulation of cholesterol biosynthesis by SREBP (SREBF) Reactome
0.00162 Influenza Infection Reactome
0.001626 mechanism of protein import into the nucleus BioCarta
0.001649 cyclins and cell cycle regulation BioCarta
0.00174 Transport of Mature mRNAs Derived from Intronless Transcripts Reactome
0.001944 TGF-beta super family signaling pathway canonical INOH
0.001945 Hypusine synthesis from eIF5A-lysine Reactome
0.001945
Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2
complexes Reactome
0.001996 TSH signaling pathway Wikipathways
0.001996 Pancreatic cancer - Homo sapiens (human) KEGG
0.001997 Oncogene Induced Senescence Reactome
0.002068 Spliceosome - Homo sapiens (human) KEGG
0.002138 Squalene and cholesterol biosynthesis EHMN
0.002168 Fluoropyrimidine Pathway, Pharmacokinetics PharmGKB
0.002187 Organelle biogenesis and maintenance Reactome
0.002229 Tenofovir/Adefovir Pathway, Pharmacokinetics PharmGKB
0.002229 CDC6 association with the ORC:origin complex Reactome
0.002272 Systemic lupus erythematosus - Homo sapiens (human) KEGG
0.002469 p53 signaling pathway BioCarta
0.002469 p53-Dependent G1 DNA Damage Response Reactome
0.002469 p53-Dependent G1/S DNA damage checkpoint Reactome
0.002469 cholesterol biosynthesis I HumanCyc
0.002469 Antimetabolite Pathway - Folate Cycle, Pharmacodynamics PharmGKB
0.002469 cholesterol biosynthesis II (via 24,25-dihydrolanosterol) HumanCyc
0.002469 cholesterol biosynthesis III (via desmosterol) HumanCyc
0.002469 Homologous recombination Wikipathways
0.002506 Trans-sulfuration and one carbon metabolism Wikipathways
0.002506 HSF1 activation Reactome
0.002506 Folate metabolism INOH
0.002506 Vpr-mediated nuclear import of PICs Reactome
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0.002675 RNA transport - Homo sapiens (human) KEGG
0.002806 skeletal muscle hypertrophy is regulated via akt-mtor pathway BioCarta
0.002806 regulation of eif-4e and p70s6 kinase BioCarta
0.002806 superpathway of cholesterol biosynthesis HumanCyc
0.002806 Fatty Acyl-CoA Biosynthesis Reactome
0.002806 Alanine Aspartate Asparagine metabolism INOH
0.002887 Pre-NOTCH Transcription and Translation Reactome
0.00311 Gluconeogenesis Reactome
0.00311 Glycolysis Reactome
0.00311 Rev-mediated nuclear export of HIV RNA Reactome
0.00311 Thiopurine Pathway, Pharmacokinetics/Pharmacodynamics PharmGKB
0.00311 Transport of the SLBP independent Mature mRNA Reactome
0.003287 Small cell lung cancer - Homo sapiens (human) KEGG
0.003438 Apoptosis Reactome
0.003578 C-MYC pathway PID
0.003578 Vitamin B9 (folate) metabolism EHMN
0.003685 Host Interactions of HIV factors Reactome
0.003758 Urea cycle Reactome
0.003758 Sepiapterin reductase deficiency SMPDB
0.003758 Segawa syndrome SMPDB
0.003758 Pterine Biosynthesis SMPDB
0.003758 Dopa-responsive dystonia SMPDB
0.003758 Hyperphenylalaniemia due to guanosine triphosphate cyclohydrolase deficiency SMPDB
0.003758
Hyperphenylalaninemia due to 6-pyruvoyltetrahydropterin synthase deficiency
(ptps) SMPDB
0.003758 Hyperphenylalaninemia due to dhpr-deficiency SMPDB
0.003758 cycling of ran in nucleocytoplasmic transport BioCarta
0.003818 Copper homeostasis Wikipathways
0.003821 Fluoropyrimidine Activity Wikipathways
0.0039 miR-targeted genes in muscle cell - TarBase Wikipathways
0.004501 One Carbon Metabolism Wikipathways
0.004501 DNA Damage/Telomere Stress Induced Senescence Reactome
0.004506 Intraflagellar transport Reactome
0.004572 Assembly of the RAD51-ssDNA nucleoprotein complex Reactome
0.004572 dTMP <i>de novo</i> biosynthesis (mitochondrial) HumanCyc
0.004572 folate polyglutamylation HumanCyc
0.004572 fructose 2,6-bisphosphate synthesis HumanCyc
0.004587 Programmed Cell Death Reactome
0.004912 Alcoholism - Homo sapiens (human) KEGG
0.005027 TSLP NetPath
0.005032 Methotrexate Pathway (Cancer Cell), Pharmacodynamics PharmGKB
0.005032 Early Phase of HIV Life Cycle Reactome
0.005032 Unfolded Protein Response (UPR) Reactome
0.005593 Glyoxylate and dicarboxylate metabolism - Homo sapiens (human) KEGG
0.005615 Lysosome Vesicle Biogenesis Reactome
0.005615 Transport of Mature mRNA Derived from an Intronless Transcript Reactome
0.0057 Arginine and proline metabolism - Homo sapiens (human) KEGG
0.0057 snRNP Assembly Reactome
0.0057 Metabolism of non-coding RNA Reactome
0.005869 e2f1 destruction pathway BioCarta
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0.005869 ifn alpha signaling pathway BioCarta
0.006278 FAS pathway and Stress induction of HSP regulation Wikipathways
0.006358 Hepatitis B - Homo sapiens (human) KEGG
0.00645 Simvastatin Action Pathway SMPDB
0.00645 Hyper-IgD syndrome SMPDB
0.00645 Cholesteryl ester storage disease SMPDB
0.00645 Lysosomal Acid Lipase Deficiency (Wolman Disease) SMPDB
0.00645 Mevalonic aciduria SMPDB
0.00645 Wolman disease SMPDB
0.00645 Smith-Lemli-Opitz Syndrome (SLOS) SMPDB
0.00645 Chondrodysplasia Punctata II, X Linked Dominant (CDPX2) SMPDB
0.00645 CHILD Syndrome SMPDB
0.00645 Desmosterolosis SMPDB
0.00645 Hypercholesterolemia SMPDB
0.00645 Steroid Biosynthesis SMPDB
0.00645 Pravastatin Action Pathway SMPDB
0.00645 Atorvastatin Action Pathway SMPDB
0.00645 Rosuvastatin Action Pathway SMPDB
0.00645 Lovastatin Action Pathway SMPDB
0.00645 Cerivastatin Action Pathway SMPDB
0.00645 Fluvastatin Action Pathway SMPDB
0.00645 Alendronate Action Pathway SMPDB
0.00645 Risedronate Action Pathway SMPDB
0.00645 Pamidronate Action Pathway SMPDB
0.00645 Zoledronate Action Pathway SMPDB
0.00645 Ibandronate Action Pathway SMPDB
0.00645 Lysine degradation INOH
0.00645 Terpenoid backbone biosynthesis - Homo sapiens (human) KEGG
0.006451 Influenza Virus Induced Apoptosis Reactome
0.006451 glycine/serine biosynthesis HumanCyc
0.006451 UMP biosynthesis HumanCyc
0.006451 Cytosolic iron-sulfur cluster assembly Reactome
0.006659 Lysine metabolism EHMN
0.006722 Interactions of Rev with host cellular proteins Reactome
0.006763 Purine metabolism - Homo sapiens (human) KEGG
0.006841 pyrimidine deoxyribonucleotides <i>de novo</i> biosynthesis HumanCyc
0.006871 NEP/NS2 Interacts with the Cellular Export Machinery Reactome
0.006871 Transport of Ribonucleoproteins into the Host Nucleus Reactome
0.007143 TNFalpha NetPath
0.007343 Cleavage of Growing Transcript in the Termination Region Reactome
0.007343 RNA Polymerase II Transcription Termination Reactome
0.007343 Post-Elongation Processing of the Transcript Reactome
0.007389 Regulation of Telomerase PID
0.007389 p53 signaling pathway - Homo sapiens (human) KEGG
0.007591 Influenza Life Cycle Reactome
0.007918 Antigen processing and presentation - Homo sapiens (human) KEGG
0.008145 Biosynthesis of unsaturated fatty acids - Homo sapiens (human) KEGG
0.008145 Cholesterol biosynthesis Reactome
0.008145 caspase cascade in apoptosis BioCarta
0.008145 Deadenylation of mRNA Reactome
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0.008488 EGFR1 NetPath
0.008541 RAGE NetPath
0.008598 Ubiquitin-dependent degradation of Cyclin D1 Reactome
0.008598 Ubiquitin-dependent degradation of Cyclin D Reactome
0.008598 &gamma;-glutamyl cycle HumanCyc
0.008598 TP53 Regulates Metabolic Genes Wikipathways
0.008598 Presynaptic phase of homologous DNA pairing and strand exchange Reactome
0.008598 IL-10 signaling INOH
0.008598 CDK-mediated phosphorylation and removal of Cdc6 Reactome
0.008642 Association of licensing factors with the pre-replicative complex Reactome
0.008642 Hh mutants that don,t undergo autocatalytic processing are degraded by ERAD Reactome
0.008642 Hh mutants abrogate ligand secretion Reactome
0.008642 Interleukin-6 signaling Reactome
0.008642 il22 soluble receptor signaling pathway BioCarta
0.008642 Establishment of Sister Chromatid Cohesion Reactome
0.008879 Direct p53 effectors PID
0.009061 superpathway of pyrimidine deoxyribonucleoside salvage HumanCyc
0.009545 HTLV-I infection - Homo sapiens (human) KEGG
0.009931 Interferon type I signaling pathways Wikipathways
Table S 7: Over-representation analysis of genes oscillating only in SW480 cells
p-value pathway source
4.30E-09 HDACs deacetylate histones Reactome
9.93E-09 Chromatin modifying enzymes Reactome
9.93E-09 Chromatin organization Reactome
1.07E-08 RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription Reactome
1.80E-07 RNA Polymerase I Transcription Reactome
2.34E-07 HATs acetylate histones Reactome
3.60E-07 RNA Polymerase I Promoter Clearance Reactome
4.98E-07 Cell Cycle Reactome
7.06E-07 Aurora B signaling PID
1.16E-06 RMTs methylate histone arginines Reactome
1.35E-06 SIRT1 negatively regulates rRNA Expression Reactome
1.49E-06 M Phase Reactome
1.89E-06 RHO GTPase Effectors Reactome
1.99E-06 Signaling by Rho GTPases Reactome
2.06E-06 Condensation of Prophase Chromosomes Reactome
3.43E-06 Negative epigenetic regulation of rRNA expression Reactome
4.20E-06 RNA Polymerase I Chain Elongation Reactome
4.20E-06 formation of the beta-catenin:TCF transactivating complex Reactome
4.52E-06 RNA Polymerase I Promoter Opening Reactome
4.73E-06 Epigenetic regulation of gene expression Reactome
5.09E-06 Cell Cycle, Mitotic Reactome
6.22E-06 EGFR1 NetPath
8.29E-06 Transcriptional regulation by small RNAs Reactome
8.36E-06 Transcription Reactome
9.55E-06 Meiosis Reactome
1.28E-05 Amyloids Reactome
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1.28E-05 Meiotic recombination Reactome
1.54E-05 NoRC negatively regulates rRNA expression Reactome
1.94E-05 PRC2 methylates histones and DNA Reactome
2.03E-05 RHO GTPases activate PKNs Reactome
2.76E-05 Mitotic Prometaphase Reactome
2.89E-05 DNA methylation Reactome
4.02E-05 Polo-like kinase mediated events Reactome
4.22E-05 Lysosome - Homo sapiens (human) KEGG
4.48E-05 Cellular responses to stress Reactome
4.81E-05
Activated PKN1 stimulates transcription of AR (androgen receptor)
regulated genes KLK2 and KLK3 Reactome
5.01E-05 G2/M DNA damage checkpoint Reactome
5.09E-05 PLK1 signaling events PID
9.06E-05 Recruitment of repair and signaling proteins to double-strand breaks Reactome
9.06E-05 DNA Double Strand Breaks Response Reactome
9.68E-05 Regulatory RNA pathways Reactome
0.000114234 Signaling events mediated by HDAC Class I PID
0.000145706 Factors involved in megakaryocyte development and platelet production Reactome
0.000185057 Oxidative Stress Induced Senescence Reactome
0.000226947 Condensation of Prometaphase Chromosomes Reactome
0.000241343 Systemic lupus erythematosus - Homo sapiens (human) KEGG
0.000257463 Cellular Senescence Reactome
0.000329855 Senescence-Associated Secretory Phenotype (SASP) Reactome
0.00036891 Gene Expression Reactome
0.000371421 RNA Polymerase III Transcription Termination Reactome
0.000424944 FOXM1 transcription factor network PID
0.000585899 HDMs demethylate histones Reactome
0.000633043 Resolution of Sister Chromatid Cohesion Reactome
0.00071913 PKMTs methylate histone lysines Reactome
0.000792444 Kinesins Reactome
0.00083642 Clathrin derived vesicle budding Reactome
0.00083642 trans-Golgi Network Vesicle Budding Reactome
0.000870163 ATM Signaling Pathway Wikipathways
0.000944467 RHO GTPases Activate Formins Reactome
0.001009042 Alpha6Beta4Integrin NetPath
0.001036295 Mitotic Prophase Reactome
0.00112716 TCF dependent signaling in response to WNT Reactome
0.001147993 ATM mediated phosphorylation of repair proteins Reactome
0.001147993 ATM mediated response to DNA double-strand break Reactome
0.001147993 Mitotic G2-G2-M phases Wikipathways
0.001153103 RNA Polymerase III Abortive And Retractive Initiation Reactome
0.001153103 RNA Polymerase III Transcription Reactome
0.001160279 BMP2 signaling TGF-beta MV INOH
0.001386299 G2/M Checkpoints Reactome
0.001446958 Adherens junction - Homo sapiens (human) KEGG
0.001453483 Cell cycle - Homo sapiens (human) KEGG
0.001552102 p53 signaling pathway - Homo sapiens (human) KEGG
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0.00203656 E2F transcription factor network PID
0.002129523 Spliceosome - Homo sapiens (human) KEGG
0.002227818 Golgi Associated Vesicle Biogenesis Reactome
0.00231452 Histone Modifications Wikipathways
0.002610849 RORA activates gene expression Reactome
0.002672245 Mitotic G2-G2/M phases Reactome
0.002678169 Direct p53 effectors PID
0.002711887 Validated transcriptional targets of TAp63 isoforms PID
0.002853964 cell cycle: g2/m checkpoint BioCarta
0.002853964 p38 signaling mediated by MAPKAP kinases PID
0.002947859 Disease Reactome
0.002980914 Transcriptional misregulation in cancer - Homo sapiens (human) KEGG
0.00309782 Spermidine and Spermine Biosynthesis SMPDB
0.003118515 Validated targets of C-MYC transcriptional activation PID
0.003284364 Alcoholism - Homo sapiens (human) KEGG
0.003655759 Aurora A signaling PID
0.004215335 Synthesis of substrates in N-glycan biosythesis Reactome
0.004335829 G2/M Transition Reactome
0.004460154 Meiotic synapsis Reactome
0.004497353 RNA Polymerase III Transcription Initiation From Type 2 Promoter Reactome
0.004651555 mRNA Splicing - Minor Pathway Reactome
0.004680258 Fluoropyrimidine Pathway, Pharmacodynamics PharmGKB
0.004725101 RNA polymerase - Homo sapiens (human) KEGG
0.004755542 Validated transcriptional targets of AP1 family members Fra1 and Fra2 PID
0.005423447 RNA Polymerase I Transcription Initiation Reactome
0.005450451 AP-1 transcription factor network PID
0.005896613 Arylhydrocarbon receptor (AhR) signaling pathway Wikipathways
0.005896613 RNA Polymerase III Transcription Initiation From Type 1 Promoter Reactome
0.00646572 TP53 Network Wikipathways
0.00646572 RNA Polymerase III Chain Elongation Reactome
0.00646572 regulation of cell cycle progression by plk3 BioCarta
0.00646572 atm signaling pathway BioCarta
0.006864214 Separation of Sister Chromatids Reactome
0.007025465 Signaling by TGF-beta Receptor Complex Reactome
0.007322169 Vitamin K Metabolism SMPDB
0.007322169 phospholipase c delta in phospholipid associated cell signaling BioCarta
0.007354011
Homologous recombination repair of replication-independent double-strand
breaks Reactome
0.007354011 Homologous Recombination Repair Reactome
0.007354011 1D-<i>myo</i>-inositol hexakisphosphate biosynthesis II (mammalian) HumanCyc
0.007354011 D-<i>myo</i>-inositol (1,3,4)-trisphosphate biosynthesis HumanCyc
0.007588053 BMP signaling Dro INOH
0.007608657 RNA Polymerase III Transcription Initiation From Type 3 Promoter Reactome
0.007608657 Gastric Cancer Network 1 Wikipathways
0.007694008 apoptotic dna-fragmentation and tissue homeostasis BioCarta
0.007747909 Apoptosis Wikipathways
0.008859471 Cell Cycle Wikipathways
Supplementary information
 ___________________________________________________________________________
150
0.008859471 HIF-1 signaling pathway - Homo sapiens (human) KEGG
0.00887877 superpathway of D-<i>myo</i>-inositol (1,4,5)-trisphosphate metabolism HumanCyc
0.00887877 tgf beta signaling pathway BioCarta
0.00944541 ATM pathway PID
0.00944541 HIF-2-alpha transcription factor network PID
0.009466005 DNA Damage Response Wikipathways
0.009544442 Signaling by Wnt Reactome
0.009674878 Fructose Mannose metabolism INOH
Table S 8: Over-representation analysis of genes oscillating only in SW620 cells
p-value pathway source
1.08E-08 proteasome complex BioCarta
9.47E-08 The citric acid (TCA) cycle and respiratory electron transport Reactome
1.04E-06 Warburg Effect SMPDB
1.28E-05 Huntington,s disease - Homo sapiens (human) KEGG
1.40E-05 Pyruvate metabolism and Citric Acid (TCA) cycle Reactome
1.63E-05 Pyruvate dehydrogenase deficiency (E3) SMPDB
1.63E-05 Pyruvate dehydrogenase deficiency (E2) SMPDB
1.63E-05 2-ketoglutarate dehydrogenase complex deficiency SMPDB
1.63E-05 Mitochondrial complex II deficiency SMPDB
1.63E-05 Fumarase deficiency SMPDB
1.63E-05 Congenital lactic acidosis SMPDB
1.63E-05 Citric Acid Cycle SMPDB
1.84E-05 Protein processing in endoplasmic reticulum - Homo sapiens (human) KEGG
1.97E-05 Asparagine N-linked glycosylation Reactome
3.12E-05 TNF INOH
5.95E-05 Metabolism Reactome
6.52E-05 RNA transport - Homo sapiens (human) KEGG
7.66E-05 Mitochondrial Electron Transport Chain SMPDB
8.23E-05 Thyroid cancer - Homo sapiens (human) KEGG
0.000102855 Electron Transport Chain Wikipathways
0.000107415
Respiratory electron transport, ATP synthesis by chemiosmotic coupling,
and heat production by uncoupling proteins. Reactome
0.000119469 Parkinson,s disease - Homo sapiens (human) KEGG
0.000130335 Organelle biogenesis and maintenance Reactome
0.000187421 Pravastatin Action Pathway SMPDB
0.000187421 Atorvastatin Action Pathway SMPDB
0.000187421 Rosuvastatin Action Pathway SMPDB
0.000187421 Lovastatin Action Pathway SMPDB
0.000187421 Cerivastatin Action Pathway SMPDB
0.000187421 Fluvastatin Action Pathway SMPDB
0.000187421 Simvastatin Action Pathway SMPDB
0.000187421 Hyper-IgD syndrome SMPDB
0.000187421 Cholesteryl ester storage disease SMPDB
0.000187421 Lysosomal Acid Lipase Deficiency (Wolman Disease) SMPDB
0.000187421 Mevalonic aciduria SMPDB
0.000187421 Wolman disease SMPDB
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0.000187421 Smith-Lemli-Opitz Syndrome (SLOS) SMPDB
0.000187421 Chondrodysplasia Punctata II, X Linked Dominant (CDPX2) SMPDB
0.000187421 CHILD Syndrome SMPDB
0.000187421 Desmosterolosis SMPDB
0.000187421 Hypercholesterolemia SMPDB
0.000187421 Steroid Biosynthesis SMPDB
0.000187421 Alendronate Action Pathway SMPDB
0.000187421 Risedronate Action Pathway SMPDB
0.000187421 Pamidronate Action Pathway SMPDB
0.000187421 Zoledronate Action Pathway SMPDB
0.000187421 Ibandronate Action Pathway SMPDB
0.000210436 N-Glycan biosynthesis EHMN
0.000279828 Cholesterol biosynthesis Reactome
0.00029203 Hedgehog INOH
0.000297685 Signaling events mediated by HDAC Class II PID
0.00035078 Recruitment of mitotic centrosome proteins and complexes Reactome
0.00035078 Centrosome maturation Reactome
0.000378947 Cholesterol Biosynthesis Wikipathways
0.000406414 Regulation of nuclear beta catenin signaling and target gene transcription PID
0.000461683 Alzheimer,s disease - Homo sapiens (human) KEGG
0.000519086 Metabolism of proteins Reactome
0.000577583 HIV Life Cycle Reactome
0.000583689 3-Methylglutaconic Aciduria Type I SMPDB
0.000583689 Valine, Leucine and Isoleucine Degradation SMPDB
0.000583689 2-Methyl-3-Hydroxybutryl CoA Dehydrogenase Deficiency SMPDB
0.000583689 Isovaleric Aciduria SMPDB
0.000583689 3-Methylcrotonyl Coa Carboxylase Deficiency Type I SMPDB
0.000583689 Propionic Acidemia SMPDB
0.000583689 Maple Syrup Urine Disease SMPDB
0.000583689 3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency SMPDB
0.000583689 Isobutyryl-coa dehydrogenase deficiency SMPDB
0.000583689 3-hydroxyisobutyric aciduria SMPDB
0.000583689 3-hydroxyisobutyric acid dehydrogenase deficiency SMPDB
0.000583689 Isovaleric acidemia SMPDB
0.000583689 Methylmalonate Semialdehyde Dehydrogenase Deficiency SMPDB
0.000583689 Methylmalonic Aciduria SMPDB
0.000583689 3-Methylglutaconic Aciduria Type IV SMPDB
0.000583689 3-Methylglutaconic Aciduria Type III SMPDB
0.000583689 Beta-Ketothiolase Deficiency SMPDB
0.000583689 Citrate cycle (TCA cycle) - Homo sapiens (human) KEGG
0.000584992 Post-translational protein modification Reactome
0.000613805 TCA Cycle and PDHc Wikipathways
0.00062429 Androgen receptor signaling pathway Wikipathways
0.000726218 Mitochondrial translation Reactome
0.000758689 Peroxisomal lipid metabolism Reactome
0.000776677 Mitochondrial translation elongation Reactome
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0.000911746 Processing of Capped Intron-Containing Pre-mRNA Reactome
0.000950885 TCA Cycle Wikipathways
0.000950885 Bisphosphonate Pathway, Pharmacodynamics PharmGKB
0.001035737 Benzo(a)pyrene metabolism Wikipathways
0.001066306 IL-1 p38 INOH
0.001085127 Pyruvate Dehydrogenase Complex Deficiency SMPDB
0.001085127 Primary hyperoxaluria II, PH2 SMPDB
0.001085127 Pyruvate kinase deficiency SMPDB
0.001085127 Leigh Syndrome SMPDB
0.001085127 Pyruvate Metabolism SMPDB
0.001085127 Pyruvate Decarboxylase E1 Component Deficiency (PDHE1 Deficiency) SMPDB
0.001085127 Pyruvate metabolism Reactome
0.001090671 N-Glycan biosynthesis - Homo sapiens (human) KEGG
0.001090671 Valine, leucine and isoleucine degradation EHMN
0.001122506 Respiratory electron transport Reactome
0.001199999 SUMOylation of DNA damage response and repair proteins Reactome
0.001199999 SUMO E3 ligases SUMOylate target proteins Reactome
0.001415586 TGF-beta super family signaling pathway canonical INOH
0.001415586 mRNA Splicing - Major Pathway Reactome
0.001415586 mRNA Splicing Reactome
0.001415586 G2/M Transition Reactome
0.001418181 TCA cycle HumanCyc
0.001436718 Late Phase of HIV Life Cycle Reactome
0.001439725 allopregnanolone biosynthesis HumanCyc
0.001468946 Glyoxylate and dicarboxylate metabolism - Homo sapiens (human) KEGG
0.001468946 Signaling by FGFR4 mutants Reactome
0.001556962 Non-alcoholic fatty liver disease (NAFLD) - Homo sapiens (human) KEGG
0.001560644 Loss of Nlp from mitotic centrosomes Reactome
0.001560644
Loss of proteins required for interphase microtubule organizationfrom the
centrosome Reactome
0.001560644 IL-1 JNK INOH
0.001560644 TLR JNK INOH
0.001746394
the prc2 complex sets long-term gene silencing through modification of
histone tails BioCarta
0.001754773 Infectious disease Reactome
0.001778706 RNA Polymerase II Transcription Reactome
0.001797969 Mitotic G2-G2/M phases Reactome
0.001847434 TLR p38 INOH
0.001847434 Proteasome Degradation Wikipathways
0.001856701 Anchoring of the basal body to the plasma membrane Reactome
0.001867891 HIV Infection Reactome
0.00196427 Fanconi anemia pathway PID
0.002029834 Mitochondrial translation termination Reactome
0.002046936 Citric acid cycle (TCA cycle) Reactome
0.002068459 Fas INOH
0.002232855 Oxidative phosphorylation - Homo sapiens (human) KEGG
0.002350716 Eukaryotic Transcription Initiation Wikipathways
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0.002423989 Cell Cycle Reactome
0.00251725 Retinoic acid receptors-mediated signaling PID
0.002547572 SUMOylation Reactome
0.002658026 Synthesis of bile acids and bile salts via 27-hydroxycholesterol Reactome
0.002705735 Oxidative phosphorylation Wikipathways
0.002769849 superpathway of cholesterol biosynthesis HumanCyc
0.002794736 miR-targeted genes in lymphocytes - TarBase Wikipathways
0.002897652
superpathway of conversion of glucose to acetyl CoA and entry into the
TCA cycle HumanCyc
0.003084264 Long-chain-3-hydroxyacyl-coa dehydrogenase deficiency (LCHAD) SMPDB
0.003084264 Fatty Acid Elongation In Mitochondria SMPDB
0.003084264 Aflatoxin B1 metabolism Wikipathways
0.003307436 Transcription Reactome
0.003360227 Regulation of PLK1 Activity at G2/M Transition Reactome
0.003377534 Ubiquitin mediated proteolysis - Homo sapiens (human) KEGG
0.003485943 miR-targeted genes in muscle cell - TarBase Wikipathways
0.003643701 ID NetPath
0.003643701 Vitamin B9 (folate) metabolism EHMN
0.004075669 Alpha-oxidation of phytanate Reactome
0.004084807 Noncanonical Wnt signaling pathway PID
0.004161687 snRNP Assembly Reactome
0.004161687 Metabolism of non-coding RNA Reactome
0.004276984 Proteasome - Homo sapiens (human) KEGG
0.004637878 TLR NFkB INOH
0.004666234 Influenza Infection Reactome
0.004716363 Signaling by FGFR2 mutants Reactome
0.004716363 Signaling by FGFR2 in disease Reactome
0.004716363 Synthesis of bile acids and bile salts Reactome
0.00497158 Mitochondrial translation initiation Reactome
0.004992114 map kinase inactivation of smrt corepressor BioCarta
0.004992114 Vitamin B5 (pantothenate) metabolism Reactome
0.00542558 Wnt Canonical INOH
0.00542558 Wnt Mammals INOH
0.00552047 Glycine, serine, alanine and threonine metabolism EHMN
0.005665197 Gene Expression Reactome
0.005665335 MAP kinase cascade HumanCyc
0.005665335 sumoylation as a mechanism to modulate ctbp-dependent gene responses BioCarta
0.005665335
nuclear receptors coordinate the activities of chromatin remodeling
complexes and coactivators to facilitate initiation of transcription in
carcinoma cells BioCarta
0.005833539 Influenza Life Cycle Reactome
0.005841352 IL-1 NFkB INOH
0.005995941 AndrogenReceptor NetPath
0.006142235 Integrin-linked kinase signaling PID
0.006142235 Aryl Hydrocarbon Receptor Wikipathways
0.006326131 p38 MAPK Signaling Pathway Wikipathways
0.006848521 Fanconi anemia pathway - Homo sapiens (human) KEGG
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0.006889913 SHC-mediated cascade:FGFR4 Reactome
0.006889913
Antigen Presentation: Folding, assembly and peptide loading of class I
MHC Reactome
0.007287488 Valine, leucine and isoleucine degradation - Homo sapiens (human) KEGG
0.007429047 cholesterol biosynthesis I HumanCyc
0.007429047 cholesterol biosynthesis II (via 24,25-dihydrolanosterol) HumanCyc
0.007429047 cholesterol biosynthesis III (via desmosterol) HumanCyc
0.007465324 Cellular responses to stress Reactome
0.007518024 Activation of gene expression by SREBF (SREBP) Wikipathways
0.007518024 Activation of gene expression by SREBF (SREBP) Wikipathways
0.00771552 FGF INOH
0.00854022 DNA Repair Reactome
0.008816433 Transcription of the HIV genome Reactome
0.008816433 SREBP signalling Wikipathways
0.008875218 Doxorubicin Pathway (Cardiomyocyte Cell), Pharmacodynamics PharmGKB
0.008875218 Activation of gene expression by SREBF (SREBP) Reactome
0.008875218 Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol Reactome
0.008875218 tumor suppressor arf inhibits ribosomal biogenesis BioCarta
0.009369013 UDP-acetyl-D-galactosamine biosynthesis II HumanCyc
0.009369013 spliceosomal assembly BioCarta
0.009369013 COPII (Coat Protein 2) Mediated Vesicle Transport Reactome
0.009369013 ER to Golgi Transport Reactome
0.00940484 pyruvate decarboxylation to acetyl CoA HumanCyc
0.00940484 Pentose Phosphate Pathway (Erythrocyte) PharmGKB
0.009405877 TCA cycle EHMN
0.009405877 IGF1 pathway PID
0.009409047 Transport to the Golgi and subsequent modification Reactome
Figure S 6: Expression of metabolic candidate genes
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24 h expression patterns of selected metabolic genes in SW480 and SW620 cells. The expression is based on 24 h
time course microarray data. Relative expression compared to the mean.
Figure S 7: Knockdown efficiency after shRNA-mediated KD of p53
Gene expression analysis of p53 in human fallopian tube organoids after shRNA-mediated p53-KD. Gene
expression is shown compared to the corresponding control gene. Mean ± SEM, n = 3. KD efficiency: 96 %.
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Figure S 8: Viability, cytotoxicity and apoptosis in SW480 and SW620 cells
Viability (A, B), cytotoxicity (C, D) and apoptosis (E, F) in SW480 and SW620 control and shHkdc1 cells
synchronised at different timepoints. Cells were either untreated or treated with WZB117 or oxaliplatin.
Mean ± SEM, n = 3. Significant changes (p < 0.05) between different synchronisation timepoints of the same
condition are marked with *. * = p < 0.05, ** = p < 0.01, *** = p < 0.001.
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